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Stellingen behorende bij het proefschrift 
The inflammatory response In COPD 
In mice and men 
1. Het feit dat kortdurend roken in muizen ontstekingsremmende effecten heeft, is geen 
adequaat excuus voor COPD patienten om te (blijven) roken (dit proefschrift). 
2. Blootstelling aan stikstofdloxide versterkt de rook-gei'nduceerde ontstekingsreactie in 
muizen niet, maar draagt wel bij aan de gevoeligheid voor infecties. 
3. Roken veroorzaakt een antigeen specifieke immuunrespons (di! proefschrift). 
4. Het is zeer aannemelijk dat de rook-geinduceerde specifieke immuunrespons bijdraagt 
aan de pathogenese van COPD. 
5. Om de rel van regulatoire T cellen in COPD le onderzoeken, meet de functionaliteit van 
deze cellen speclfiek in longweefsel bestudeerd warden. 
&. H0-1 lnductie zorgt via een toename van regulatoire T cellen voor een verminderd aantal 
rook-geinduceerde B-cel-infiltraten in muizen (dit proefschrift). 
7. Een rokende muis raakt weliswaar verslaafd, maar zal nooit volledig COPD ontwikkelen. 
8. Gezonde rokers bestaan niet. 
9. Een 'gezonde' roker onderwerpen aan longfunctieonderzoek voor een wetenschappelijke 
studie leidt tot het risico op voortzetting van diens schadelijke rookgedrag. 
10. Het feit dat tegenwoordig erg veel geluisterd word! naar de leerling (en zijn ouders) en 
amper naar de leraar is fnuikend voor de kwaliteit van het onderwijs (A. Brandsma). 
Corry-Anke Brandsma, 8 september 2008 
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Definition and epidemiology of COPD 
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of death 
worldwide and its morbidity and mortality are still rising. According to the WHO, 
80 million people suffer from moderate to severe COPD and three million people 
died of COPD in 2005. Furthermore, the WHO predicts that COPD will become 
the fourth leading cause of death worldwide by 2030 [1]. 
COPD is defined by the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) as "a preventable and treatable disease with some significant 
extrapulmonary effects that may contribute to the severity in individual patients. 
Its pulmonary component is characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually progressive and associated with an 
abnormal inflammatory response of the lungs to noxious particles or gases" [2]. 
COPD is mostly diagnosed in individuals above 40 years. The first signs of 
COPD are often chronic cough, increased sputum production, and dyspnea. 
The pulmonary manifestation of COPD is documented by a decrease in FEV1 
relative to the predicted normal FEV1 and a decreased FEV/FVC ratio. GOLD has 
stratified the severity of COPD into stages I-IV [2]. Individuals with stage I have 
a mild airflow limitation and are often unaware of their decreased lung function. 
Individuals with stage IV have a severely limited lung function accompanied 
by symptoms like chronic dyspnea on exertion and in rest, chronic cough, and 
sputum production. In addition, respiratory insufficiency is present in a subset of 
COPD stage IV and exacerbations may be life threatening in these individuals. 
Problem definition and aim 
Smoking is widely accepted as the most important risk factor for the development 
of COPD in the Western world. Until now, the only effective treatment to diminish 
the accelerated lung function decline associated with COPD development and 
progression is smoking cessation. Nevertheless, the inflammatory response in 
the lungs persists after smoking cessation in COPD [3,4] and as yet it is not known 
whether and to what extent this contributes to ongoing disease progression. The 
mechanisms behind the smoke induced lung damage and the continuation of 
this inflammation after smoking cessation are largely unknown. 
Next to smoking, other factors must be involved in COPD development as 
well, since also some non-smokers develop the disease and only a minority of 
smokers does. These factors include exposure to other toxic environments like air 
pollution, and genetic factors like a-1 antitrypsin deficiency and polymorphisms 
in genes encoding for proteases (matrix metalloproteases (MMPs)), antioxidants 
(gluthatione-S-transferases, heme oxygenase-1 (HO-1)) and inflammatory 
mediators (TNF-a, TGF-�) [2,5]. Whether these risk factors interact with cigarette 
smoke and to what extent they contribute to COPD development is currently 
unknown. 
This lack of knowledge greatly hampers the development of new and effective 
treatments. To find better treatment targets for COPD patients and to understand 
why the chronic inflammatory response persists after stopping smoking, more 
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information is needed about the origin and nature of the chronic inflammatory 
response in COPD. 
The aim of this thesis was to investigate both the early and late effects of cigarette 
smoking, together with the involvement of the air pollutant nitrogen dioxide 
(NO) and HO-1 in animal models for COPD. In addition, we investigated the role 
of the specific immune response, i.e. the involvement of B cells and regulatory T 
cells in the inflammatory response in COPD. 
First an overview of the current knowledge on the pathogenesis of COPD will 
be given, followed by a rationale for studying the different aspects of the 
inflammatory response in COPD as assessed in this thesis. 
Pathogenesis of COPD 
COPD is a complex, heterogeneous disease consisting of chronic bronchitis, 
emphysema, and small airways disease. Chronic bronchitis and small airways 
disease are characterized by inflammation of the airways resulting in inflammatory 
cell infiltrates, chronic mucus production, and fibrosis that all contribute to airway 
obstruction. Emphysema is characterized by tissue destruction of the parenchyma 
leading to loss of alveolar attachments. This can lead to loss of elastic recoil and 
hence to airway obstruction, but also contributes to a decreased surface area for 
oxygenation, which can lead to a disturbed diffusion capacity. The loss of alveolar 
tissue is also associated with a local inflammatory response. 
The pathogenesis of COPD encompasses three major injurious processes 
including an abnormal inflammatory response in the lungs and failure to resolve 
inflammation, a protease/antiprotease imbalance, and increased oxidative stress 
(oxidant/antioxidant imbalance), all contributing to persistent inflammation and 
ongoing lung matrix changes [6,7]. 
Proteases are produced by several inflammatory cells and can destroy matrix 
components of the lung, contributing to emphysema development. Important 
proteases linked with COPD are serine proteases e.g. neutrophil elastase, which 
is inhibited by al- antitrypsin (al-AT) and MMPs, in particular MMP-1, MMP-2, 
MMP-9 and MMP-12 [7-9]. 
Normally proteases are counteracted by antiproteases. Well known examples 
of antiproteases are al-AT, secretory leukoprotease inhibitor (SLPI) and tissue 
inhibitors of metalloproteases (TIMPs). Inherited al-AT deficiency leads to early 
onset emphysema and both al-AT and SLPI can be inactivated by cigarette 
smoke and oxidative stress [9,10]. The increased TIMP-1 secretion from alveolar 
macrophages in response to inflammatory stimuli is blunted in cells derived from 
COPD patients, and there is an increased frequency of loss-of-function mutations 
of TIMP-2 in COPD patients [9,10]. 
Oxidative stress is a well known feature of COPD. The main external sources 
of oxidative stress are environmental exposures like cigarette smoke and air 
pollution. Additional endogenous producers of oxidative stress are inflammatory 
cells like activated neutrophils, macrophages and eosinophils. Oxidants are 
counteracted by antioxidants, of which the glutathione system is thought to be 
the most important in the airways. An additional antioxidant mechanism in the 
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lung is the increase in HO-1 activity after oxidative stress, resulting in high levels 
of the antioxidant bilirubin [9-11]. 
Since the inflammatory response is the central outcome parameter in all studies 
that will be described in this thesis, we will discuss the different inflammatory and 
resident cell types involved in the inflammatory response in COPD below, which 
will be followed by a more extensive introduction of the involvement of NO2 
exposure and HO-1 expression in COPD. 
Epithelial cells 
The epithelium is the first line of defense of the airways. Mucus production by 
goblet cells and secretion of defensins is important in the protection against 
microbial infections and inhaled particles. On the other hand, increased mucus 
production, from goblet cell and bronchial glands hyperplasia contributes to 
airway obstruction [12]. Additionally, epithelial cells are an important source 
of inflammatory mediators, particularly when activated by cigarette smoke 
exposure [13-16] and will contribute to the inflammatory environment in COPD. 
Next to the production of inflammatory mediators, bronchial epithelial cells have 
been shown to exhibit an increased TGF-� production in smokers [17], which can 
contribute to the development of airway wall fibrosis. 
Neutrophils 
Neutrophils are an important component of the innate immune system, mediating 
the acute inflammatory responses against bacterial infections. Neutrophils 
contain granules filled with enzymes and proteases which play a role in the 
phagocytosis and destruction of microbes. During phagocytosis reactive oxygen 
species (ROS) are formed as well. Increased numbers of neutrophils have been 
found in bronchoalveolar lavage (BAL), sputum, bronchial glands, and airway 
smooth muscle of patients with COPD [4,18-21]. In contrast, only a few reports 
showed increased numbers of neutrophils in the airways or the parenchyma of 
patients with COPD [22,23]. 
Large numbers of activated neutrophils in the lungs can result in increased 
levels of ROS and proteases. The increase in ROS can shift the balance between 
oxidants and antioxidants, and the increase in proteases can shift the protease­
antiprotease balance, both in favour of lung destruction. Additionally, release 
of neutrophil elastase can stimulate macrophages to the release of even more 
ROS, causing epithelial damage and increased mucus production [24]. Neutrophil 
elastase itself can also directly stimulate mucus production by submucosal glands 
and goblet cells in the epithelium [25-27]. Both contribute to development of 
chronic bronchitis. 
Macrophages 
Like neutrophils, macrophages also are important regulators of the innate 
immune response against infections. Additionally, macrophages play a role in 
adaptive immunity by acting as antigen presenting cells producing cytokines and 
providing co-stimulation. 
Increased numbers of macrophages have been found in the airways, parenchyma, 
BAL, and sputum of patients with COPD [4,9,22,23]. Interestingly, macrophage 
13 
CHAPTER 1 
numbers in lung tissue have been shown to positively correlate with COPD 
severity [22,23]. 
Macrophages are thought to play an important role in COPD development 
as they are activated by cigarette smoking to secrete several inflammatory 
substances i.e. ROS, proteases, cytokines, and chemokines. Increased cytokine 
and chemokine production can lead to increased leukocyte recruitment and 
in turn to the production of pro-inflammatory cytokines, which contributes to 
the chronic inflammatory reaction ultimately leading to tissue remodelling with 
destruction of parenchyma and airway wall fibrosis. Additionally, macrophages 
also can produce TGF-� which contributes to the development of airway wall 
fibrosis [9,28]. 
Eosinophils 
The eosinophil is a granulocyte which is involved in allergic reactions and the 
protection against parasites. Increased numbers of eosinophils are often seen 
in asthma and allergic diseases. However, the relevance of eosinophils in the 
inflammatory response in COPD is uncertain. Nevertheless, increased eosinophil 
numbers have been reported in patients with COPD, and particularly so during 
exacerbations [29-31]. Furthermore, several eosinophilic products i.e. eosinophil 
cationic protein and eosinophil peroxidase can cause serious damage to the 
lungs, which may lead to inflammatory changes such as can be seen in COPD. 
B lymphocytes 
B lymphocytes are the key players of the adaptive immune system with respect 
to providing humoral immunity via the production of antibodies. 
Bosken et al [32] were the first to detect B lymphocytes organized in follicle-like 
structures in the airway adventitia of smokers. More recently, Hogg and coworkers 
more extensively assessed the inflammation in the small airways of patients with 
COPD [33]. They described increased numbers of small airways containing B 
lymphocytes together with a marked increase of small airways with lymphoid 
follicles in GOLD stage III-IV compared to stage 0-11. Recently our group has 
demonstrated an increase of B lymphocytes in the mucosa of large airways of 
COPD patients compared to controls [34]. However, the role, and thus relevance, 
of these B lymphocytes and lymphoid follicles in COPD remains unclear. 
We hypothesized that B lymphocytes contribute to the development of COPD by 
means of an antigen specific reaction. In order to test whether our hypothesis 
is tenable we studied the presence, organization, and clonality of these cells 
both in human lung tissue and in our mouse model of cigarette smoke-induced 
emphysema (chapter 4). 
T lymphocytes 
T lymphocytes are key players in the adaptive immune response with respect to 
regulation of cellular immunity. CD4+ T lymphocytes control immune responses to 
extracellular antigens and function as helper T lymphocytes. CDS+ T lymphocytes 
are involved in the response to intracellular microbes, i.e. viral, tumor, and certain 
microbial antigens, and function as cytotoxic T lymphocytes killing the cells that 
produce or harbor the foreign antigen. 
14 
INTRODUCTION 
Increased numbers of both CD4· and CDS· T lymphocytes are present in lung 
tissue of COPD patients, with a predominance of CDS· T lymphocytes [23,35-37]. 
In addition, the number of CDS· T lymphocytes is correlated with a decreased 
lung function [23,36]. One theory is that the increased recruitment of CDS· T 
lymphocytes may be a result of viral infections, which occur frequently in COPD 
patients [38]. Increased numbers of cos• T lymphocytes may then contribute to 
tissue damage by their release of perforins and granzyme-B. CD4· T lymphocytes 
may contribute to the inflammatory response in COPD by the production of 
several pro-inflammatory cytokines or by acting as helper cells, priming CDS· 
T lymphocytes responses or maintaining immunological memory. By this 
immunological memory CD4· T lymphocytes could possibly be involved in the 
perpetuation of the inflammatory response after smoking cessation. Interestingly, 
Sullivan et al showed the presence of oligoclonal CD4· T lymphocytes in lung 
tissue of patients with severe emphysema. This indicates the presence of an 
antigen-specific T lymphocyte-response in the lungs of these patients and a 
possible role for the adaptive immune system in COPD [39]. 
Regulatory T cells 
Regulatory T cells (Tregs) are a special subset of CD4· T lymphocytes, which are 
important in controlling immunological tolerance and preventing auto-immune 
reactions by inhibiting T-cell responses [40]. Additionally, Tregs can also directly 
suppress B cell responses without having to suppress the adjacent T cells [41], 
indicating that activated T cells are not the only target for Tregs. Dysfunction 
of Tregs can lead to auto-immune diseases, allergy, and chronic inflammatory 
diseases [40,42]. The currently best described subset of Tregs is that of the 
naturally occurring Tregs. Naturally occurring Tregs are generated in the thymus 
and express CD4, high levels of CD25 and Forkhead transcription factor 3 (Foxp3). 
The suppressive effects of Tregs are mediated by cell-cell contact and possibly 
also by HO-1 expression and membrane bound TGF� [43-45]. Tregs have been 
the subject of investigations in allergy and asthma [46]. However, very little is 
known so far about their contribution to the chronic inflammatory response in 
COPD. Until now, only three studies have assessed the presence of Tregs in COPD 
and reported different findings. The first showed decreased CD4·CD25· Tregs 
in lung tissue of emphysema patients compared to control subjects [47]. The 
second showed increased CD4·CD25b,ight Tregs in BAL from COPD patients and 
healthy smokers compared to healthy never smokers [48], and the third study 
showed increased CD4·CD25· Tregs in BAL of healthy smokers compared to 
COPD patients and never smokers [49]. Recently, we have found the presence 
of Foxp3 positive T cells as a component of lymphoid follicles in the lungs of 
patients with COPD (figure 1), which suggests a role for Tregs in controlling this 
local B cell response. 
In chapter 5 the presence and phenotype of Tregs and B cells in peripheral blood 
of COPD patients and healthy volunteers will be discussed. We hypothesize that 
the B-cell reaction in COPD is antigen driven and contributes to progression of 




Figure 1. Example of a single Foxp3(red) and double CD3(blue)/Foxp3(red) staining in a 
lymphoid follicle in a human COPD lung. Positive cells are indicated with an arrow. 
Nitrogen dioxide exposure and COPD 
As already described, next to cigarette smoking, other environmental exposures 
such as nitrogen dioxide (NO) may contribute to COPD development. N02 is 
an important air pollutant, that has been associated with increased respiratory 
symptoms and decreased lung function in humans [50-53] and with emphysema 
development in animal models [54-58]. N02 is mainly formed by the combustion 
of fossil fuels. Motor vehicle and industry emissions are important outdoor 
sources of N01, whereas indoor cooking and heating with fossil fuels and 
cigarette smoke are important indoor sources [59-62]. It is difficult to disentangle 
the separate effects of exposure to different air pollutants and/or cigarette 
smoke in epidemiologic studies, because individuals are never exposed to a 
single pollutant. To what extent environmental N02 exposure contributes to the 
development of COPD and can add to the noxious effects of smoking is largely 
unknown. It is known however, that N02 exposure can form nitrate, nitrite, and 
nitrous acid in the epithelial lining of the lungs. When combined with cigarette 
smoke exposure, hydroxyl radicals are formed, which are extremely reactive and 
cause increased oxidative stress in the lungs [38]. 
To gain more insight into the contribution of N02 exposure to COPD development 
we studied the effects of N02, cigarette smoke, and their combined exposure on 
pulmonary inflammation and emphysema development in mice. We hypothesized 
that combined exposure to N02 and cigarette smoke would enhance pulmonary 
inflammation and emphysema development in mice. In chapter 2 the short term 
and in chapter 3 the long term effects of N02 and cigarette smoke exposure and 
their interaction are described. 
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Heme oxygenase-1 and COPD 
An intriguing protein that may play a role in COPD development is the 'protective' 
enzyme heme oxygenase-1 (HO-1). HO-1 is the rate limiting enzyme involved in 
the breakdown of heme to equimolar amounts of bilirubin, free iron and carbon 
monoxide (CO). HO-1 is a stress response protein, which is rapidly upregulated 
after oxidative stress and has potent anti-oxidative, anti-inflammatory, anti­
apoptotic and anti-proliferative effects [11,63,64]. The anti-inflammatory 
and cytoprotective effects of HO-1 are mediated by its products, of which in 
particular CO [65-67]. CO is a molecule with potent anti-inflammatory effects; in 
vitro and in vivo CO has been shown to inhibit LPS (lipopolysaccharide) induced 
TNF-a and IL-1� production, while increasing the IL-10 production [65]. The 
antioxidative effects are mainly mediated by the production of bilirubin, a well 
known antioxidant [8]. 
Notwithstanding this knowledge, the exact mechanisms behind the protective 
effects of HO-1 are still poorly understood. 
Interestingly, in patients with COPD, a reduced HO-1 expression has been shown 
in macrophages in lung tissue and bronchoalveolar lavage (BAL) [68,69]. One of 
the possible explanations could be a genetic polymorphism in the HO-1 promoter 
gene, which is associated with a lower induction of HO-1 by reactive oxygen 
species (ROS) and is associated with emphysema development in a Japanese 
population [70]. 
We hypothesize that in COPD patients HO-1 is insufficiently upregulated leading 
to a higher vulnerability to the effects of cigarette smoke and oxidative stress. 
In chapter 6 we tested whether HO-1 modulation in our smoking mouse model 
could influence the development of cigarette smoke-induced emphysema and 
lung inflammation. We hypothesized that HO-1 induction attenuates cigarette 
smoke induced emphysema and inflammation and conversely HO-1 inhibition 
worsens the noxious effects of cigarette smoke. 
Subsequently, we developed a new non-invasive method for HO-1 induction in 
mice, which is described in chapter 7. 
Finally, all results described in this thesis are summarized and discussed in chapter 
8, with a perspective to the future. 
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Smoking is recognized as the most important cause for development of COPD. 
Other factors have to be involved as well, since some non-smokers and only a 
minority of smokers develops COPD. The air pollutant nitrogen dioxide (N02) is 
associated with respiratory symptoms and with emphysema in animal models. 
We hypothesized that N02 interacts with cigarette smoke to enhance pulmonary 
inflammation. This was studied in mice that were exposed to 40 puffs of cigarette 
smoke in 2.5 hours, 25 ppm N02 for 3 hours, or 25 ppm N02 for 3 hours followed 
by 40 puffs of cigarette smoke, or to air. 
N02 exposure increased the levels of several pro-inflammatory cytokines and the 
numbers of eosinophils and neutrophils, and decreased levels of IL-10. Cigarette 
smoke exposure increased the numbers of macrophages and T cells, and the levels 
of IL-6, MCP-1, and GMCSF. Interestingly, the N02 induced cytokine production 
was abolished when N02 exposure was followed by cigarette smoke exposure. In 
an additional experiment, we showed that these effects can partly be mimicked 
by carbon monoxide, a component of cigarette smoke. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a leading cause of death 
worldwide and its morbidity and mortality are rising. Although the pathogenesis 
of the disease is still largely unknown, smoking is widely accepted as the most 
important cause for the development of the disease in the industrialized world. 
The majority of patients with COPD are current or ex smokers, yet only a minority 
of smokers eventually develops COPD. The factors causing these individuals to 
develop COPD are currently largely unknown. 
Since not all COPD patients have smoked, cigarette smoke cannot be the 
sole contributing factor to disease development. Environmental factors may 
contribute as well and the air pollutant NO2 is such a factor, known to be capable 
of inducing respiratory symptoms. NO2 is mainly formed by the combustion of 
fossil fuels. Motor vehicle and industry emissions are important outdoor sources 
of NO2, whereas cooking and heating with fossil fuels and cigarette smoke are 
important indoor sources [1-4]. Different epidemiological studies have shown 
associations between environmental pollution, NO2 exposure, and level of lung 
function [5-7]. A recent study showed that increased environmental NO2 exposure 
is associated with a reduced growth in forced expiratory volume in one second 
(FEV1) in childhood [6] and Ponka et al described a positive association between 
levels of environmental NO2 and numbers of emergency room admissions for 
COPD exacerbations [7]. 
In vitro and in vivo studies in mice and humans have shown that acute NO2 
exposure results in increased levels of the inflammatory cytokines TNF-a, IL-1�, 
IL-6, IL-8 and RANTES together with an increased expression of heme oxygenase-
1 (HO-1) and inducible nitric oxide synthase (iNOS) [8-11]. Although chronic 
exposure to NO2 has been shown to induce emphysema in some animal models 
[12-14] it is uncertain whether NO2 exposure alone is sufficient to elicit full-blown 
emphysema in humans. 
To provide more information on the first processes that initiate COPD and the 
role of environmental pollution, especially NO2 exposure, in relation to cigarette 
smoke in this process, we studied the short-term effects of cigarette smoke and 
NO2 exposure; either alone or in combination in mice. We hypothesized that NO2 
and cigarette smoke interact to enhance pulmonary inflammation. 
Methods 
Animals 
Female A/J mice (aged 8-10 weeks) were obtained from Harlan (Horst, the 
Netherlands) and were held at the Central Animal Facility of the University of 
Groningen. The experiments were approved by the local Committee on Animal 
Experimentation and were performed under strict governmental and international 




Four groups of mice (n=8 per group) were exposed to either 1) 40 puffs of 
cigarette smoke in 2.5 hours, 2) 25 ppm NO2 for 3 hours, 3) 25 ppm NO2 for 3 
hours followed by 40 puffs of cigarette smoke in 2.5 hours, or 4) air. The mice 
were sacrificed seventeen hours after exposure. The left lung was removed, lung 
cells were isolated and used for flow cytometric analysis; the right lung was partly 
snap-frozen or Nakane-fixed and kept at -80°C until it was used for histology, 
cytokine and western blot analyses. Nakane fixation was used to obtain a better 
morphology for histology [15]. 
Smoke exposure 
The smoke exposure system of the Tobacco and Health Research Institute of 
the University of Kentucky was used for the nose-only exposure of mice to 
mainstream smoke. The system was set up according to the instructions of the 
manufacturer for generation of mainstream smoke [16,17]. The smoking machine 
was checked for the delivery of total particulate matter (TPM) as described by 
Griffith et al. and calibrated before every smoking session to ensure accurate 
and standardized smoke delivery. The mice were placed in restrainers and 
subsequently exposed to 40 puffs of cigarette smoke from 4 2Rl Reference 
Cigarettes (University of Kentucky) during 2.5 hours. Control mice were sham­
exposed in a separate animal exposure unit, which was placed under similar but 
smokeless circumstances. These mice were exposed to room air for the same 2.5 
hours the smoke exposure took. 
NO2 exposure 
The NO2 exposure system was developed in co-operation with the National 
Institute of Public Health and the Environment (RIVM, Bilthoven, the Netherlands). 
The mice were placed in mesh cages within an airtight box, with a continuous 
flow (5.5 m3/hr) of NO2• The desired NO2 concentration of 25 ppm was generated 
by diluting liquid NO2 with compressed air. The NO2 concentration was measured 
using a nitrogen oxides analyzer (Eco Physics CLD 700AL, CleanAir, Marseille, 
France) and was kept at the desired range of 25 ppm +/- 10%. The mice were 
exposed to NO2 for 3 hours. Control mice received the same treatment as NO2 
exposed mice; they were exposed to room air in similar mesh cages and in parallel 
with the NO7 exposure. During the exposure mice freely moved and had access 
to water and standard rodent food ad libitum. 
Cytokines 
Frozen lung tissue was homogenized 5 or 10% w/v in a 50 mM Tris-HCI buffer, 
containing 150 mM NaCl, and 0.002% Tween-20 (pH 7.5) and centrifuged at 
12000xg for 10 min to remove any insoluble material. Concentrations of murine 
I L-1�, IL-5, IL-6, IL-9, IL-10, IL-13, monocyte chemoattractant protein-1 (MCP-1), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), RANTES and TNF­
cx in lung homogenate were measured with a multiplex ELISA system (Lincoplex 
Systems, St Charles, USA). 
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Flow cytometry 
Single-cell leukocyte suspensions were obtained from lungs for flow cytometric 
analysis as described previously [18]. Cells were quantified using a Coulter Counter 
Zl (Coulter, Hialeah, USA). Expressions of CD3, CD4, CD25, and 8220 cell surface 
markers on isolated leukocytes were examined with four-color flow cytometry to 
determine frequencies of B cells and T-cell subsets. The leukocytes were stained 
with a combination of directly conjugated antibodies directed against these cell 
surface markers as described previously [18]. All antibodies were obtained from 
Pharmingen (San Diego, USA) and were conjugated with one of the following 
fluorochromes: FITC, phycoerythrin (PE), peridinin chlorphyll protein (PerCP), 
and allophycocyanin (APC). Frequencies of B cells and T-cell subsets were based 
on the label combinations: CD3-APC, CD4-PE, 8220-PerCP, and CD25-FITC. Cell 
populations (4 x104 events) were analyzed using an Epics Elite flow cytometer 
(Coulter Epics, Hialeah, USA) and data analysis was performed using FlowJo 
software (ThreeStar, San Carlos, USA). 
Histology 
Eosinophil numbers were determined in 4 µm sections of frozen lung tissue 
by staining for cyanide resistant endogenous peroxidase activity with 
diaminobenzidine (Sigma-Aldrich, St. Louis, USA). Neutrophil and macrophage 
numbers were identified in 4 µm sections of Nakane-fixed frozen lung tissue 
with the rat monoclonal antibodies anti-GRl (Pharmingen) and anti-Mac3 
(Pharmingen) respectively. Eosinophils and macrophages were quantified by 
morphometric analysis and expressed as volume percentages [18]. Total numbers 
of neutrophils were scored and expressed as numbers of GRl positive cells per 
microscopic field. 
NO2 + CO experiment 
In order to unravel the dampening effects of cigarette smoke exposure on the 
NO2 induced inflammation, we performed an additional, similar, experiment 
with carbon monoxide (CO) exposure. CO was chosen since it is known to have 
potent anti-inflammatory capacities [19], and is present in high concentrations in 
cigarette smoke [20]. 
Four groups of mice (n=8 per group) were exposed to either 1) 250ppm CO for 
3 hours, 2) 25 ppm NO2 for 3 hours, or 3) 25 ppm NO2 for 3 hours followed by 
250ppm CO for 3 hours, or 4) air. Mice were sacrificed after exposure and lung 
tissue was snap-frozen and kept at -80°C until it was used for cytokine analyses. 
CO exposure 
The mice were placed in a Plexiglas exposure chamber (5 liters) with a continuous 
flow of 250 ppm +/- 10% CO. Mice were exposed for 3 hours and could freely 
move during exposure. Control mice received the same treatment as CO exposed 
mice; they were exposed to room air in a similar exposure chamber and in parallel 




Multiple linear regression analysis was used to establish the statistical 
significances of differences in terms of NO2, cigarette smoke and CO exposure for 
each parameter. This method disentangles the separate effects of NO2, cigarette 
smoke, CO, and their interactions. A significant interaction signifies that the 
effect of the combination is different (larger or smaller) than the addition of the 
separate effects of the exposures. When the interaction was not significant, the 
regression analysis was performed again without this interaction term. The normal 
distribution of the residuals was tested with a Kolmogorov-Smirnov test and data 
were log -, -x2, or 1/x-transformed when needed to normalize distributions. A 
value of p<0.05 was considered significant. Mann Whitney U tests were used for 
post-hoc analysis to test whether NO2 exposure alone differed from NO2 + CS or 
NO2 + CO exposure. 
Results 
Effects of short-term NO2 exposure on the presence of cytokines and 
inflammatory cells in the lung 
Short-term NO2 exposure significantly increased the levels of the pro-inflammatory 
mediators TNF-a, IL-1�, and IL-6, and of the cytokines involved in the recruitment, 
activation and d ifferentiation of eosinophils like IL-5, IL-9, IL-13, RANTES, and MCP-
1 in lung tissue (Figure 1 and Table 1). In addition, NO2 exposure decreased the 
level of the anti-inflammatory cytokine IL-10. With respect to inflammatory cells, 
short-term NO2 exposure increased the numbers of eosinophils and neutrophils 
in lung tissue (Figure 2A,B), but had no effect on the numbers of macrophages 
(Figure 2C), T cells, and B cells (Table 2). 
Table 1: Cytokine protein levels in lung homogenate after N02 and cigarette smoke 
exposure. 
Cytokines Values P-values 
(pg/g lung 
tissue) 
Control cs NO, NO, + CS cs effect NO, effect cs NO, X 
interaction 
TNF-a 2.4+/-0.2 2.4+/-0.1 5.4+/-0.4 2.B+/-0.2 • n.s. < 0.01 i < 0.01 .j. 
IL-113 8.0+/-1.0 8.0+/-0.6 16.7+/-l.3 9.1+/-1.1 • n .s .  < 0.01 i < 0.01 .j. 
IL-9 * 30,6+/-11.4 25.8+/-l.0 90.l+/-11 .3 25.B+/-2.7 • n .s.  < 0.01 i < 0.01 .j. 
IL-13 9.3+/-0.7 8.B+/-0.3 12.0+/-0.5 B.4+/-0.8 • n.s. < 0.01 i < 0.01 .j. 
IL-10 96.6+/·14.1 104.0+/-7.6 60.1+/-B.7 130.0+/-ll . 1  • n .s .  < 0.05 .j. < 0.01 i 
GM-CSF * 12.8+/-3 37.9+/-15.3 10.4+/-0.4 21 .4+/-3.4 < 0.01 < 0.05 .j. n.s. 
Values expressed as mean +/- standard error of the mean (SEM). * indicates that the data were nat 
normally distributed and geometric mean +/- SEM is depicted. P-value <0.05 is considered significant. 
The orraws indicate the direction of the effect. A significant interaction signifies that the value in the 
group that received both N01 and cigarette smoke is either significantly greater (arrow pointing up) 
or significantly smaller (arrow pointing down) than the added effects of N02 and cigarette smoke. # 
indicates a significant difference between N01 exposure and N01 + CS exposure. CS "' cigarette smoke 
exposure. n.s. = not significant. 
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Effects of short-term cigarette smoke exposure on the presence of 
inflammatory cells and cytokines in the lung 
Short-term cigarette smoke exposure increased the numbers of macrophages 
(Figure 2(), CD4+ T cells, CD4+CD25+ T cells, and CD8+ T cells in lung tissue, with a 
trend for an increase in B cells (Table 2). Smoking had no effect on the numbers 
of neutrophils and eosinophils in lung tissue (Figure 2A,B). Additionally, smoking 
significantly increased the levels of IL-6, MCP-1 and GM-CSF in lung tissue (Figure 
1 and Table 1). 
Short-term cigarette smoke exposure abolishes N02 induced cytokine 
production 
There were significant negative interactions between the effect of NO2 exposure 
and the effect of cigarette smoke exposure for the levels of TNF-a, IL-1�, IL-5, 
IL-6, IL-9, IL-13, RANTES, and MCP-1 in lung tissue (Table 1 and Figure 1). These 
interactions are the result of increased cytokine levels after NO2 exposure alone 
and the lack of such an effect in animals exposed to the combination of NO2 and 
cigarette smoke (NO2 vs. NO2 + CS, p< 0.05). Additionally, there was a significant 
positive interaction between the effect of NO2 exposure and the effect of cigarette 
smoke exposure for the level of IL-10, which is caused by a decrease in IL-10 after 
NO2 exposure alone and an increase in animals exposed to the combination of 
NO2 and cigarette smoke (Table 1) (NO2 vs. NO2 + CS, p< 0.05). These interactions 
signify that the effect of NO2 exposure on cytokine production was different 
when it was followed by cigarette smoke exposure. Smoking had no significant 
dampening effect on the NO2 induced increase in numbers of eosinophils and 
neutrophils in the lung (Figures 2A,B). 
Table 2: Lymphocytes in lung homogenate after NO2 and cigarette smoke 
exposure. 
Lymphocytes Values P-values 
(cell numbers 
per mg lung 
Control cs NO, NO, + CS CS effect NO, effect cs NO2 tissue) X 
Interaction 
CD4· T cells 518+/-71 .5  733+/-96.5 616+/-98.7 968+/-192.9 < 0.05 t n.s. n.s. 
CD4•CD25• 25.5+/-5.0 42.3+/-7.3 29.2+/-4.7 57.6+/-10.1 < 0.01 t n.s. n.s. 
T cells 
CDS• T cells 239+/-33.1 401+/-50.3 334+/-64.4 480+/-99.2 < 0.01 t n.s. n.s. 
B cells 872+/-139 1373+/-216 1275+/-247 1792+/-391 p=0.06 t n.s. n.s. 
Values expressed as mean +/- SEM. P-value <0.05 is considered significant. The arrows indicate the 
direction of the effect. CS = cigarette smoke exposure. n.s. = not significant. 
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Effects of short-term CO exposure on inflammatory cytokines in lung 
tissue 
To investigate whether the inhibitory effects of cigarette smoke exposure could 
be explained by the presence of CO in cigarette smoke, the model was repeated 
with CO exposure instead of cigarette smoke exposure. CO exposure inhibited 
the NO2 induced increase in the level of MCP-1 in lung tissue (NO2 vs. NO2 + CO, 
p< 0.05), but had no effects on NO2 induced increases in the levels of IL-6 and IL-5 
(Figure 3). Additionally CO exposure decreased the levels of MCP-1 and RANTES, 
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Figure 1. Cytokines in lung homogenate a�er NO2 and cigarette smoke exposure. 
MCP-1, /L-6, /L-5 and RANTES levels expressed as pg/g lung homogenate after NO2 and 
cigarette smoke exposure. # indicates a significant difference between NO2 exposure and 
NO2 + CS exposure. Results of the regression analysis are depicted beneath the figures. 
CS = cigarette smoke exposure. n.s. = not significant 
Discussion 
In this study we showed that short-term NO2 exposure elicits increased levels of 
pro-inflammatorycytokines in the lung, while short-term cigarette smoke exposure 
elicits increased numbers of inflammatory cells in the lung. Intriguingly, the NO2 
induced cytokine production was completely abolished when NO2 exposure was 
followed by short-term cigarette smoke exposure. We demonstrated that this 
can partly be explained by CO, which is present in cigarette smoke. 
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There was a negative interaction between short-term NO2 and cigarette smoke 
exposure with respect to levels of pro-inflammatory cytokines (TNF-a, Il­
l� and IL-6) and cytokines involved in eosinophil recruitment, activation and 
differentiation (IL-5, IL-9, IL-13, RANTES, and MCP-1). These negative interactions 
are in contrast to our original hypothesis, i.e. NO2 and cigarette smoke interact 
positively to enhance pulmonary inflammation. However, these unexpected 
results are in line with more recently published data in which we and others 
have shown dampening effects of smoking on ovalbumin (OVA)-induced airway 
inflammation in mice [21,22]. 
A possible explanation for the 'down regulatory' effects of cigarette smoke on 
the NO2-induced inflammatory response is the presence of anti-inflammatory 
molecules in cigarette smoke, e.g. carbon monoxide (CO), nitric oxide (NO) [23] 
and nicotine [24-26]. CO is present in high concentrations in cigarette smoke and 
can also be produced locally in the lung by heme oxygenases (HO). 
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Figure 3: Cytokines in lung homogenate after N02 and CO exposure. 
MCP-1, /L-6, IL-5 and RANTES levels expressed as pg/g lung homogenate after NO2 and 
CO exposure. # indicates a significant difference between NO2 exposure and NO2 + CO 
exposure. Results of the regression analysis are depicted beneath the figures. n.s. = not 
significant 
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CO is a molecule with potent anti-inflammatory effects. It has been shown to 
inhibit lipopolysaccharide (LPS) induced TNF-a and IL-1� production in vitro 
and in vivo, while it increased IL-10 production [19]. This is compatible with the 
effects on cytokine production we found after exposing mice to NO2 followed 
by cigarette smoke, i.e. a decrease in TNF-a and IL-1� levels together with an 
increase in IL-10. 
To investigate whether CO was involved in the inhibitory effects of cigarette 
smoke in our model, the experiment was repeated with CO instead of cigarette 
smoke exposure. In this experiment we focused on the effects of CO exposure 
on cytokine levels. CO exposure inhibited the NO2 induced increase in the levels 
of MCP-1, which is in accordance with the results found after smoke exposure. 
However, CO exposure had no effect on NO2 induced increases in the levels of 
IL-5 and IL-6. Therefore, the 'down regulatory' effects of cigarette smoke can only 
partly be explained by the presence of CO in cigarette smoke. Nevertheless, CO 
exposure decreased the levels of MCP-1, RANTES, and IL-5, showing the anti­
inflammatory capacity of CO. 
In this model, short-term NO2 exposure increased the levels of the pro­
inflammatory cytokines TNF-a, IL-1� and IL-6. These results correspond with 
human in vitro and in vivo studies showing that acute NO2 exposure results 
in increased levels of TNF-a, IL-1�, IL-6 and IL-8 [9-11]. After short-term NO2 
exposure, we also found increased levels of the cytokines IL-5, IL-9, IL-13 and 
chemokines RANTES and MCP-1 together with increased numbers of eosinophils 
in the lung. These results are similar as found in other studies assessing short­
term NO2 exposure. RANTES was shown to be increased in bronchial epithelial 
cells of asthmatic subjects after short-term NO2 exposure [27] and IL-5 and IL-13 
were shown to be increased in the epithelium of healthy human airways after 
repeated NO2 exposure [28]. Additionally, short-term NO2 exposure increased 
mRNA expression of RANTES, eotaxin, MIP-la, MIP-2, interferon-y-inducible 
protein-10 (IP-10) and MCP-1 in mice [8] and overexpression of IL-9 together with 
IL-9 induced chemokine expression (i.e. eotaxin, MIP-la, MCP-1, -3 and -5) was 
described to be associated with airway eosinophilia [29-31]. 
In this model, the numbers of macrophages, CD4+ T cells, CD4+CD2S· T cells and 
CD8+T cells increased in the lung after short-term cigarette smoke exposure. This 
increased cellular influx after cigarette smoke exposure is compatible with other 
studies assessing the effects of short-term smoke exposure in mice. Increased 
numbers of macrophages have been shown in bronchoalveolar lavage (BAL) after 
one day exposure [32,33]. Effects on numbers of lymphocytes were not reported 
in these one day studies. However, increased numbers of lymphocytes in BAL and 
increased numbers of activated CD4 and CDS T cells in lung tissue were shown 
after 1-or 2-week smoke exposure [34,35]. In contrast to other in vivo models of 
acute cigarette smoke exposure [32,34,36], we did not find increased neutrophil 
numbers after cigarette smoke exposure. This difference in effect on neutrophils 
can be explained by different time points of assessment i.e. 17 hours after exposure 
in our study versus 24 hours in the others. Our study also differed with respect to 
measurement of inflammatory cells in different lung compartments (lung tissue 
versus BAL fluid), and with respect to the mouse strain (AJ vs. C57BL/6). The latter 
is important as it has now been shown that susceptibility to cigarette smoke 
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induced lung inflammation and emphysema development is strain dependent 
in mice [37]. 
In conclusion, we showed strong, but different, inflammatory responses after 
short-term NO2 and cigarette smoke exposure in mice. After long term exposure, 
both might contribute to the development of COPD. In contrast to our original 
expectation, most of the inflammatory effects of NO2 exposure were abolished 
when NO2 exposure was followed by cigarette smoke exposure. Since COPD is a 
chronic disease, clinically manifest after 20 years of smoking, we suggest that after 
chronic exposure, as opposed to our one-day exposure, the initial dampening 
effects of cigarette smoke will be gone and the combination of cigarette smoke 
and NO2 will cause increased airway inflammation and enhanced development 
of COPD. 
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CHAPTER 3 
Abstract 
Cigarette smoke is the most important cause for the development of chronic 
obstructive pulmonary disease (COPD). Since only a minority of smokers and 
some nonsmokers develop COPD, other factors must be involved as well. NO2 is 
an important air pollutant associated with respiratory symptoms in humans and 
emphysema development in animal models. We hypothesized that combined 
exposure to NO2 and cigarette smoke will enhance pulmonary inflammation and 
emphysema development. Mice were exposed to 20 ppm NO2 for 17 h/day, to 24 
puffs of cigarette smoke 2 times per day, to their combination, or to control air for 
5 days/wk during 4 wk. Following the last NO2 exposure and within 24 h after the 
last smoke exposure the mice were sacrificed. Lungs were removed and analyzed 
for several inflammatory parameters and emphysema. Cigarette smoke exposure 
increased eosinophil numbers and levels of tumor necrosis factor (TNF)-a, KC, 
monocyte chemoattractant protein (MCP)-1, and interleukin (IL)-6. NO2 exposure 
increased goblet cells, eosinophils, and the levels of IL-6, while it decreased the 
levels of IL-10. Four weeks of NO2, cigarette smoke, or their combination was 
not sufficient to induce significant emphysema, nor did it lead to increased 
numbers of lymphocytes, neutrophils, or macrophages in lung tissue. Instead, 
NO2 exposure attenuated the smoke-induced increases in levels of TNF-a, KC, 
and MCP-1. These dampening effects of NO2 may be due to modulating effects 
of NO2 on cytokine production by macrophages and epithelial cells, which have 
been reported earlier. The next step is to translate these findings of combined, 
controlled exposure in animals to the human situation. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a major global health problem 
with an increasing morbidity and mortality [1]. In western countries smoking is 
widely accepted as the most important cause for the development of the disease, 
still only a minority of the smoking population eventually develops COPD and 
the factors causing these individuals to develop COPD are currently unknown. 
Besides smoking, other factors that may contribute to COPD development are 
genetic factors, such as al anti-trypsin deficiency, and environmental factors like 
air pollution. 
Animal models for COPD are crucial to explore the underlying mechanisms of the 
inflammatory response in COPD. Several models have been tested in the past, 
using different species and different experimental approaches [2,3]. Since cigarette 
smoking is considered the most important risk factor for COPD development, in 
particular smoke inhalation models have been used to study COPD pathogenesis 
[4-10]. Whole body and nose only smoke exposure models have been described 
and a minimum exposure period of 4 to 6 months was shown to be necessary 
to induce significant emphysema development, which is quite a long period for 
animal models. In addition to cigarette smoke, other inhalation atmospheres 
have been employed in the development of inhalation models for COPD as well, 
among them nitrogen dioxide (NOJ N02 is an important environmental air 
pollutant, and is associated with increased respiratory symptoms and decreased 
lung function in humans [11-14] and with emphysema development in animal 
models [15-19]. 
In epidemiologic studies it is difficult to disentangle the separate effects of 
exposure to different air pollutants and/or cigarette smoke, because people are 
never exposed to a single pollutant. To what extent environmental N02 exposure 
contributes to the development of COPD and can add to the noxious effects of 
smoking is therefore largely unknown. Nevertheless, N02 exposure is known to 
form nitrate, nitrite, and nitrous acid in the epithelial lining of the lungs. When 
combined with smoke exposure, hydroxyl radicals are formed, which are extremely 
reactive and cause oxidative stress in the lungs [20]. To gain better insight into 
the contribution of N02 exposure to COPD development, we studied the effects 
of combined N02 and cigarette smoke exposure on pulmonary inflammation and 
emphysema development in mice. For this purpose mice were exposed for four 
weeks to N02 and cigarette smoke separately or to the combination of both 
agents. We hypothesized that combined exposure to N02 and cigarette smoke 
enhances pulmonary inflammation and emphysema development. 
Methods 
Animals 
Female A/J Ola HSD mice (aged 8-10 weeks), which are known to be sensitive 
to the effects of cigarette smoke [8,10], were obtained from Harlan (Horst, the 
Netherlands) and were held at the Central Animal Facility of the Groningen 
University. The experiments were approved by the local Committee on Animal 
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Experimentation and were performed under strict governmental and international 
guidelines on animal experimentation. 
Study design 
Four groups of mice (n=12 per group) were exposed to either 1) air, 2) 24 puffs of 
cigarette smoke twice daily, 5 days a week, 3) 20ppm NO2 continuously from 3pm 
until 8am, 5 days a week, or 4) 20ppm NO2 continuously from 3pm until 8pm in 
combination with 24 puffs of cigarette smoke twice daily, 5 days a week. 
Following the last NO2 exposure and within 24 hours after the last smoke exposure 
the mice were sacrificed. The trachea was cannulated, the right lung was ligated, 
and lung lobes were either snap-frozen and stored at -80°C (n=8) or used directly 
for flow cytometry analysis (n=8). The left lung was inflated, and fixed for 24h 
with formalin with a constant pressure of 25 cm Hp (n=8). 
NO1 exposure 
The NO2 exposure system was developed in collaboration with the National 
Institute of Public Health and the Environment (RIVM, Bilthoven, the Netherlands). 
The mice were placed in mesh cages within an airtight box, with a continuous 
flow (5.5 m3/hr) of NO2• The desired NO2 concentration of 20ppm was generated 
by diluting liquid NO2 with compressed air. The NO2 concentration was measured 
using a nitrogen oxides analyzer (Eco Physics CLD 700AL, CleanAir, Marseille, 
France) and was kept at the desired range +/- 10%. The mice were exposed to NO2 
continuously from 3pm until 8am, 5 days a week, for a period of 4 weeks. Control 
mice received the same treatment as NO2 exposed mice; they were exposed to 
room air in similar mesh cages and in parallel with the NO2 exposure. During the 
exposure mice could freely move and had access to water and standard rodent 
food ad libitum. 
Smoke exposure 
The smoke exposure system of the Tobacco and Health Research Institute of 
the University of Kentucky was used for the nose only exposition of mice to 
mainstream smoke. The system was set up according to the instructions of the 
manufacturer for generation of mainstream smoke [21,22). The standard puffing 
regimen of 35ml puffs of 2.1 sec. taken once a minute was used and the cigarette 
smoke was diluted 1:1 with fresh air before exposure. The smoking machine 
was checked for the delivery of total particulate matter (TPM) as described by 
Griffith et al. and calibrated before every smoking session to ensure accurate 
and standardized smoke delivery. Average TPM values ranged between 38 
and 40 mg per cigarette. Actual smoke exposure was assessed by measuring 
carboxyhemoglobin levels, which ranged from 15-35 % immediately after smoke 
exposure. The mice were placed in restrainers and subsequently exposed to 
24 puffs of cigarette smoke from two 2Rl Reference Cigarettes (University of 
Kentucky, unfiltered, containing 32.9 mg tar and 2.19 mg nicotine per cigarette) 
two times per day, 5 days a week, for a period of 4 weeks. Control mice were 
sham-exposed in a separate animal exposure unit, which was placed under similar 
but smokeless circumstances. These mice were exposed to room air for the same 
24 minutes the smoke exposure took. 
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Morphometrical evaluation of emphysema 
Three-micron paraffin sections were cut and stained with haematoxylin and 
eosin. Approximately 25-30 photo microscopic images per tissue section were 
prepared at 2.5x20 magnification using a standardized sequence of image 
capturing. Alveolar airspace enlargement was assessed by mean linear intercept 
(Lmi) by two independent individuals in a blinded manner [23]. Images with large 
vessels, conducting airways or pleura occupying 25% or more of the total image 
were not used. 
Flow cytometric analysis 
Single-cell leukocyte suspensions were obtained from lungs for flow cytometric 
analysis as described previously [24]. Leukocytes were stained with a combination 
of directly conjugated antibodies directed against the following cell surface 
markers CD4-PerCP, CD25-FITC, B220-APC, and Grl-APC to determine the 
frequencies of different T-cell subsets, B cells, and neutrophils. All antibodies were 
obtained from Pharmingen (San Diego, USA). Cell populations (4 x104 events) 
were analyzed using an Epics Elite flow cytometer (Coulter Epics, Hialeah, FL) and 
data analysis was performed using FlowJo software (ThreeStar, San Carlos, CA). 
Histology 
Macrophage numbers were identified in 3 µm sections of paraffin embedded 
lung tissue with the rat monoclonal antibody anti-Mac3 (Pharmingen). Eosinophil 
numbers were determined in 4 µm sections of frozen lung tissue by staining 
for cyanide resistant endogenous peroxidase activity with diaminobenzidine 
(Sigma-Aldrich, St. Louis, USA). Eosinophils and macrophages were quantified by 
morphometric analysis and expressed as volume percentages [24]. Goblet cells 
were determined in 3 µm sections of paraffin embedded lung tissue by a Periodic 
Acid Schiff (PAS) staining. The total number of PAS positive cells was counted and 
expressed per mm airway, as determined by morphometric analysis. 
Cytokines 
Frozen lung tissue was homogenized in 50 mM Tris-HCI buffer, containing 150 
mM NaCl, and 0.002% Tween-20 (pH 7.5) and centrifuged at 12000xg for 10 min 
to remove any insoluble material. Concentrations of TNF-a, IL-6, KC (mouse IL-
8), IL-10, and MCP-1 (monocyte chemoattractant protein-1) in the supernatants 
were measured with a multiplex ELISA system (Lincoplex Systems, St Charles, MO, 
USA). 
Statistics 
Multiple linear regression analysis was used to establish the statistical 
significances of differences in terms of NO2 and cigarette smoke exposure for 
each parameter. This method disentangles the separate effects of cigarette 
smoke and NO2 and their interaction. A significant interaction signifies that the 
effect of the combination is different (larger or smaller) than the addition of 
the separate effects of the exposures. When the interaction was not significant, 
the regression analysis was performed again without this interaction term. The 
normal distribution of the residuals was tested with a Kolmogorov-Smirnov test 
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and data were log -or 1/x-transformed when needed to normalize distributions. 
A value of p<0.05 was considered significant. 
Results 
Effects of N02 and/or cigarette smoke exposure on inflammatory cells in 
the lung 
Both cigarette smoke (p< 0.05) and NO2 (p< 0.01) exposure increased the numbers 
of eosinophils in lung tissue (Figure 1). Additionally, there was a significant 
negative interaction between NO2 and smoking (p< 0.01) caused by a decreased 
number of eosinophils in the mice that were exposed to both NO2 and cigarette 
smoke, when compared to NO2 exposure alone. 
NO2 exposure increased the numbers of goblet cells, while there was no effect of 
smoking and no interaction between smoking and NO2 exposure (Figure 2, p< 
0.05). 
Both NO2 and/or cigarette smoke exposure had no effects on the numbers of 
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Figure 1. Eosinophils expressed as volume 
percentages after subchronic NO2 and/or 
cigarette smoke exposure. Results of the 
regression analysis are depicted beneath 
the figures. CS: cigarette smoke. 
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Figure 2. Goblet cell numbers per mm 
airway after subchronic NO2 and/or 
cigarette smoke exposure. Results of the 
regression analysis are depicted beneath 
the figures. CS: cigarette smoke. n.s. = 
not significant. 
Effects of N02 and/or cigarette smoke exposure on cytokine levels in the 
lung 
Cigarette smoke exposure significantly increased the levels of TNF-a, KC, and 
MCP-1 in lung homogenate (p< 0.01), while NO2 exposure had no effects on 
these cytokines (Figure 3). Additionally, NO2 exposure significantly decreased 
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Figure 3. TNF-a, KC, MCP-1, /L-10, and /L-6 levels expressed as pg/g lung homogenate 
after subchronic NO 1 and/or cigarette smoke exposure. Results of the regression analysis 
are depicted beneath the figures. CS: cigarette smoke. n.s. = not significant. 
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the levels of the anti-inflammatory cytokine IL-10 (p< 0.05) and both NO2 and 
cigarette smoke exposure increased the levels of IL-6 (p< 0.05). 
There was a significant negative interaction between NO2 exposure and smoking 
for the levels of TNF-a and KC (p< 0.01) and a trend for MCP-1 (p=0.07), which 
was caused by the increased cytokine levels after cigarette smoke exposure and 
the lack of such an effect in the mice that were exposed to both NO2 and cigarette 
smoke. 
Effects of NO2 and/or cigarette smoke exposure on emphysema 
development 
Four weeks of exposure to NO2, cigarette smoke or their combination was not 
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Control cs NO2 NO2 + CS 
Figure 4. Mean linear intercept (LMI) after subchronic 
NO7 and/or cigarette smoke exposure. There were no 
significant effects of NO2 or cigarette smoke exposure. 
CS: cigarette smoke. 
In this study we hypothesized that the combination of NO2 and cigarette 
smoke exposure would lead to an enhanced inflammatory response and more 
pronounced emphysema in mice. Contradictory to our hypothesis, NO2 exposure 
dampened the cigarette smoke induced increases in the inflammatory cytokines 
TNF-a and KC. 
These dampening effects can be due to immune modulatory effects of NO2 which 
have been described earlier [11,25,26]. NO2 exposure can impair the function of 
macrophages and epithelial cells, leading to increased susceptibility to infections 
and development of alternatively activated macrophages. Kienast et al. showed 
that NO2 exposure decreased LPS induced pro inflammatory cytokine production 
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by alveolar macrophages in vitro, while baseline cytokine levels produced by non­
stimulated macrophages were not affected by N02 exposure [25]. These results 
correspond well with our in vivo results, showing no effects of N02 exposure 
alone, but a dampening effect of N02 in combination with cigarette smoke. 
Probably, macrophage and epithelial cell function is impaired after subchronic 
N02 exposure leading to decreased pro inflammatory cytokine production. The 
latter then only becomes apparent after an inflammatory stimulus, like cigarette 
smoke exposure in this study. By decreasing the immune response to infections, 
N02 exposure may also lead to enhanced susceptibility to exacerbations in 
patients with COPD, since the majority of exacerbations is associated with viral 
or bacterial infections [27]. This is in accordance with data showing associations 
between hospital admissions for COPD exacerbations and levels of air pollutants 
like N02 [28]. 
Four weeks of cigarette smoke exposure resulted in increased levels of TNF-a, KC, 
IL-6, and MCP-1 together with increased numbers of eosinophils. This increase 
in eosinophils is interesting since increased presence of eosinophils has been 
reported in patients with COPD, and particularly so during exacerbations [29-31]. 
The importance of eosinophils in the inflammatory response in stable COPD and 
during exacerbations is controversial and the mechanisms and consequences 
remain to be elucidated [29]. Nevertheless, several eosinophilic products can 
cause serious damage to the lungs, which may lead to inflammatory changes as 
can be seen in COPD. 
There was no effect of cigarette smoke exposure on numbers of neutrophils, 
macrophages, and lymphocytes, nor did it result in emphysema development. 
The latter is not surprising since there 4 to 6 months of smoke exposure was 
shown to be necessary to establish significant emphysema in other smoking 
mouse models [4-9]. However, the lack of an effect of smoking on neutrophils, 
macrophages, and lymphocytes is remarkable, since both cell types have shown 
to be increased after smoke exposure in other studies [4,32]. The lack of an 
effect in this study could be explained by the fact that inflammatory cells were 
measured in lung tissue versus BAL fluid in the other studies, by the difference 
in smoke exposure (whole body versus nose only}, and by the fact that different 
mouse strains were being used. The latter is important as it has been shown that 
susceptibility to cigarette smoke induced lung inflammation and emphysema 
development is strain dependent in mice [8]. 
Four weeks of N02 exposure resulted in increased numbers of goblet cells and 
eosinophils, together with a small increase in the levels of IL-6 and decreased 
levels of IL-10. 
Goblet cells are mucous producing cells and goblet cell hyperplasia and increased 
mucous production are an important characteristic of COPD [33]. Although, this 
study did not show emphysema development and increases in neutrophils and 
macrophages after subchronic N02 and cigarette smoke exposure, the increased 
number of goblet cells suggests a first step to a chronic bronchitis model. 
The lack of increased levels of inflammatory cytokines after N02 exposure is in 
contrast to our model with acute N02 exposure (one day exposure to 25ppm for 
3 hours)[34], in which several pro-inflammatory cytokines like TNF-a, KC, IL-6 and 
IL-1� were increased after N02 exposure. Other in vitro and in vivo studies have 
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shown increased levels of inflammatory cytokines after acute N02 exposure as 
well [35-39], whereas Garn et al showed decreased levels of TNF-a and IL-10 after 
subchronic N02 exposure in rats [26]. These findings indicate that there might 
be a difference in cytokine responsiveness between acute and subchronic N02 
exposure. Additionally, after isolation of the macrophages Garn et al showed that 
these cells produced less pro-inflammatory cytokines in response to LPS in vitro, 
classifying these macrophages as alternatively activated. 
In contrast to our expectations, subchronic N02 exposure alone did not result in 
significant emphysema development in this model. In several rat models [15,16,18] 
and recently also in a mouse model [19], significant emphysema development was 
shown after 4 weeks of N02 exposure. In these models, emphysema development 
was often accompanied by increased numbers of neutrophils and macrophages, 
while in our study only increases in goblet cells were found and no effects on 
neutrophils and macrophages. Differences in the N02 exposure protocol and 
species or strain differences may account for these discrepant findings. Our lack 
of effect on neutrophils and macrophages is in line with this suggestion. 
In conclusion, subchronic N02 exposure dampened smoke-induced increases in 
pro-inflammatory cytokines, suggesting an impairment of the immune response. 
These data correspond with existing literature describing immune modulatory 
effects of N02 exposure, which may lead to increased susceptibility to infections. 
Future studies are needed to further disentangle the contribution of N02 
exposure to the inflammatory response in COPD, in particular with respect to 
susceptibility to infections and exacerbations. Combining N02 exposure with an 
infectious stimulus might result in a pronounced inflammatory response in the 
lungs, resembling an animal model for COPD exacerbations. Longer exposure 
durations, as in the human situation, should also be attempted to extend our 
findings. 
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CHAPTER 4 
Abstract 
Rationale: Little is known about what drives the inflammatory reaction in the 
development of chronic obstructive lung disease. B cells have been found. 
Objective: To study the involvement of B cells in the development of 
emphysema. 
Methods: The presence of B-cell follicles and their interaction with other cells 
were investigated in lungs of patients with chronic obstructive pulmonary 
disease and of smoking mice. B cells were isolated from lymphoid follicles 
by laser microdissection and analyzed for the presence of immunoglobulin 
rearrangements and somatic mutations. 
Main Results: Lymphoid follicles consisting of B cells and follicular dendritic cells 
with adjacent T cells were demonstrated both in the parenchyma and in bronchial 
walls of patients with emphysema. A clonal process was observed in all follicles 
and the presence of ongoing somatic mutations was observed in 75% of the 
follicles, indicating oligoclonal, antigen-specific proliferation. Similar lymphoid 
follicles were detected in mice that had developed pulmonary inflammation 
and progressive alveolar airspace enlargement after smoking. The increase in 
the number of B-cell follicles was progressive with time and correlated with the 
increase in mean linear intercept. Specific bacterial or viral nucleic acids could 
not be detected. 
Conclusions: B-cell follicles with an oligoclonal, antigen-specific reaction 
were found in men and mice with emphysema. In mice, the development was 
progressive with time and correlated with the increase in airspace enlargement. 
We hypothesize that these B cells contribute to the inflammatory process and/ 
or the development and perpetuation of emphysema by producing antibodies 
against either tobacco smoke residues or extracellular matrix components. 
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Introduction 
Although the pathogenesis of chronic obstructive pulmonary disease (COPD) is 
still not clear, it is obvious that smoking is a major etiologic factor in the Western 
world. More than 90% of patients with COPD actively smoke or have done so. 
However, only 15 to 20% of all smokers eventually develop COPD, suggesting an 
interindividual variability in susceptibility to cigarette smoke (1). Imbalances in 
proteases/antiproteases, oxidants/antioxidants, or more generally inflammatory/ 
antiinflammatory effects have been postulated to play a role in the development 
of COPD, but none has been proven to play a pivotal independent role (2,3). 
It is widely accepted that the proteolytic potential of neutrophils and macrophages 
is important for the destruction of the extracellular matrix in emphysema. This is 
supported by increased numbers of neutrophils and macrophages in both airways 
and parenchyma of patients with COPD (4,5). Moreover, animal studies have 
demonstrated that macrophages and their proteolytic activity are a prerequisite 
for the development of cigarette smoke-induced emphysema (6,7). In addition, 
Churg and coworkers (8) demonstrated that neutrophil elastase, and thus the 
neutrophil, is essential for cigarette smoke-induced emphysema in mice. 
Little is known about the role lymphocytes play in the development of COPD. 
Several studies in human tissue sections have demonstrated increased numbers 
of CDS and CD4 T cells in the circulation, airways, and parenchyma of patients 
with COPD (9-12). Even less is known about the role B cells might have in the 
development of COPD. Bosken and coworkers (13) detected B cells organized in 
follicle-like structures that were present in airway adventitia of smokers. Hogg 
and coworkers (12) assessed the inflammation in small airways of surgically 
resected lung tissue from patients with stage 0-4 COPD according to the severity 
classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
(1). They described the presence of increased numbers of small airways containing 
CD4 and CDS lymphocytes, and B cells. As in the earlier work from their group 
(13), they found a marked increase in lymphoid follicles in the small airways of 
patients with GOLD stage 3-4 COPD compared with stage 0-2. The role, and thus 
importance, of these lymphoid follicles remained unclear (12). We hypothesize 
that B cells contribute to the development of COPD by means of a specific 
antigen-driven process. Therefore, we studied the presence, organization, and 
clonality of these cells both in human lung tissue and in our mouse model for 
cigarette smoke-induced emphysema. 
Some of the results of these studies have been previously reported in the form 
of an abstract (14, 15). 
Methods 
Subjects 
Human lung tissue from surgical resection material of eight patients with COPD 
(two lung volume reduction surgery, the others lung transplantation) was used 
(16). COPD was certified by the GOLD lung function criteria (1) and the presence 
of emphysema was based on histologic examination of lung tissue. The mean 
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FEV 1 was 23% predicted, the mean FEV/VC was 35%. For further details, see the 
supplement. 
Characterization of Lymphoid Follicles in Human Lung Sections 
Three-micron-thick paraffin-embedded lung sections were stained by a three­
step immunoperoxidase procedure (16). Antibodies were directed against B cells; 
follicular dendritic cells; CD27 memory B cells; CD3, CD4, and CD8 T cel ls; CD38 
and CD138 (plasma cells); the costimulatory molecule CD40; and proliferation 
marker Ki-67, which is normally expressed in active germinal centers (for details, 
see the supplement). 
lmmunoglobulin Gene Analyses of 8-Cell Infiltrates in Human Lungs 
CD20-positive B-cell follicles were harvested from 20-m-thick frozen sections 
by laser microdissection. The dissected cells were captured in polymerase chain 
reaction (PCR) buffer. The cells were incubated at 60°C for 1 h and protease 
K was subsequently inactivated by heating at 98°C for 15 min, and stored at 
-20°( until further use. Immunoglobulin gene analyses were performed by a 
nested PCR as described previously (17). FRl and FR3 primers were used. The 
PCR products were excised from the gel and cloned. The presence of inserts was 
checked by PCR, using MB primers. The PCR products were purified, sequenced, 
and subsequently subjected to alignment analyses with SeqManll and MegAlign 
software (both from DNASTAR, Madison, WI), and where possible phylogenetic 
trees were constructed. Twenty-five to 30 clones were analyzed per follicle. For 
details, see the supplement. 
Mouse Smoke Exposure 
C57BL/6J mice were exposed to cigarette smoke from 2Rl reference cigarettes 
twice daily (2 cigarettes/session, 10 puffs/cigarette), 5 d/wk by nose-only 
exposure (18, 19). The animal experiments were approved by the local ethics 
board for animal experiments. 
Evaluation of Emphysema and Inflammation in Mice 
For all details, see the supplement. 
After 2, 4, and 6 mo of smoke or sham exposure, the mice were killed. The 
right lung was snap frozen. The left lung was inflated and fixed with formalin 
with 25 cm Hp for 24 h. The mean linear intercept was determined on 25 to 
30 photomicroscopic images per animal as a measure of alveolar airspace 
enlargement by two independent individuals in a blinded manner (20). 
Inflammatory infiltrates were assessed semiquantitatively on hematoxylin- and 
eosin-stained paraffin-embedded lung sections. Neutrophils, macrophages, and 
B cells were detected with anti-GR-1, anti-MAC-3, and anti-B220, respectively, in 
lung material treated with Nakane's fixative and double stainings were performed 
on frozen lung sections. The presence of follicular dendritic cells was investigated 
with FDC-Ml and FDC-M2. Cytokine Analysis in Murine Lung Homogenates The 
proinflammatory cytokines interleukin 1 (IL-1), tumor necrosis factor, IL-6, and 
KC (murine homolog of IL-8) and cytokines involved in the differentiation and 
proliferation of B cells, such as IL-4, IL-6, and IL-13, were measured in a multiplex 
ELISA system on whole lung homogenates. 
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Statistics 
Mann-Whitney U tests were performed to detect differences between smoking 
and nonsmoking groups. Differences were considered significant at p 0.05. The 
analyses were performed with the SPSS version 11 statistical software package 
(SPSS, Chicago, IL). 
Results 
Characterization of Lymphoid Follicles in Human Lung Tissue 
Lymphoid follicles were detected both in the airway walls and in the parenchyma 
in lung sections of patients with emphysema (Figure 1). The majority of these 
follicles (80%) were detected in the parenchyma of the lung rather than in the 
airway walls. As indicated, follicles in the airway wall were found, but only a minority 
were within the subepithelial area and thus compatible with bronchus-associated 
lymphoid tissue (BALT). Changes in the epithelium overlaying the follicles that are 
indicative of BALT were rarely seen. The majority of cells in the follicles were B 
cells and follicular dendritic cells were additionally present (Figures lA-lD). The 
predominant immunoglobulin expressed on the surface of the B cells was IgM 
(Figure lE), whereas cells with other immunoglobulin isotypes were present in 
low numbers (not shown). The B cells in the infiltrates were predominantly CD27 
positive, suggestive of memory B cells (Figure 2A) (21). CD138 plasma cells were 
detected in the near vicinity of the follicles (data not shown). Almost all cells 
within follicles expressed the costimulatory molecule CD40 (Figure 2B) on their 
membrane. In addition, the proliferation marker Ki-67 was found in the lymphoid 
follicles (Figure 2C) (22). Both CD4 and CD8 T cells were found directly adjacent 
to the B cells, the majority (80-90%) being CD4 positive. 
lmmunoglobulin Gene Analyses of 8 Cells from Infiltrates from Humans 
Ten lymphoid follicles were isolated by laser microdissection from the lung 
tissue of eight patients with COPD. Sequence analysis of the immunoglobulin 
rearrangements revealed the presence of 12  different B-cell contigs with one or 
more sequence variations in 10 of the contigs. In seven of eight patients clonal B­
eel! populations were observed, whereas in one patient only unrelated sequences 
were observed. The seven patients with related immunoglobulin sequences 
demonstrated the presence of ongoing mutations (Table 1). 
Mouse Model of Cigarette Smoke-induced Emphysema: Airspace 
Enlargement 
A 7% increase in mean linear intercept was observed in smokers as compared with 
nonsmoking control subjects (p==0.03) after 4mo of cigarette smoke exposure, 
indicating the onset of emphysema (Figure 3). After 6 mo of smoke exposure the 
mean linear intercept was increased by 13% (p==0.007). 
Characterization of Lymphoid Follicles in Murine Lung Tissue 
Histologic evaluation of hematoxylin and eosin staining of paraffin-embedded 
tissue revealed the presence of pigmented macrophages in lung parenchyma 
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of smoking mice (Figure 4). Inflammatory infiltrates, with a predominantly 
lymphoid character, were found to be present both in the parenchyma and around 
terminal bronchioles (Figure 4). Semiquantitative scoring on tissue sections of 
smoking mice showed that both the number and the size of these inflammatory 
infiltrates increased during prolonged exposure to cigarette smoke. The number 
of infiltrates was significantly higher after 6 mo of smoke exposure than after 2 
and 4 mo of smoke exposure (Figure 5). 
Double staining for CD3 and B220 indicated that the inflammatory infiltrates 
consisted mainly of B cells surrounded by T cells (Figure 6A). IgM was present 
on the membranes of these Bcells (Figure 6B), but not IgD, IgG, IgE, and IgA. 
Macrophages and neutrophi ls were present in the perimeter of the infiltrates. 
Only scattered plasma cells were seen in the parenchyma; most were IgM positive 
and generally not related to the follicular aggregates. 
58 
B CELLS IN EMPHYSEMA 
Similar to human emphysematous tissue, the murine B-cell aggregates were 
lymphoid follicles, given the presence of follicular dendritic cells (Figure 6C). Both 
CD4 and CD8 T cells were present around the lymphoid fol l icles, the majority 
(80%) being CD4 positive (data not shown). 
Table 1. Results of Vh gene analyses of B cells harvested by laser dissection from 
parenchymal follicles in surgical specimens of humans with chronic obstructive 
pulmonary disease 
Patient No. No. Clones Single No. B-cell Contigs 
No. Follicles Sequenced Sequences (No. Clones per 
Contig) 
1 1 32 17 2 (9 and 6 seq) 
2 1 29 10 1 (19 seq) 
3 1 27 6 3 (6, 9, and 6 seq) 
4 2 27 2 1 (25 seq) 
26 10 2 (10 and 6 seq) 
6 2 25 12 1 (13 seq) 
28 0 1 (28 seq) 
7 1 9 2 1 (7 seq) 
8 1 24 24 0 
Definition of abbreviation: seq = sequences. 
Figure 2: lmmunohistochemical 
characterization of B cells in 
lymphoid follicles in lung tissue of 
COPD patients. (A) the majority of 
the lymphocytes are CD27' memory 
B cells (200x). (8) The co-stimulatory 
marker CD40 is present on nearly 
all cells within the lymphoid follicle 
(400x). (CJ Ki-67 antigen is expressed 




No. Sequence Variants Ongoing 
per Contig (No. Mutations 
Sequences per Variant) 
2 variants (5/4) Yes 
2 variants (4/2) Yes 
6 variants (3/4/3/2/5/2) Yes 
1 variant (6) Yes 
3 variants (5/3/1) No 
4 variants (2/2/1/1) Yes 
5 variants (14/3/1/4/3) Yes 
3 variants (4/4/2) Yes 
6 variants (1/1/1/1/1/1) Yes 
4 variants (9/2/1/1) Yes 
7 variants Yes 
(10/3/2/3/2/3/5) 
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Figure 3: Time course of change in mean linear intercept due to cigarette smoke 
exposure in mice. From 4 months cigarette smoke exposure, mean linear intercepts 
are significantly increased in smoking mice compared to non-smoking mice. 
Figure 4: Pulmonary inflammation after cigarette smoke exposure in mice. 
Pigmented macrophages and inflammatory infiltrates can be observed, both (A) 
around the bronchioles and (B) in the parenchyma (both lO0x). 
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Figure 5: Semiquantitative assessment of pulmonary inflammation after smoke 
exposure in mice. The number of inflammatory infiltrates is increased in smoking 
mice (o) compared to non-smoking mice (•) at all time points. Within the smoking 
mice group, there is also a significant increase at later time points compared to 





Figure 6: Lymphoid follicles in murine 
lung tissue after 6 months smoke 
exposure. 
(A) Double staining for CD3 (blue) and 
B cell marker 8220 (red). Pigmented 
macrophages are also visible (200x). 
(B): 8-cells express lgM (400x). (C) The 
presence of follicular dendritic cells was 
determined using the specific antibody 
FDCM2 (400x). 
Cytokine Analyses on Murine Lung Homogenates 
B CELLS IN EMPHYSEMA 
w 
Significantly higher levels of the proinflammatory cytokines IL-1, tumor necrosis 
factor-a, IL-6, and KC (murine IL-8) were found after 4 mo of smoking (Figure 7). 
IL-6, IL-4, and IL-13 are all thought to play a role in 8-cell proliferation, and were 
elevated. 
Discussion 
Our data show the presence of lymphoid aggregates in the airways and in the 
lung parenchyma of humans with emphysema. The aggregates consisted mainly 
of B cells interspaced by follicular dendritic cells and surrounded by T cel ls. 
Sequence variations in the individual 8-cell contigs were demonstrated in the B 
cells, indicating oligoclonal 8-cell proliferation in response to stimulation with as 
yet unknown antigen(s) (22). 
8-cell follicles have been demonstrated previously in the small airways of patients 
with COPD by the group of Hogg and coworkers, both more recently (12) and 
in earlier work (13). Our findings are novel in several ways. First, we assessed 
not only the small airways but also the parenchyma. We found that more than 
80% of the follicles were located in the parenchyma. This is much more than 
can be attributed only to effects of airways being adjacent to (either directly 
above or below) the sampled section. Furthermore, the composition of the B­
eel !  fol licles was analyzed: the 8-cel l  follicle core was surrounded by T cel ls, the 
majority being CD4 positive. The B cel ls were interspaced by fol licular dendritic 
cells that are necessary for antigen presentation and affinity maturation. 
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Expression of Ki-67 antigen and the costimulatory molecule CD40 indicates local 
blast transformation compatible with an (early) germinal center reaction (22). In 
addition, sequence analysis of rearranged immunoglobulin genes in individual B­
cell clones harvested from follicles by laser microdissection revealed the presence 
of ongoing mutations in clonally related B cells. Together, these data indicate 
(oligo)clonal B-cell proliferation and support a true germinal center reaction. 
Interestingly, analogous to our findings in humans with COPD, similar lymphoid 
follicles were observed in lung tissue in our smoking mouse model. This model 
produces progressive emphysema over time. Starting at 4 mo of exposure, a 
progressive increase in both size and number of these follicles was found. As in 
humans, the follicles contained B cells surrounded by CD4 and CD8 T cells and 
additionally centrally located follicular dendritic cells. 
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Figure 7: Inflammatory cytokines and chemokines in murine lung homogenates 
after 4 months smoke exposure. Asterisks (*) indicate statistically significant 
differences in chemokine/cytokine concentrations between smoking animals and 
controls. 
B CELLS IN EMPHYSEMA 
We found associations between follicle formation and increased levels of 
cytokine that are involved in B-cell proliferation. IL-4, IL-6, KC (IL-8), and IL-13 
were observed in the lung tissue homogenates of our smoking mice. These 
cytokines are essential for the formation and differentiation of germinal centers 
(23). Overexpression of IL-6 has been shown to give rise to areas of proliferating 
B-cell follicles in mice (24). In addition, overexpression of IL-13 in mice results in 
severe emphysema (25). 
Thus, the presence of 8-cell follicles has now been demonstrated in human and 
murine lung tissue in association with emphysema, and in both the airway wall 
and lung parenchyma. The important question that arises from these findings 
is the potential role of these B cells in the development of emphysema. The 
observed ongoing mutations in clonally relatedBcells within the lymphoid 
follicles suggest an antigen-driven selection process. At present, it is unclear 
against which antigen(s) this 8-cell proliferation is directed. We would like to put 
forward the following speculative but tempting considerations. At least three 
potential sources of antigens should be considered: microbial, cigarette smoke 
components or derivatives, and degradation products of extracellular matrix. 
Part of the reactivity of the observed B cells may be directed against bacterial or 
viral antigens. Indeed, most patients with COPD are colonized with bacteria (26). 
In particular, adenovirus has been implied in COPD (27,28) and B cells may play 
a role in this respect, even though the major part of an antiviral response is of 
a cellular (cytotoxic) nature (29). Hogg and coworkers have demonstrated 8-cell 
follicles in the small airways of humans with emphysema that were labeled as BALT 
because of their subepithelial localization. The authors expressed the expectation 
that the 8-cell follicles represented a response against microbial antigens (12,30), 
but did not include further support. In our study, the majority of 8-cell follicles 
were not seen within the subepithelial area. The few follicles we observed in 
relation to the airways were not covered by recognizable lymphoepithelium or M 
cells that transport antigens across the epithelium and are specific to BALT (31). 
Moreover, the littermate control mice we used in our studies were exposed to the 
same housing and (sham) handling, but did not develop these follicles. Analysis 
of fresh frozen tissue samples by real-time PCR did not indicate any presence 
of mycoplasma, chlamydia, adenovirus, or Pneumocystis jiroveci. Real-time PCR 
analysis of these samples using broad-range primers reactive with 16S RNAs from 
prokaryotes did not show any reactivity above baseline levels, thus providing no 
evidence for the presence of specific bacterial pathogens. A second source of 
antigens that could theoretically cause specific 8-cell proliferation is cigarette 
smoke. Cigarette smoke contains approximately 4,500 different compounds (31), 
of which some are proteins and therefore potentially immunogenic (32). Some of 
these compounds will precipitate in the lung, possibly bind to the extracellular 
matrix, and may elicit an antibody response. Alternatively, reactive components 
from smoke can react with proteins in the tissue to form new, immunogenic 
protein adducts (33). Subsequently, immune complex formation may occur, 
eliciting an inflammatory response and subsequently tissue degradation. 
Finally, the extracellular matrix (ECM) itself may be a source of antigens. Earlier 
studies have demonstrated that breakdown products of several ECM proteins 
such as hyaluronic acid, elastin, and collagen have chemotactic and activating 
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effects on neutrophils and macrophages, resulting in the release of oxidants 
and proteases that are detrimental to the ECM (34,35). In addition, hyaluronic 
acid causes activation and proliferation of B cells (36). Apart from this general 
chemotactic and activating role, we hypothesize that cigarette smoke-induced 
breakdown products of the ECM might additionally be immunogenic and trigger 
a specific B-cell reaction. The induced anti-ECM antibodies may subsequently 
bind to fragments of, or to intact, ECM, causing further degradation of ECM 
by phagocytes. This would also be compatible with our observation that the 
immunoglobulins we found were ofthe igM isotype because these can be involved 
in antibody reaction to extracellular matrix products, especially polysaccharides 
(37). The response to polysaccharides is often T-cell independent in mice and 
related in particular to the Bl B-cell (IgM and IgD) CDS subset, whereas in 
humans this involves the (spleen-based) marginal zone B-cell subset (IgM and 
IgD-, strongly CD21, and CDS-). The lung B cells in our study were CDS- and 
weakly CD21 in humans, and also CDS- in mice (our unpublished results). The 
absence of IgD may thus indicate an activated state of lung B cells, but does not 
indicate a specific origin or nature. Moreover, the fact that it was already known 
that CDB and CD4 T cells are prominent in COPD enables the suggestion that CD4 
cells in particular may result from nonspecific activation and provide specific help 
to cytotoxic COB cells and for T-cell dependent B-cell responses. 
Our reasoning regarding B cells in the lung is speculative, yet it is supported 
by the presence of similar B-cell follicles in the inflamed synovia and a humoral 
response against ECM fragments that has been documented in rheumatoid 
arthritis (38-40). It is conceivable that a viral or bacterial infection or colonization, 
as frequently seen in COPD, could lead to breakdown of tolerance, facilitating 
such a reaction against selfantigens. Such events are thought to play a role also 
in the initial phase and during exacerbations of several autoimmune diseases 
(41). 
Both mechanisms described above, that is, smoke- or ECM derived antigens as 
inductors of an inflammatory process, may also explain the observation that 
pulmonary inflammation continues in patients with COPD after smoking cessation 
(42). We did not investigate the effects of smoking cessation in this mouse model. 
It is well known that at least some tobacco residues remain in the lung for a long 
time and thus may maintain inflammation of the airways and lung parenchyma. 
Direct or indirect antibody-mediated degradation of ECM results in newly formed 
ECM fragments, which in turn may contribute to perpetuation of the inflammatory 
reaction. These findings and considerations regarding the antigen specificity of 
the B-cell response are also compatible with a hypothesis that an autoimmune 
component may play a role in the development or perpetuation of COPD (43, 44), 
in which, therefore, besides CD4 and COB T cells, B cells may also be implicated. 
In summary, we demonstrate the presence of B-cell follicles in the parenchyma of 
patients with emphysema. Immunoglobulin gene analysis revealed an oligoclonal 
process with ongoing mutations, suggesting an antigen-driven process that is 
probably not of microbial origin. Putative roles for these B cells include a reaction 
to cigarette smoke components or to extracellular matrix degradation products. 
The presence of similar B-cell follicles in a smoking mouse model opens additional 
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avenues for further research into the exact role of B cells in the pathogenesis of 
emphysema. 
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Online data supplement 
Methods 
Subjects 
Human lung tissue from our bank of surgical resection material of patients 
with COPD were used 1. COPD was certified by the combination of forced 
expiratory flow in one second (FEV1) and FEV/ forced vital capacity (FVC) as 
per GOLD criteria 2 and the presence of emphysema was based on histological 
examination of lung tissue performed by an experienced pulmonary 
pathologist (WT). When resection had been carried out for tumors, only lung 
tissue d istant from the tumor was included. Tissue of the severe emphysema 
group was obta ined from lung resections of patients without al-antitrypsin 
deficiency who underwent single or double lung transplantation or lung 
volume reduction surgery. 
lmmunohistochemical characterization of lymphoid follicles in human 
lung sections 
Three-m icron thick paraffin embedded lung tissue sections were stained by 
three step immunoperoxidase procedure with amino-ethyl-carbazole (AEC, 
Sigma Aldrich, Zwijndrecht, The Netherlands) as the chromogen, as described 
previously 1. The specific antibodies and their sources are presented in Table 
El. Antibodies were directed against B cells, fol l icular dendritic cells, CD27+ 
memory B cells, CD3+, CD4+, and CD8+ T-cells. CD38 and CD138 antibodies 
were used to detect plasma cells, and CD40 antibodies to detect the presence 
of this co-stimulatory molecule. Antibodies against ki-67 were used to detect 
this proliferation marker which is normally expressed in parts of fol l icular 
germinal center cells. The expression of immunoglobul ins (lg) in  lymphoid 
follicles was investigated according to a standard, three-step indirect staining 
method, see also Table El. 
lmmunoglobulin-gene analyses of 8 cell infiltrates in human lungs 
Frozen h uman lung tissue sections of 20 µm thick were stained for B cel ls 
(CD20) and the immunopositive fol l icles were subsequently harvested using 
a laser-microdissecting microscope (Pa lm, Bernried, Germany). The micro 
dissected cells were captured in 30µ1 polymerase chain reaction (PCR) buffer 
(RB, Pharmacia, Roosendaal, The Netherlands) with the addition of lµI Protease 
K per vial . The cells were i ncubated at 60°C for 1 h to purify the DNA and 
protease K was subsequently inactivated by heating at 98°C for 15 min. The 
resulting DNA solutions were stored at -20°C u ntil further use. 
Immunog lobulin-gene analyses were performed using a nested PCR as 
described previously 3• Primers located in  frame work region 1 and 3 (FRl 
and FR3) of the immunoglobulin heavy chain gene were used in  combination 
with a J-segment primer in  the first and in the second amplification round, 
respectively. The PCR products were ana lyzed on a 4% agarose gel (Biozym). 
PCR products (± 120 bp) were excised from the gel, purified, and cloned 
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in the pCR2.l vector using the TopoII-cloning kit (Invitrogen, Breda, The 
Netherlands). The presence of inserts was checked by PCR using MB-primers, 
which flank the multiple cloning site of the pCR2.1 vector. The PCR products 
were purified, sequenced, and subsequently subjected to alignment analyses 
using SeqManIITM and MegAlignTM software (DNA star, Madison, WI, USA), 
and where possible phylogenetic trees were constructed. Approximately 25-
30 clones, obtained from one follicle, were purified and analyzed from each 
patient, see Table 1 in main text. 
Animals 
Specified pathogen free male C578l/6j mice were bought from Harlan, Zeist, 
The Netherlands and kept at the Central Animal Facility of the Groningen 
University. The animals received standard rodent food (Hope Farms, Woerden, 
The Netherlands) and water ad libitum. The animal experiments were approved 
by the local ethical board for animal experiments. 
Smoke exposure 
Mice were exposed to cigarette smoke from 2Rl reference cigarettes from 
the University of Kentucky (Kentucky Tobacco Research and Development 
Center, formerly the Tobacco Health Research Institute, Lexington, KY). The 
animals were placed in a restrainer in the smoking machine (Kentucky Tobacco 
Research and Development Center) and subjected to cigarette smoke by their 
nose only 4·5• Smoke was administered twice daily (2 cigarettes per session, 
10 puffs per cigarette), 5 days per week. Non-smoking mice were also placed 
in the restrainers and exposed to room air with the same schedule. The 
smoking machine was checked for the delivery of total particulate matter as 
described by Griffith et al 4·5 and calibrated before every smoking session to 
ensure accurate and standardized smoke delivery. Actual smoke exposure was 
assessed by measuring carboxyhemoglobin levels. These ranged from 15-35 
% immediately after smoke administration. 
Morphometrical evaluation of emphysema 
After 2, 4, and 6 months smoke or sham exposure, the mice were anaesthetized 
with a mixture of isoflurane, Np, and oxygen and their trachea was cannulated. 
Subsequently, the mice were exsanguinated via the abdominal aorta. The right 
lung was ligated, lung lobes were taken out and either snap frozen or fixed 
in paraformaldehyde and an increasing concentration up to 20% sucrose 
buffer with 10% glycerine was added, according to Nakane's method for 
immunohistochemical evaluation 6• After this fixation, tissue was snap frozen 
at -80°C in isopentane and stored at -80°C until further use. The left lung 
was removed, inflated, and fixed with formalin with a constant pressure of 25 
cm Hp for 24 h. Subsequently, the lung was dissected from the trachea and 
embedded in paraffin. Three-micron paraffin sections were cut and stained 
with hematoxylin and eosin. Approximately 25-30 photomicroscopic images 
per tissue section were prepared at 10x20 magnification using a standardized 
sequence of image capturing. Images with large vessels, conducting airways 
or pleura occupying 25% or more of the total image were not used for the 
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mean linear intercept analysis which was assessed as a measure of alveolar 
airspace enlargement by two independent individuals in a blinded manner 7• 
Quantification and characterization of lymphoid follicles in murine lung 
tissue 
The number and size of inflammatory infiltrates in murine lung tissues was 
assessed in a semiquantitative manner on hematoxylin and eosin stained 
paraffin embedded lung sections. The lung sections of all animals were 
evaluated in at least 30 microscopic fields per animal in a standardized 
sequence at 10x20 magnification. The infiltrates were scored, based on the 
size and number of the inflammatory infiltrates. The summed score per animal 
was divided by the number of microscopic fields assessed. Tissue sections 
(4 µm) from either snap frozen or Nakane-fixed lung tissue were prepared. 
Nakane fixation was used in order to obtain a better morphology. However, 
some antibodies cannot be used on Nakane-fixed tissue and in those cases, 
snap frozen tissue was used instead. Specific monoclonal antibodies GR-1, 
MAC-3 and B220 (BD Pharmingen) were used on Nakanefixed lung sections 
to detect the presence of neutrophils, macrophages and B cells respectively. 
An immuno alkaline phosphatase procedure was used with fast red RB salt as 
the chromogen. Double stainings were performed on frozen lung sections to 
detect CD3+/CD4· and CD3·/CD8· T cells (see Table El). In addition, a double 
staining with CD3/B220 was performed on frozen lung sections to distinguish 
T cells from B cells. Anti-CD19 was used on frozen lungs as a control for the 
detection of B cells, since it is known that B220, besides B cells, also stains 
a subpopulation of antigen presenting cells 8• Specific antibodies directed 
against IgD, IgM, IgG, IgA and IgE were applied on frozen lung sections. The 
presence of follicular dendritic cells was investigated using FDCMl and FDCM2. 
For data on the antibodies and techniques use, see Table El. 
Cytokine analysis in murine lung homogenates 
Lung homogenates were prepared from female C57B1/6j mice that were 
exposed to cigarette smoke for 4 months. Lung tissue was homogenized 
in (50 mM Tris-HCI buffer, containing 150 mM NaCl, and 0.002% Tween-20, 
pH 7.5) in 10% w/v. Supernatants were stored at -80° C until analyzed. The 
concentrations of the pro-inflammatory cytokines 11-1� TNFa, IL-6, and KC 
(murine homologue of IL-8) and cytokines that are known to be involved in 
the differentiation and proliferation of B cells such as IL-4, IL-6, and IL-13, were 
measured in a multiplex ELISA system (Lincoplex Systems, St Charles, MO, 
USA). 
Statistics 
Mann-Whitney U tests were performed to detect differences between smoking 
and nonsmoking groups. Differences were considered significant at p< 0.05. 
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Results 
Subjects 
Human lung tissue from surgical resection material of patients with COPD 
were used as described previously n_ They were collected consecutively from 
our tissue bank provided the amount of material was sufficient for analysis. 
Two patients had received lung volume reduction surgery, the remainder 
lung transplantation. COPD was certified by the GOLD lung function criteria 
E2• The mean age was 56, all were ex-smokers, with a mean of 38 packyears, 
the FEV1 was 23%predicted, and the mean FEV/VC was 35%. The presence of 
emphysema was based on histological examination of lung tissue by WT. 
Table El: Sources of antibodies used 
First antibody Source Against Supplier 
Human lung tissue 
antl-CD20 mouse B-cells Dake, Glostrup, Denmark 
antl-CD27 mouse Memory B-cells BO Pharmlngen, Alphen a/d Rljn, NL 
anti-CD3S mouse Plasma cells BO Pharmingen, Alphen a/d Rijn, NL 
anti-CD13S mouse Plasma cells IQ products, Gronlngen, NL 
antl-CD21 mouse Follicular dendritlc cells Dake, Glostrup, Denmark 
anti-CD35 mouse Follicular dendritic cells Sanbio, Uden, NL 
anti-CD40 mouse Co-stimulatory molecule Immunotech, Marseille, France 
antl-kl67 mouse Proliferation marker BO Pharmlngen, Alphen a/d Rijn, NL 
antl-CD3 rabbit T-cells Dake, Glostrup, Denmark 
antl-CD4 mouse T-helper cells BO Pharmlngen, Alphen a/d Rljn, NL 
anti-CDS mouse T-cytotoxic cells Dake, Glostrup, Denmark 
anti-IgA mouse Immunoglobulin A Dake, Glostrup, Denmark 
anti-Igo mouse Immunoglobulln D BO Pharmlngen, Alphen a/d Rijn, NL 
anti-lgE rabbit Immunoglobulin E Dake, Glostrup, Denmark 
antl-lgG rabbit Immunoglobulin G Dake, Glostrup, Denmark 
antl-IgM mouse Immunoglobulln M BO Pharmingen, Alphen a/d Rijn, NL 
Murine lung tissue 
antl-B220 rat B-cells, APC's BO Pharmingen, Alphen a/d Rijn, NL 
anti-CD19 rat B-cells BO Pharmingen, Alphen a/d Rljn, NL 
FDCml rat Follicular dendrltlc cells BO Pharmlngen, Alphen a/d Rijn, NL 
FDCm2 rat Follicular dendritic cells BO Pharmingen, Alphen a/d Rijn, NL 
anti-CD3 hamster T-cells BO Pharmlngen, Alphen a/d Rijn, NL 
antl-CD4 rat T-helper cells BO Pharmlngen, Alphen a/d Rijn, NL 
anti-CDS rat T-cytotoxic cells BO Pharmingen, Alphen a/d Rljn, NL 
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antl-Mac3 rat macrophages BO Pharmingen, Alphen a/d Rljn, NL 
IgA goat immunoglobulin A BO Pharmingen, Alphen a/d Rljn, NL 
IgD goat immunoglobulln D BO Pharmlngen, Alphen a/d Rijn, NL 
IgE rat immunoglobulin E BO Pharmingen, Alphen a/d Rljn, NL 
lgG goat immunoglobulin G SBA, Uthoorn, NL 
IgM goat immunoglobulln M SBA, Uthoorn, NL 
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Specific immunity plays a role in COPD pathogenesis, since B-cell follicles are 
present in lung tissue and increased anti-elastin titers in plasma of COPD patients. 
Additionally, regulatory T cells (Tregs) have been implicated in its pathogenesis as 
they control immunological reactions. We investigated the presence of Tregs and 
B cells in peripheral blood of COPD patients and healthy individuals in relation to 
their current smoking status. 
Peripheral blood mononuclear cells obtained from 20 COPD patients and 29 
healthy individuals were analyzed for CD4, CD25, Foxp3, H0-1, CD20, CD27, and 
IgM expression using flow cytometry. 
COPD patients had higher Treg percentages and lower B cell percentages in 
peripheral blood than healthy individuals, with a significant correlation between 
these cells. Interestingly, current smokers had higher percentages of (class­
switched) memory B cells in peripheral blood than ex-smokers and never smokers 
irrespective of COPD. 
The increase in (class-switched) memory B cells in current smokers is intriguing 
and suggests that smoke-induced nee-antigens are constantly induced in the 
lung. The negative correlation between Tregs and B cells corroborates previously 
published observations that Tregs can suppress B cells. Finally, an altered specific 
immune response in COPD may contribute to the development and/or persistence 
of the inflammatory response. 
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Introduction 
COPD is a leading cause of death worldwide and its morbidity and mortality are still 
rising. Although the pathogenesis of the disease is still not fully defined, tobacco 
smoke is widely accepted as the most important cause for the development 
of the disease. Until now, the only effective treatment to stop the accelerated 
lung function decline that is present in COPD is smoking cessation, even though 
the inflammatory response may persist [1]. More information is needed about 
the origins and nature of the chronic inflammatory response in COPD to find 
better treatment targets for COPD patients and to understand why this chronic 
inflammatory response persists after stopping smoking. 
The role of the innate immune response, i.e. neutrophils and macrophages is 
well established in COPD [2], yet the role of specific immunity, i.e. CD4 T cells 
and B cells has only recently attracted attention. We and others have found both 
oligoclonal T- and B cells in the lungs of COPD patients suggesting an antigen 
driven immune response [3,4]. Additionally, an increased number of small airways 
containing B cells and lymphoid follicles has been shown to be present in patients 
with GOLD stage III-IV compared to stage 0-II [5]. Finally, an increase of B cells 
in the mucosa of large airways was demonstrated in COPD patients compared to 
controls [6] . 
An important modulator of the immune system is the regulatory T cell (Treg). 
Tregs are a special subset of CD4· T lymphocytes, which is important in 
controlling immunological tolerance and preventing auto-immune reactions by 
inhibiting T-cell responses [7]. Tregs can also directly inhibit B-cell responses, 
by suppressing class switch recombination and lg production in B cell follicles 
without requiring suppression of adjacent T cells [8,9]. Dysfunction of Tregs 
has been shown to contribute to auto-immune diseases, allergy, and chronic 
inflammatory diseases [7,10]. The currently best described subset of Tregs is that 
of the naturally occurring Tregs, which express high levels of CD25 and Forkhead 
transcription factor 3 (Foxp3). The suppressive effects of Tregs are mediated 
by cell-cell contact and possibly also by heme oxygenase-1 (H0-1) expression 
and membrane bound transforming growth factor (TGF)-� [11-13). Three recent 
studies have investigated the presence of Tregs in COPD, but they reported 
different findings in lung tissue and bronchoalveolar lavage (BAL). The first study 
showed decreased numbers of CD4·CD25· Tregs and Foxp3 mRNA levels in lung 
tissue of emphysema patients compared to control subjects [14]. The second 
showed increased numbers of CD4·CD25b,ight Tregs in BAL from COPD patients 
and healthy smokers when compared to healthy never smokers [15], while the 
third study showed decreased CD4·CD25· Tregs in BAL of COPD patients and 
never smokers compared to healthy smokers [16]. In all three studies, the Treg 
presence was analyzed by measuring CD4·CD25· T cells. Foxp3 was used in 
separate analyses to prove that a high percentage of these CD4·CD2S· T cells 
were positive for Foxp3 and thus Tregs. This way of analyzing Tregs could explain 
the discrepant findings, since CD25 expression varies with the activation state of 
T cells, which might differ between lung and BAL T cells. None of these studies 




We hypothesize that the 8-cell reaction in COPD is antigen driven and contributes 
to progression of the disease, and that Tregs are involved in the suppression of 
this B cel l mediated response. In order to find support for this hypothesis we 
investigated the presence of both (memory) B cel ls and Tregs, together with HO-
1 expression in peripheral blood mononuclear cel ls obtained from COPD patients 
and healthy volunteers. In comparison to the above mentioned studies, we defined 
Tregs by co-expression of CD4, CD25 and Foxp3, and analyzed the percentage 
of Foxp3 expressing co4+co2s+ T cel ls. In order to disentangle separate effects 
of COPD and current smoking status on the presence of the different cell types, 
equal numbers of COPD smokers and ex-smokers as well as healthy smokers, ex­
smokers and never smokers were recruited for this study. 
Materials and Methods 
Subjects 
COPD patients and healthy individua ls were recruited to participate in this 
study. Inclusion criteria for COPD patients were; clinical diagnosis of COPD, 
postbronchodilator FEV1 < 80% predicted, postbronchodilator FEV/FVC < 70%, 
and no exacerbation in the 6 weeks preceding the study. Inclusion criteria for 
healthy ind ividuals were; no signs and symptoms of pu lmonary disease, FEV1 > 
90% predicted, and FEV/FVC > 70%. 
All participants met the fol lowing criteria: age > 40 years, negative skin prick 
tests for the most common aeroal lergens, no use of ( inhaled) corticosteroids 
in  the 6 weeks preceding the study, and no comorbidities. To avoid the effect 
of gender only males were included i n  the study. Smokers and ex-smokers had 
to have a smoking h istory of at least 10 packyears and ex-smokers had to have 
quit smoking for a least one year. The medical ethics committee of the University 
Medical Center Groningen approved the study and a l l  participants gave their 
written informed consent. 
Flow cytometry analysis 
All participants donated 20 ml of peripheral blood. Peripheral  blood mononuclear 
cells (PBMCs) were isolated using ficol l-paque plus (GE Healthcare, UK) density 
gradient centrifugation. Total isolated cells were counted using a Sysmex pocH­
lO0i cell counter (Sysmex, Roche, Germany). 
Two antibody cocktails were used to sta in PBMCs for 1) Tregs and 2) B cells. 
1. CD4-AmCyan (8D Biosciences, San Jose, USA}, CD25-Pe-Cy7 (eBioscience, San 
Diego, USA}, Foxp3-Alexa Fluor 700 (eBioscience}, and HO-1-FITC (StressGen, 
Victoria, Canada) 
2. CD20-PE-Cy5, CD27-FITC, and IgM-biotin fol lowed by Streptavidin-PE (all 8D 
Biosciences). 
Appropriate isotype controls were used for the CD25 (mouse IgG1-Pe-Cy7, 
eBioscience) and Foxp3 (rat IgG2a-Alexa Fluor 700, eBioscience) stain ing. 
To stain for surface markers, 1*106 cel ls were first incubated for 15 minutes 
with 0.5% human serum (Sigma-Aldrich, Zwijndrecht, the Netherlands}, and 
then centrifuged and incubated with the appropriate antibody cocktai l  for 30 
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minutes on ice, protected from light. After washing the cells of both cocktails 
with phosphate buffered saline solution (PBS) supplemented with 2% bovine 
serum albumine (BSA, Serva, Heidelberg, Germany), the cells of cocktail 2 were 
incubated for 15 minutes with Streptavidin-PE, washed three times with PBS/ 
2%BSA, resuspended in FACS lysing solution (BD Biosciences), and kept in the 
dark on ice until flow cytometry analysis. The cells of cocktail 1 were fixed and 
permeabilized for 30 minutes using a fixation and permeabilization buffer kit 
(eBioscience), and then washed with permeabilization buffer, blocked with 2% 
human serum and then incubated with anti-Foxp3 for 1 hour. Afterwards the cells 
were washed with permeabilization buffer, resuspended in FACS lysing solution, 
and kept in the dark on ice until flow cytometric analysis. The fluorescent staining 
of the cells was measured on a LSR-II flowcytometer (BD Biosciences) and data 
were analyzed using FlowJo Software (Tree Star, Ashland, USA). 
Statistical analysis 
A multiple linear regression model was used to establish whether there was 
a significant interaction between the presence of COPD and current smoking 
status for the different Treg and B cell parameters. The model was tested with 
the effects of COPD, current smoking, and with the interaction between COPD 
and current smoking as independent variables. The normal distribution of the 
residuals was analyzed with a Kolmogorov-Smirnov test and when needed the 
data were log-transformed to normalize distributions. When the interaction 
between COPD and current smoking was not significant, Mann Whitney U tests 
were used to establish differences between the groups. The relation between B 
cells and CD4+CD25+Foxp3+ T cells was evaluated with the Spearman correlation. 
A value of p<0.05 was considered significant. 
Results 
Patient characteristics 
The characteristics of the twenty COPD patients (current and ex-smokers) and 
twenty-nine healthy volunteers (current, ex- and never smokers), included in the 
study, are shown in table 1. COPD patients were slightly older than the healthy 
individuals, which was mainly caused by the younger age of the healthy smokers. 
Additionally, COPD patients had more packyears of smoking when compared to 
healthy current and ex-smokers. One healthy "never smoker" was included who 
had a smoking history of 2.5 packyears and had stopped smoking for 40 years, 
the other never smokers had no smoking history at all. 
Regulatory T cells in peripheral blood 
Tregs were defined as CD4+CD25+Foxp3+ T cells. The positive gates for CD25 and 
Foxp3 expression were based on the expression levels of the appropriate isotype 
controls, and a separate CD25high gate was set on the high population (Figure 1). 
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Table 1: Characteristics of COPD patients and healthy individuals 
COPD patients Healthy individuals 
Current smokers Ex-smokers Current smokers Ex-smokers Never smokers 
Subjects (n) 10 10 9 10 10 
Age (years) 65.9 (4.3) * 66.7 (7.4) * 52.8 (4.1) II 61.1 (9.3) 58.1 (6.5) 
Packyears 34 (13,5) * 36.7 (18.2) * 24.6 (11) 20.6 (5.9) 0.3 (0.8) 
FEV1 post 44.9 (14.9) $ 60.7 (14.7) 105.6 (8.7) 115.7 (15.9) 111 .1  (12.1) 
BD (% pred.) 
FEVl/FVC 37.6 (10) 43.8 (10.7) 76.4 (4) 78.2 (5.9) 78.5 (4.1) 
post BD, (%) 
Mean (standard deviation) is depicted. Mann Whitney U tests were used to test differences 
between the groups. FEV1= Forced expiratory volume in 1 second. FVC= Forced vital capacity. BD= 
Bronchodilator. 
* COPD patients versus healthy individuals p < 0.05 
• Healthy current smokers versus healthy ex- and never smokers p< 0.05 
1 COPD smokers versus COPD ex-smokers p < 0.05 
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Figure 1. Flow cytometry plots of regulatory T cells in peripheral blood. 
The CD25 expression (red curve) compared to the isotype (blue curve), and the CD25 
total and CD25high gates are depicted in the upper panel. The Foxp3 expression (red 
curve) compared to the isotype (blue curve), and an example of the difference in Foxp3 
expression between COPD (red curve) and healthy (blue curve) are depicted in the lower 
panel. 
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COPD versus healthy 
COPD patients had higher percentages of CD4·CD2S·Foxp3•T cells (p=0.04, Figure 
2A) and CD4·CD25high Foxp3·T cells (p=0.05, Figure 2C) than healthy individuals. 
When analyzing the groups based on their current smoking status, COPD smokers 
had a higher percentage of CD4·CD2ShighFoxp3•T cells than healthy smokers 
(p=0.049, Figure 2D), which was also true for the CD4·CD25·Foxp3·T cells (trend 
(p=0.065), Figure 2C). No differences were found between COPD and healthy 
individuals with respect to CD4 T cells, CD4·CD25· T cells, and CD4·CD2Shigh T 
cells (Figure 3). 
The differences in percentages of CD4·CD2S·Foxp3•T cells could not be explained 
by the difference in age or packyears of smoking between COPD patients and 
healthy individuals (p> 0.05, when age or packyears was added to the multiple 
regression analysis). 
HO-1 expression was analyzed in CD4·CD25·Foxp3•T cells as a crude measure 
for Treg functionality [11]. Because all cel ls were positive for HO-1, the resu lts 
are expressed as mean fluorescence intensity (MFI). There were no significant 
differences in HO-1 expression of CD4·CD25·Foxp3•T cells between COPD 
patients and healthy individuals (Figure 4). 
Effect of current smoking 
There were no significant interactions between COPD and current smoking 
status, nor were there effects of current smoking with respect to percentages of 
CD4·CD25·Foxp3•T cells in peripheral blood or HO-1 expression in these cells. 
B cells and memory B cells in peripheral blood 
Based on the expression of CD20, CD27, and membrane IgM, different B-cell 
subsets were distinguished. Within the lymphocyte gate, total B cells were 
analyzed based on CD20 expression, and total memory B cells were analyzed 
based on co-expression of CD20 and CD27 (Figure 5). Within the CD20 population, 
naive B cells (CD27'IgM•), IgM• memory B cells (CD27+IgM•), and class-switched 
memory B cells (CD27•IgM-) were distinguished (Figure 5). 
COPD versus healthy 
COPD patients had lower percentages of total B cells (p=0.02, Figure 6A) and 
there was a trend for a lower percentage of memory B cells (p=0.10) compared to 
healthy individuals. When analyzing the groups based on their current smoking 
status, there was a lower B cell percentage in COPD ex-smokers compared to 
healthy smokers (p=0.01), ex-smokers (p=0.02) and never smokers (p=0.03) and 
a trend (p=0.05) when compared to COPD smokers (Figure 6B). 
The lower percentages of B cells in COPD could not be explained by the difference 
in age or packyears between COPD patients and healthy individuals (p>0.05, 
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Figure 2_ Regulatory T cells in peripheral blood 
A) Foxp3 percentages of CD4·CD2S· T cells and C) CD4·CD2SM9h T cells in peripheral 
blood of COPD patients (closed symbols) and healthy individuals (open symbols). In B 
and D the same results are depicted, but divided in subgroups based on the current 
smoking status. The results of the fvlann Whitney U tests are depicted in the figures. * 
indicates that p< 0.05 
Effect of current smoking 
There were no significant interactions between COPD and current smoking status 
with respect to B cells and memory B cells. However, current smokers (COPD 
and healthy combined) had higher percentages of memory B cells compared to 
ex-smokers and never smokers (p<0.01, Figure 7A). When analyzing the effect 
of current smoking within COPD, COPD smokers had higher percentages of 
memory B cells than COPD ex-smokers (p= 0.03, Figure 78). Also within healthy 
individuals, current smokers had higher percentages of memory B cells than ex­
smokers (p=0.03, Figure 7B) and never smokers (p=0.02, Figure 7B). This memory 
B cell- population in current smokers mainly consisted of class-switched memory 
B cells, which are characterized by the lack of IgM expression (Figure 7C, p<0.01). 
When analyzing the groups based on their current smoking status, healthy 
smokers had higher percentages of class-switched memory B cells than healthy 
ex-smokers (p<0.01, Figure 7D) and never smokers (p<0.01, Figure 7D). 
There were no effects of COPD or current smoking on IgM• memory B cells and 
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Figure 3: CD4 T cell subsets in 
peripheral blood 
Percentages of CD4· T cells, 
co4·co2s· T cells and 
CD4·CD2Sh,gh Tee/ls in peripheral 
blood of COPD patients (closed 
symbols) and healthy individuals 
(open symbols). There were no 
significant effects of COPD or 
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Figure 4: H0-1 expression in regulatory T cells 
HO-1 expression in co4•co2s• Foxp3• T cells in peripheral blood of COPD patients (closed 
symbols) and healthy individuals (open symbols). There were no significant effects of 
COPD or current smoking status. 
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Figure 5. Flow cytometry plots of B cells and memory B cells in peripheral blood. 
A representative example of the difference in percentage of CD20· B cells between COPD 
(blue) and healthy (red) and the CD20 • CD27' gate to analyze the memory B cells is 
depicted in the upper panel. The CD27•/gf.1· gate for class switched memory B cells, the 
CD27•/gf.1+ gate for lgf.1+ memory B cells, and the CD27" /gf.1• gate for nai've B cells are 
shown for a current and a never smoker in the lower panel. 
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Figure 6: B cells in peripheral blood 
A) Percentages of total B cells, in peripheral blood of COPD patients (closed symbols) 
and healthy individuals (open symbols). In B the same results are depicted, but divided in 
subgroups based on the current smoking status. The results of the Mann Whitney U tests 
are depicted in the figures. * indicates that p< 0.05 
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Figure 7: Memory B cells in peripheral blood 
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A) Percentages of memory B cells, and class switched memory B cells (C) in peripheral 
blood of current smokers (closed symbols) and non smokers (open symbols). In B and D 
the same results are depicted, but divided in subgroups based on the presence of COPD 
and the current smoking status. The results of the Mann Whitney U tests are depicted in 
the figures. * indicates that p< 0.05 
Correlation between regulatory T cells and B cells 
The percentages of CD4+CD2S+Foxp+T cells were negatively correlated with the 
percentage of B cells (Spearman's rho= -0.36, p=0.01, Figure 8) and memory B 
cells (Spearman's rho= -0.34, p=0.02). For COPD alone, the correlation between 
CD4+CD25+Foxp+T cells and B cells was of the same magnitude, but due to less 
power it did not reach statistical significance (Spearman's rho = -0.4, p=0.08). 
Discussion 
We found higher percentages of Tregs and lower percentages of B cells in 
peripheral blood of patients with COPD compared to healthy individuals. 
Additionally, higher Treg percentages correlated with lower B cell and memory B 
cell percentages. Interestingly, higher percentages of memory B cells, particularly 
class-switched memory B cells, were present in peripheral blood of current 
smokers, regardless of the disease state. 
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In addition to our earlier studies regarding B cells in lung tissue of COPD patients 
[3,6], we now have studied the presence of B cells and memory B cells in peripheral 
blood of COPD patients and healthy individuals. Except for one earlier publication 
from our group which showed decreased B-cell percentages in COPD non­
smokers compared to COPD smokers [17], we could not find any data assessing 
the presence of these B-cell populations in peripheral blood of patients with 
COPD. The current study showed lower percentages of B cells and a similar trend 
for memory B cells in COPD patients compared to healthy individuals. The lowest 
B-cell percentages were detected in the COPD ex-smokers, and this is consistent 
with the earlier findings of de Jong et al. [17]. Although speculative, this decrease 
in total B cells in peripheral blood in COPD patients and the already described 
increased presence of B cells in lung tissue of COPD patients [5,6] could reflect 
an increased recruitment of B cells from the periphery to the lung, probably 
in response to increased presence of antigens in the lungs. Since B cells were 
expressed as the percentage of total lymphocytes, the decreased percentage of 
B cells in peripheral blood in COPD patients could also be due to an increase in T 
cells, which has already been demonstrated for CD8 T cells in COPD [18]. 
Intriguingly, there was a strong increase in memory B cells, and in particular 
class-switched memory B cells in current smokers compared to ex- and never 
smokers. Class-switched memory B cells are mature B cells that have replaced 
their primary encoded membrane receptor (lgM) by IgG, IgA or IgE in response 
to repeated antigen recognition [19]. This process of class-switch recombination 
is dependent on presence of specific antigen-antibody complexes in germinal 
centers (GC), and thus the extent of this GC mediated level of class-switching 
is related to actual presence of antigen and recognizing antibody. The finding 
of increased class-switched memory B cells in current smokers suggests the 
possibility of a chronic antigen specific immune response that is particularly 
caused by ongoing smoke-induced formation or release of (neo)-antigens (e.g. 
matrix degradation products or smoke particles). The primary immune response 
to these antigens may be weak, but may still lead to the formation of memory 
B cells. When the antigen stimulus (tobacco smoke) is present for a prolonged 
period, secondary immune responses may lead to increased numbers of memory 
B cells and plasma cells, and a continued presence of memory B cells, as shown 
in the current smokers in our study. 
As mentioned in the introduction, the presence of CD4·CD25· Tregs in COPD 
has been investigated in three earlier studies. These studies reported different 
findings in lung tissue and bronchoalveolar lavage (BAL), and found no differences 
in CD4·CD25· Tregs in peripheral blood. Two studies investigated Tregs in BAL; 
the first showed increased numbers of CD4·CD25bright Tregs in COPD patients 
and healthy smokers compared to healthy never smokers [15], while the second 
study showed decreased CD4·CD25· Tregs in COPD patients and never smokers 
compared to healthy smokers [16]. These differences in the BAL results are 
remarkable, and may be explained by the different gating of the CD25 expression; 
i.e. CD25· versus CD25b,ight_ In addition, the current smokers of the second study 
had to refrain from smoking 12 hours before bronchoscopy to avoid acute smoke 
effects, whereas this was not mentioned in the other study. This could also explain 
different findings in BAL. In contrast to our study, none of these studies found 
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differences in Tregs in peripheral blood of COPD patients and healthy individuals. 
Similar to the other studies we also assessed the presence of CD4+CD2S+ T cells 
in peripheral blood of COPD patients and healthy individuals, and detected no 
differences in CD4+CD2S+ or CD4+CD2Shigh T cells between COPD patients and 
healthy individuals, nor were effects of current smoking observed. However, we 
analyzed Tregs by measuring the percentage of Foxp3 expressing CD4+CD25+ 
T cells and with this method increased Treg percentages in peripheral blood of 
COPD patients were found when compared to healthy individuals. The findings 
of Lee et al [14] showing a decreased presence of Tregs in the lung in COPD 
patients together with our observed increase in peripheral blood could suggest 
a decreased infiltration of Tregs to the lung in COPD. 
Notwithstanding the relevance of these findings, the functionality of Tregs is 
probably more important than the mere presence of these cells. Lee et al were 
the first to investigate Treg function in COPD, and found similar Treg function in 
peripheral blood of COPD patients and healthy individuals [14]. Based on earlier 
findings [11], HO-1 expression was used as a crude measure for Treg functionality 
in our study. Although this is a surrogate marker for Treg functionality and not 
comparable to the standard suppression assays, we also did not find differences 
in Treg function between COPD patients and healthy individuals with this method, 
nor effects of current smoking. However, since Treg function can be different 
at the site of inflammation, depending on the local inflammatory environment 
[20], overall conclusions as to their relevance in COPD can only be drawn when 
investigating local Tregs in the lung. 
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Figure 8: Correlation between regulatory T cells and B cells 
Correlation between co4•co2s·Foxp3·T cells and total B cells for COPD patients (black 
circles) and healthy individuals (open squares). The result of the Spearman correlation is 
depicted in the figure. 
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The presence of Tregs and B cells was only assessed in peripheral blood in this 
study; this does not necessarily reflect the inflammatory response in the lungs. 
Indeed, our findings confirmed this and as already mentioned, it is appropriate to 
study presence and particularly functionality of local Tregs in the lung. However, 
when regarding B cells, this study showed for the first time an increased percentage 
of (class switched) memory B cells in peripheral blood of current smokers. This 
finding shows that smoking, which primarily has its effects in the lungs, can also 
have systemic effects leading to increased levels of circulating memory B cells. 
Given the fact that B cells traffic to the circulation after antigen recognition in 
the lung, this smoke induced response might be of a different magnitude when 
analyzing the lung compartment. 
Combining our findings with those in the existing literature, we propose that 
smoking elicits an antigen specific immune response in addition to the effects 
on the innate immune system. This antigen specific immune response is possibly 
directed against lung tissue matrix degradation products or smoke particles. In 
healthy smokers this smoke-induced immune response is still counterbalanced 
by a normally functioning specific immune response, including adequate Treg 
function. In COPD patients, there is an altered specific immune response with 
increased percentages of Tregs and decreased percentages of B cells in peripheral 
blood together with a decrease of Tregs and an increase of B cells in the lungs 
[5,6,14]. This altered specific immune response in COPD may contribute to the 
development and/or persistence of the chronic inflammatory response in the 
lungs of patients with COPD. 
Our study supports the hypothesis that specific immunity is important in COPD. 
Future studies focusing on the specific immune response in COPD should further 
elicit the functionality of local Tregs in the lung, including the influence of the 
local environment on these cells, and the antigen(s) causing the presumed 
smoke-induced memory B cell response. 
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CHAPTER 6 
Abstract 
Smoking is the most important cause for the development of COPD. Since not 
all smokers develop COPD, it is obvious that other factors must be involved 
in disease development. We hypothesize that heme oxygenase-1 (HO-1), a 
protective enzyme against oxidative stress and inflammation, is insufficiently 
upregulated in COPD. 
The effects of HO-1 modulation on cigarette smoke induced inflammation and 
emphysema were tested in a smoking mouse model. 
Mice were either exposed or sham exposed to cigarette smoke exposure for 20 
weeks. Cobalt protoporphyrin or tin protoporphyrin was injected during this 
period to induce or inhibit HO-1 activity, respectively. Afterwards, emphysema 
development, levels of inflammatory cells and cytokines, and the presence of B­
cell infiltrates in lung tissue were analyzed. 
Smoke exposure induced emphysema and increased the numbers of inflammatory 
cells and numbers of B-cell infiltrates, as well as the levels ofinflammatorycytokines 
in lung tissue. HO-1 modulation had no effects on smoke induced emphysema 
development, or the increases in neutrophils and macrophages and inflammatory 
cytokines. Interestingly, HO-1 induction prevented the development of smoke 
induced B-cell infiltrates and increased the levels of CD4+CD2S+ T cells and Foxp3 
positive cells in the lungs. Additionally, the co4+co2s· T cells correlated positively 
with the number of Foxp3 positive cells in lung tissue, indicating that these cells 
were regulatory T cells. 
These results support the concept that HO-1 expression influences regulatory T 
cells and indicates that this mechanism is involved in the suppression of smoke 
induced B-cell infiltrates. The translation of this interaction to human COPD 
should now be pursued. 
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Background 
Chronic obstructive pulmonary disease (COPD) is a major global health problem 
with increasing morbidity and mortality. Smoking is widely accepted as the 
most important cause for development of the disease, still 'only' 15-20% of the 
smoking population eventually develops COPD [l]. COPD is characterized by a 
chronic inflammatory process, which ultimately leads to airway obstruction and 
emphysema. The important role of neutrophils, macrophages and cytotoxic T 
cells in its development is well established [2], yet the role of CD4 T cells and 
B cells has only recently re-attracted attention. We and others have found 
oligoclonal T- and B cells in the lungs of COPD patients suggesting an antigen 
driven immune response [3,4]. These T-and B cells are aggregated in lymphoid 
infiltrates. Similar infiltrates have been shown in the lungs of mice chronically 
exposed to cigarette smoke [3]. We hypothesize that these lymphoid infiltrates 
contribute to the development and/or persistence of the inflammatory response 
in COPD [3]. 
Since not all patients with COPD have actively smoked, cigarette smoke cannot 
be the sole contributing factor in COPD development. Other factors involved are 
genetic factors, such as al anti-trypsin deficiency, and environmental factors, 
such as air pollution. Another intriguing factor that may play a role in COPD 
development is the 'protective' enzyme heme oxygenase-1 (HO-1). HO-1 is the 
rate limiting enzyme involved in the breakdown of heme to equimolar amounts 
of biliverdin, free iron and carbon monoxide (CO). HO-1 is rapidly upregulated 
with oxidative stress and has potent anti-inflammatory, anti-apoptotic and anti­
proliferative effects [5-7]. The anti-inflammatory and cytoprotective effects of HO-
1 are mediated by its products, of which in particular CO [8-10]. Notwithstanding 
this knowledge, the exact mechanisms behind the protective effects of HO-1 are 
still poorly understood. 
Interestingly, a reduced HO-1 expression in macrophages in lung tissue and 
bronchoalveolar lavage (BAL) in patients with COPD has been shown [11,12]. In 
some people this may be due to a genetic polymorphism in the HO-1 promoter 
gene, which causes a lower HO-1 inducibility by reactive oxygen species (ROS) [13]. 
Additionally, adenoviral mediated HO-1 overexpression in the lung suppresses 
porcine pancreatic elastase induced emphysema development in mice [14], again 
suggesting involvement of HO-1 in emphysema development. 
Our general hypothesis is that if HO-1 is insufficiently upregulated, this contributes 
to a higher susceptibility to noxious effects of cigarette smoke and subsequent 
development of COPD. We tested whether HO-1 modulation in our smoking 
mouse model [3] influences the development of cigarette smoke induced 
emphysema and lung inflammation, in particular with respect to lymphoid 
infiltrates. We hypothesized that HO-1 induction attenuates cigarette smoke 
induced emphysema and inflammation and conversely HO-1 inhibition worsens 
the noxious effects of cigarette smoke. 
This study showed that long term HO-1 upregulation prevented the development 
of cigarette smoke induced B-cell infiltrates, while it had no effect on smoke 
induced emphysema and increase in inflammatory cells and cytokines. Increased 
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numbers of CD4+CD25+ Tregs could be an explanation for the reduced presence 
of these B-cell infiltrates. 
Methods 
Study design 
Female A/J mice were divided into six groups (n=ll per group); 1 .  Phosphate 
buffered saline (PBS) + smoke, 2. Cobalt protoporphyrin (CoPP) + smoke, 3. Tin 
protoporphyrin (SnPP) + smoke, 4. PBS + sham smoke, 5. CoPP + sham smoke, 6. 
Sn PP + sham smoke. During 20 weeks the mice were subjected to protoporphyrin 
(or PBS) treatment and smoke (or sham smoke) exposure. After 20 weeks the 
mice were sacrificed, the trachea was cannulated, the right lung was ligated, and 
lung lobes were either snap-frozen and stored at -80°C (n=7) or freshly used for 
flow cytometry analysis (n=7). The left lung was inflated, and fixed for 24h with 
formalin with a constant pressure of 25cm Hp (n=8). 
Experiments were approved by the local committee on animal experimentation. 
Smoke exposure 
Mice were exposed to 24 puffs of cigarette smoke from two 2Rl reference 
cigarettes (University of Kentucky) two times per day, for 5 days a week during 
20 weeks, as described previously [3]. 
Protoporphyrin treatment 
CoPP and SnPP (Frontier Scientific, Logan, USA) were dissolved in lM NaOH, 
diluted to the proper concentration with PBS and adjusted to pH 7.3-7.5 with 
HCI. The mice received a subcutaneous injection with CoPP (25µM/kg = 16.4mg/ 
kg) every two weeks, or with SnPP (lOµM/kg = 7.Smg/kg), or PBS weekly. These 
concentrations and dosing regimens were based on a pilot, in which different 
protoporphyrin concentrations were tested for a maximum period of two 
weeks. 
Morphometrical evaluation of emphysema 
Alveolar airspace enlargement was assessed by mean linear intercept (Lmi) by 
two independent individuals in a blinded manner, as described previously [3,15]. 
Cytokines 
Frozen lung tissue was homogenized in 50 mM Tris-HCI buffer, containing 150 
mM NaCl, and 0.002% Tween-20 (pH 7.5) and centrifuged at 12000 g for 10 min 
to remove any insoluble material. Concentrations of TNF-a, IL-la, IL-1�, IL-6, KC 
(mouse IL-8) and MCP-1 (monocyte chemoattractant protein-1) in supernatants 
were measured with a multiplex ELISA system (Lincoplex Systems, St Charles, MO, 
USA). 
Flow cytometry 
Single-cell leukocyte suspensions were obtained from lungs for flow cytometric 
analysis as described previously [16]. Numbers of CD4+CD2S+ T cells and 
neutrophils were calculated based on the label combinations: CD3-APC, CD4-PE, 
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CD25-FITC and Grl-APC. All antibodies were obtained from Pharmingen (San 
Diego, USA). 
Histology 
HO-1 expression was demonstrated with the rabbit polyclonal antibody anti-HO-
1 (Stressgen, V ictoria, Canada). Macrophage numbers were identified with an 
anti-Mac3 antibody (Pharmingen) and were quantified by morphometric analysis 
using Leica Qwin image analysis software (Leica Microsystems BV, Rijswijk, the 
Netherlands). With this computerized method the total Mac3 positive stained 
surface area was measured and divided by the total surface area lung tissue, and 
expressed as volume percentages [16]. B-cell infiltrates were detected with an 
anti-B220 antibody (Pharmingen). The total surface of the B220 positive infiltrates 
(clusters of at least 10 cells) was quantified by morphometric analysis and divided 
by the total surface area lung tissue, and expressed as volume percentages. 
Forkhead transcription factor 3 (Foxp3) expression, a marker for regulatory T cells, 
was detected in 4 µm sections of frozen lung tissue by staining with a monoclonal 
anti-Foxp3 antibody (Alexis, Breda, the Netherlands). The total number of Foxp3 
positive cells was counted at 25x magnification and expressed per surface area 
lung tissue determined by morphometric analysis. A fluorescent double staining 
with hamster anti mouse-CD3 (Pharmingen), followed by mouse anti hamster 
FITC-labeled (eBioscience) and rat anti mouse-Foxp3 (Alexis) followed by biotin 
conjugated goat anti rat (SBA, Birmingen, USA) and Strep-APC (Pharmingen) was 
performed on 4 µm frozen sections of spleen and lung tissue to confirm that 
Foxp3 positive cells were T cells. 
Western blot analysis 
HO-1 protein expression was measured with western blot in whole lung 
homogenate (see cytokine analysis). The proteins were separated for molecular 
weight and blotted on a nitrocellulose membrane. The membrane was blocked 
overnight in 5% skim milk and incubated with rabbit-anti-HO-1 (Stressgen) 
followed by a peroxidase labeled goat-anti-rabbit antibody (DakoCytomation, 
Heverlee, Belgium). For protein loading control the membrane was stripped using 
a 25mM Glycine-HCI buffer containing 1% SDS (pH:2) and stained for �-actin 
(loading control, Abeam, Cambridge, UK) fol lowed by a peroxidase labeled goat­
anti-rabbit antibody (DakoCytomation). The bands of interest were visualized 
using enhanced chemiluminescence according to standard methods. 
Statistics 
A multiple linear regression model was used to establish importance of smoke 
exposure and protoporphyrin treatment and their possible interactions [17]. 
First, the model was tested with the effects of smoking, CoPP treatment, SnPP 
treatment, together with the interactions between smoking and CoPP, and 
smoking and SnPP. When the interactions were not significant the model was 
tested again without the interaction terms. Afterwards the normal distribution 
of the residuals was analyzed and when needed the data were log or 1/x­
transformed to normalize distributions. A significant interaction signifies that the 
effect of the combination is different (larger or smaller) than the addition of the 








PBS SS CoPP SS 
Figure 1: H0-1 protein expression. 
A: Protein bands for H0-1 (above band) and {3-actin (loading control) detected by 
western blot analysis after long term smoke exposure and protoporphyrin treatment. 
Three animals per group are shown. 
B: A representative picture of the H0-1 expression (dark red) in lung tissue is shown for 
each group (25x). Particularly, alveolar macrophages (indicated with a closed arrow) show 
an increased H0-1 expression after CoPP treatment. The epithelium stains faintly in all 
groups and no differences were observed between the groups. The brown cells (indicated 
with an open arrow) are pigmented macrophages, a result of the smoke exposure. S: 
smoke, SS: Sham smoke. 
Mice were divided into 6 groups; 1. Phosphate buffered saline (PBS) + smoke, 2. Cobalt 
protoporphyrin (CoPP) + smoke, 3. Tin protoporphyrin (SnPP) + smoke, 4. PBS + sham 
smoke, 5. CoPP + sham smoke, 6. SnPP + sham smoke. 
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Mann Whitney U tests were used for post-hoc analysis to test whether significant 
effects of Co PP and Sn PP treatment were present only in smokers or sham smokers 
or in both groups. co4+co2s+ T cells and Foxp3 positive cells were evaluated with 
the Spearman correlation. A value of p<0.05 was considered significant. 
Results 
Protoporphyrin treatment and smoking upregulate H0-1 expression 
CoPP resulted in a clear upregulation of H0-1 protein expression in the lung, 
particularly in alveolar macrophages (Figure 1). Smoking also resulted in an 
increased H0-1 protein expression, leading to highest levels of H0-1 in smoke­
exposed mice that also received CoPP. SnPP resulted in a small increase in H0-1 
expression, which was not affected by smoking. 
No effects of H0-1 modulation on smoke induced emphysema 
development 
Smoking induced emphysema after 5.5 months smoke exposure, expressed as 
a significant increase in mean linear intercept (Figure 2, p< 0.01). There were no 
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Figure 2: Emphysema development. 
Mean linear intercept (LMI) after long term smoke exposure and protoporphyrin 
treatment. Smoke groups are represented by closed symbols and sham smoke groups by 
open symbols. * indicates a significant effect of smoke exposure (p<0.05). There were no 
interactions and no effects of CoPP or Sn PP treatment. 
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Smoking increases the levels of inflammatory cytokines in lung tissue 
Smoking significantly increased the levels of the pro inflammatory cytokines TN F­
a, IL-la, IL-1�, IL-6, KC, and MCP-1 in lung homogenate (Figure 3, p<0.01). CoPP 
increased the levels of IL-6 and KC. Levels of IL-6 were significantly increased 
after CoPP only in the sham smokers (PBS sham smoke vs. CoPP sham smoke 
p<0.05). KC levels were increased after CoPP in both smokers and sham smokers 
(PBS sham smoke vs. CoPP sham smoke and PBS smoke vs. CoPP smoke p<0.01). 
In contrast, SnPP reduced the levels of TNF-a, IL-la, IL-1�, KC and MCP-1. 
Levels of these cytokines were significantly decreased after SnPP in the sham 
smokers only (PBS sham smoke vs. Sn PP sham smoke p<0.05). Additionally, there 
was a positive interaction between SnPP and smoking for KC (p<0.01) leading to 
higher KC levels in the SnPP smokers compared to the SnPP sham smokers. 
Smoking increases neutrophils and macrophages in lung tissue 
Smoking increased the numbers of neutrophils and macrophages in the lung 
(Figure 4, p<0.01). There were no effects of both protoporphyrins on the numbers 
of neutrophils and macrophages. 
CoPP treatment prevents cigarette smoke induced 8-cell infiltrates 
Smoking significantly increased the number of B-cell infiltrates in lung tissue 
(Figure 5, p<0.01). In addition, there was a significant negative interaction 
between smoking and CoPP (p<0.01) signifying that the smoke induced increase 
in B-cell infiltrates was reduced in the smoke-exposed mice that also received 
CoPP (CoPP smokers). 
Reduced number of B-cell infiltrates in CoPP smokers is accompanied by 
increased numbers of CD4·CD2S· T cells in lung homogenate 
Smoking significantly increased the numbers of co4•co2s• T cells in lung 
homogenate (Figure 6A, p<0.01). Additionally, there was a significant positive 
interaction between smoking and CoPP treatment for the numbers of CD4·CD2S· 
T cells (p<0.05), signifying that the increase of smoking was larger in combination 
with CoPP, resulting in the highest numbers of CD4·CD2S· T cells in the CoPP 
smokers. This higher expression of CD25 in the CD4· T-cell population of CoPP 
smoking compared to PBS smoking mice is illustrated in figure 6B. 
The increase in CD4·CD2S· T cells represents an increase in regulatory T 
cells 
To investigate whether the increased number of CD4·c02s• T cells in the CoPP 
smokers represented an increase in regulatory T cells (Tregs), we stained lung 
tissue for the Treg specific marker Foxp3 (Figure 7A). Smoking significantly 
increased the numbers of Foxp3 positive cells in lung tissue (Figure 7B, p<0.01) 
with a trend (p=0.07) for a similar effect of CoPP on the number of Foxp3 positive 
cells. Double staining for CD3 and Foxp3 in lung and spleen tissue (Figure 7C) 
showed that Foxp3 positive cells were indeed T cells. Furthermore, the number 
of Foxp3 positive cells in lung tissue correlated positively with the number of 
CD4·CD2S· T cells in lung homogenate (p = 0.7, p<0.01). 
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Figure 3: Inflammatory cytokines in lung homogenate 
TNF-a, IL-la, /L-1{3, /L-6, KC and MCP-1 levels expressed as pg/g lung homogenate after 
long term smoke exposure and protoporphyrin treatment. Smoke groups are represented 
by closed symbols and sham smoke groups by open symbols. The significant results of 
the regression analysis are depicted beneath the figures. # indicates a significant effect 
of SnPP treatment (SnPP vs. PBS, post-hoc analysis), and ** indicates a significant effect 
of CoPP treatment (CoPP vs. PBS, post-hoc analysis) (p<0.05). 
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Figure 4: Inflammatory cells in lung tissue 
PBS CoPP SnPP PBS CoPP SnPP 
---- Smoke ---- ---- Sham Smoke ----
Regression analysis: 
Srroke effect p < 0.01 fi 
Neutrophils and macrophages expressed in lung tissue after long term smoke exposure 
and protoporphyrin treatment. Neutrophils are expressed as numbers per mg lung 
homogenate. Macrophages are expressed as volume percentages. Smoke groups are 
represented by closed symbols and sham smoke groups by open symbols. The significant 
results of the regression analysis are depicted beneath the figures. 
Discussion 
In this study we showed that H0-1 protein upregulation by CoPP treatment 
reduced the number of cigarette smoke induced B-cell infiltrates in mice. These 
B-cell infiltrates were similar to the lymphoid follicles found in COPD patients [3] 
and are suggested to contribute to COPD development. The reduced number of 
B-cell infiltrates in the CoPP smokers was accompanied by increased numbers of 
CD4·CD2S·T cells, which most likely are Tregs. In contrast to our hypothesis, H0-1 
upregulation had no protective effect on cigarette smoke induced increases in 
other inflammatory cells and inflammatory cytokines and subsequent emphysema 
development. Additionally, SnPP treatment did not aggravate smoke induced 
damage. 
We succeeded in long term H0-1 protein upregulation in our smoking mouse 
model and to our knowledge this is the first study using an intervention that 
leads to long term H0-1 protein upregulation in vivo. Given the importance of 
macrophages and epithelium in the production of inflammatory mediators after 
an inflammatory or oxidative stimulus, these cells were carefully evaluated for their 
H0-1 expression. In both in vitro and in vivo studies oxidative stress and cigarette 
smoke have been shown to induce H0-1 expression in pulmonary epithelial 
cells and alveolar macrophages [18-21]. Furthermore, H0-1 overexpression 
in epithelial cells is protective against oxidative stress [22]. Indeed, our study 
showed an increased H0-1 expression after both cigarette smoke exposure and 
CoPP treatment. This increased H0-1 expression was highest in CoPP treated 
smoking mice and particularly seen in alveolar macrophages yet not in epithelial 
cells. Unfortunately, H0-1 upregulation provided no protective effects against the 
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smoke induced increases in inflammatory cells and cytokines, nor did it protect 
against smoke induced emphysema. These results do not fit with our hypothesis, 
but might be explained in several ways. Firstly, the epithelium did not show an 
increased H0-1 expression after CoPP treatment, which still makes it possible for 
these cells to respond to ciga rette smoke by producing inflammatory mediators. 
In fact, the majority of the inflammatory cytokines that were increased after 
smoke exposu re in our study can be produced by epithelial cells in response to 
cigarette smoke [23-26], which supports this option. 
A 
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B-cell infi ltrates in lung tissue 
.. . 
PBS CoPP SnPP PBS CoPP Sn PP 
---- Smoke ---- ---- Sham smoke ---­
Regression analysis: 
Smoke effect: p < 0.01 
Smoke * CoPP interaction :  p < 0.01 
... -. � 
Figure 5: B-cell infi ltrates in lung tissue. 
A: Volume percentage of 8220 positive infiltrates after long term smoke exposure and 
protoporphyrin treatment. Smoke groups are represented by closed symbols and sham 
smoke groups by open symbols. The significant results of the regression analysis are 
depicted beneath the figure. 
8: Example of a 8-cell infiltrate positive for 8220 (red) present in lung tissue (S0x). 
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Second ly, contra ry to what we had expected, the levels of I L -6 and KC increased 
after Co PP treatment in lung tissue, which may suggest some toxicity of the long 
term dosing of Co PP. G iven the fact that the majority of the mice showed i rritation 
of the sk in at the i njection site after approximately 4 months of Co PP treatment, 
the CoPP dose indeed might have been too h igh .  
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Figure 6: CD4·CD2S· T cells in lung tissue 
A: co4•co2s• T cells expressed as numbers per mg lung tissue after long term smoke 
exposure and protoporphyrin treatment. Smoke groups are represented by closed symbols 
and sham smoke groups by open symbols. The significant results of the regression 
analysis are depicted beneath the figure. 
B: Example of the flow cytometry analysis: The percentage of CD25 positive cells within 
the C04· T cell population is shown for a PBS (left) and a CoPP (right) smoking mouse. 
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A 
B 
Foxp3 positive cells in lung tissue 
PBS CoPP Sn PP PBS Co PP Sn PP 
---- Smoke ---- ---- Sham smoke ---­
Regression analysis: 
Smoke effect: p < 0.01 
CoPP effect: p = 0.07 
C 
Figure 7: Foxp3 positive cells in lung tissue 
A: Foxp3 positive cells (red nuclear staining) present in lung tissue (lO0x). 
B: Foxp3 positive cells expressed as total numbers per mm2 lung tissue after long term 
smoke exposure and protoporphyrin treatment. Smoke groups are represented by 
closed symbols and sham smoke groups by open symbols. The significant results of the 
regression analysis are depicted beneath the figure, as well as a trend for an effect of 
CoPP treatment. 
C: Fluorescent double staining for CD3 (green) and Foxp3 (red) in lung (upper panel, 
630x) and spleen (lower panel, 400x) showing that Foxp3 specifically stains T cells. The 
orange cells in the lung are pigmented macrophages, which show auto fluorescence. 
It is a lso conceivab le  that long term exposu re to CoPP, much longer than 
performed by others, might have other unexpected effects. For futu re long term 
experiments it is probably more appropriate to use HO-1 transgenic m ice, or  use 
less toxic downstream products of the HO-1 system e.g. CO or  b i l i rub in .  F ina l ly, 
it was not possible to rel iab ly measure HO-activity levels on the frozen materia l 
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ava i lab le  i n  this study; a sufficiently sensitive assessment of HO-activity should 
certa in ly be i nc l uded in  future experiments. 
Sn PP treatment resu lted in a s l ightly increased HO-1 protei n  expression, which was 
not affected by smoke exposure. In contrast to our hypothesis, SnPP treatment 
d id not agg ravate the damaging effects of smoke exposu re, but d id decrease 
the leve ls  of severa l inf lammatory cytokines. SnPP is known to i nh ibit the HO-
1 activity, whi le  it i ncreases HO-1 protein  expression  [27] , which supports the 
increased HO-1 expression after Sn PP treatment in  our  study. For Sn PP treatment 
both i nfla m matory and ant i- inf lam matory effects have been described [28-31] .  
Anti - i nf lam matory effects were shown wh i l e  the HO-1 protein  level was i ncreased 
but the HO-1 a ctivity downregu lated, suggesting that HO-1 induction by SnPP 
can have a nt i- inf lam matory and anti-apoptotic effects independently of the HO-
1 enzyme activity [30,31]. 
The most im portant f ind ing of this study was the protective effect of HO-1 
upregu lat ion on  the development of cigarette smoke induced 8-cel l i nfi ltrates, 
lead ing  to red u ced n u m bers of 8-cel l  i nfi ltrates in CoPP treated smoking mice. 
The 8-ce l l  i nfi ltrates consisted main ly of B cel ls su rrou nded by T cel l s  and were 
com parab le to the 8-ce l l  fo l l ic les found  in patients with COPD [3]. B ce l ls  in  
these fo l l ic les were found  to be ol igoclonal  in  nature [3], suggesti ng an  antigen 
d riven immune  response. Whether the inf lammatory response in  COPD is a true 
ant igen specific response is not fu l ly proven, nor is it c lear which antigen(s) may 
be i nvolved. We consider matrix degradation prod ucts, m icrobia l  components, 
and  c igarette smoke constituents as poss ib le  candidates. We hypothesize that 
these lymphoid infi ltrates contribute to the deve lopment and/or persistence of 
the i nf lammatory response in  COPD. This study showed that red uced numbers 
of 8-ce l l  i nfi ltrates d id  not prevent smoke induced em physema deve lopment, 
which suggests that the presence of 8-cel l  i nfi ltrates may not be a mandatory 
prerequ isite for emphysema development in this model .  This is compatib le with 
the resu lts of d ' H u lst et a l ,  showing smoke induced emphysema deve lopment in  
sc id  m ice, lack ing functional  8- and T-ce l l s  [32]. To what extent B ce l l s  contribute 
to the persistence of the i nf lammatory response in  COPD remains unc lear. 
However, s ince these mouse models of cigarette smoke ind uced em physema 
resemble  mi ld  d isease, it is a l so poss ib le  that B cel l s  might be more important in 
severe than in m i l d  d isease. This wou ld  be supported by the data of Hogg et al 
who fou n d  8-ce l l s  especia l ly  in  GOLD stage III and IV [33] . 
In this study we extended our  previous observations on 8-cel l  i nfi ltrates [3] by the 
intrigu ing  find ing  that the red uced number of 8-cel l  i nfi ltrates was acco mpanied 
by increased n u m bers of CD4·CD2S· T cel ls in  the CoPP smokers. The CD4·CD2S· 
T-cel l  popu lat ion cons ists of a m ixtu re of activated T cel ls and  Tregs. Tregs a re 
important i n  contro l l ing immunologica l  tolera nce and preventing auto- immune 
reactions by i n h i bit ing T-ce l l  responses [34, 35]. Dysfu nction of  Tregs can lead to 
auto- immune d iseases, a l lergy, and chronic inf lam matory d iseases. The cu rrently 
best described su bset of Tregs is that of the natura l ly occurr ing Tregs, expressing 
h igh l evels of  CD25 and the transcription factor Foxp3 [34] . 
In this study, the n u m ber  of CD4·CD2S· T cel ls correlated positively with the 
number  of Foxp3  positive cel l s  and the h ighest n u mbers of Foxp3 positive cel l s  
were present in  the CoPP smokers with a trend for an  effect of CoPP treatment. 
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Together, this suggests that the increase in CD4+CD25+ T ce l ls  in  the CoPP smokers 
represents an increase i n  Tregs. 
Interesting ly, a d i rect l i nk  between Foxp3 and HO-1 express ion and function of 
Tregs was reported recently; both Foxp3 and HO-1 were shown to be expressed 
in  Tregs and the suppressive effects of Tregs were shown to be mediated by HO-
1 expression [36] . Furthermore, in  a model of  a l lergic a i rway i nf lammation, HO-1 
upregu lation was shown to increase Treg numbers and their  suppress ive capacity 
[37]. 
Next to their  effects on T cel ls, Tregs can a l so d i rectly suppress B-cel l  responses 
without having to suppress the adjacent T cel l s  [38,39]. This  proves that activated 
T cel l s  a re not the on ly  target for Tregs and that Tregs can a lso be i nvolved i n  
t h e  reduced presence o f  B-ce l l  infi ltrates. Interesting ly, chron ic c igarette smoke 
exposure was shown to i ncrease the n u mbers of Tregs i n  the a i rways of hea lthy 
smokers and smokers with COPD [40], whereas decreased Treg num bers were 
found in l u ng tissue of emphysema patients [41] . Addit iona l ly, we found h igh  
nu mbers of  Foxp3 positive cel l s  present in  and  surround ing B ce l l  fo l l i c les in  the 
lungs  of COPD patients (u npub l ished resu lts). 
Altogether, these fi nd ings suggest a role for Tregs  in COPD in the smoke induced 
inf lammatory response, and poss ib ly a lso B-cel l  fo l l i cle  formation, and  support 
the idea that the HO-1 protein upregu lation affected the Treg population in our  
mode l  thereby poss ib ly contributing to the observed reduced presence of  B-cel l  
i nfi ltrates. 
Conclusions 
Long term HO-1 u pregu lation prevented the deve lopment of c igarette smoke 
ind uced B-ce l l  i nfi ltrates, whi le  it had no effect on smoke i nduced emphysema 
and increase in  neutroph i l s  and macrophages and infl ammatory cytokines. A 
poss ib le  explanation for th is  effect of HO-1 u preg ulat ion on presence of B-ce l l  
i nfi ltrates is  the increased presence of CD4+CD2S+ Tregs. The exact rol e  of these 
Tregs in  the smoke induced inflam matory response has to be elucidated and the 
tra nslat ion to human COPD should now be pursued.  
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CHAPTER 7 
Abstract 
The pu rpose of this study was to formulate hemin as a powder for i nhalation 
and to show proof of concept of heme oxygenase 1 (H0-1) expression in the 
lungs of mice by inha lation of hemin .  Hemin was spray d ried from a neutra l ized 
sod i u m  hyd roxide solution. The particle size distribution of the powder was 
between 1-5 µm. Dispersion from the Twincer d ry powder inha ler  showed a 
fine particle fraction (<5 µm) of 36%. A specia l ly designed aerosol box based on 
the Twincer®- inha ler  was u sed for a proof of concept study of H0-1 induction 
by inha lation of hemin in m ice. The aerosol in the exposure chamber of the 
aerosol box rem ained aerosol ized up to 5 minutes. A rhodamin  B conta in ing 
aerosol was used to show that the aerosol box gave deposition over the entire 
lung ind icating the su itab i l ity of the model .  Add it ional ly, inha lation of hemin 
showed a dose dependent increase in  H0-1 protein  expression in the lu ngs. In 
conclusion, hemin  was successfu l ly  formulated as a powder for inha lation and 
the inha lation m odel  a l lowed contro l led H0-1 expression in the lungs of mice. 
Future studies i nvestigati ng the ut i l ity of inhaled hem in in treati ng disease states 
a re wa rranted. 
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Introduction 
The heme oxygenase (HO) metabolic pathway has recently received an explos ion 
of research i nterest due to its potent physiological and cytoprotective p ropert ies, 
e.g. [1-3]. The induc ible (HO-1) and the constitutively expressed (HO-2 and  HO-3) 
forms of HO catalyze the oxidation of heme to biliverdin, carbon monoxide and 
i ron [4] . Subsequently, b iliverd in is rapidly converted to b il irubin which i s  a potent 
endogenous antioxidant [5]. All three downstream products (biliverd in/bil irubin, 
CO and Fe/ferritin) participate in the cellula r defense. HO-1 has an integ ral role in 
the response to oxidative stress and inflammation and is induced by n umerous 
oxidative and inflammatory stimuli [6] . 
Recently, it was shown that HO-1 expression i n  lung tissue and macrophages 
obtained by bronchoalveolar lavage of patients with chronic obstructive 
pulmonary d isease (COPD) is decreased compared with healthy controls [7, 8]. 
COPD is a respi ratory d isease characterized by a chronic inflammatory response in 
the lungs, which is pr imarily caused by the toxic effects of smoking. It is tempting 
to hypothesize that in COPD patients an imbalance between systemic reactive 
oxygen species and relative antioxidant systems exists, which is possibly caused 
by insufficient upregulation of HO-1 [9]. One of the substances that induces HO-1 
is hemin (ferriprotoporphyrin IX), the oxid ized form of heme [10, 11]. Induction of 
the heme oxygenase pathway by inhalation of natural substrates, such as hem in, 
could therefore be of g reat benefit in d iseases li ke COPD [12, 13]. So fa r, inhalation 
of hem in in humans has been performed only once as a control to show that the 
HO-1 pathway is involved in  asthma [13]. In that study, nebulization of 2 ml of 
10-4 M hemin resulted in i ncreased levels of exhaled CO, ind icat ing that the HO-1 
pathway can be induced by inhalat ion of hemin. However, no direct evidence of 
HO-1 induction was g iven. 
In the clinical setting, nebulization is characterized by a low deposition efficiency 
(typically 2-27%), and needs electricity or pressu rized air for the aerosol to be 
created. In contrast, d ry powder inhalation is characterized by higher deposition 
efficiency (up to 60%) and the patient delivers the driving force for the aerosol to 
be created [14-17]. Moreover, nebulization is accompanied by patient immobility, 
whereas d ry powder i nhalers are easy to carry and use. Furthermore, d ry powder 
inhalation is likely to result in increased patient compliance, especially in chronic 
use. 
The aim of this study was to formulate hemin as a powder for inha lation and 
to show a proof of concept for induction of heme oxygenase 1 expression in 
the lungs of mice by inhalation of hemin. To obtain the proof of concept we 
admin istered hemin as a powder for in halation to m ice by using a specially 
designed aerosol box, which is based on the Twincer® d ry powder inhaler  [18]. 
Materials 
Hemin (51280) and rhodamin B (83689) were purchased from Sigma-Aldrich 
Chemie B.V. (Zwijndrecht, The Netherlands). Inulin, with a degree of polymerization 
of 23, was a generous g ift of Sensus (Breda, The Netherlands). Sodium hydroxide 
(NaOH), hydrochloric acid (HCI) and ammonia (NH) were of analytical g rade and 
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purchased from commercial suppliers. Demineralized water was used throughout 
the experiments. 
Methods 
Quantitative determination of hemin 
Sample concentrations for determination of solubility and d rug load were 
spectrophotometrically analyzed in phosphate buffered saline (PBS) with the 
Ultraspec 4052TDS apparatus at 385 nm (LKB, Zoetermeer, the Netherlands). 
Solubility 
In order to measure the maximum solubility in different alkaline solutions, 7 
solutions with a pH between 11.0 and 14.0 were prepared in steps of 0.5 pH 
units. To these solutions excess hemin was added under constant stirring. After 
30 minutes, the solutions were centrifuged at 10,000 rpm for 10 minutes. The 
supernatant was pipetted and diluted with a phosphate buffered solution and 
measu red spectrophotometrically. 
Powder production by spray drying 
Due to an excess of sodium hydroxide in the solution to increase dissolution of 
hemin, the pH of that solution remains high. If such a solution is spray d ried, 
the resultant powder causes an alkaline pH shift upon reconstitution. To avoid 
alkaline pH changes upon reconstitution of the spray d ried powder, the pH needs 
adjustments during or before spray d rying. Two methods were used for pH 
adjustment. I n  the first method a sodium hydroxide solution (0.7% w/v) with pH 
13.5 was immediately before spray d rying adjusted to  pH 7.6 with hydrochloric 
acid. The second method consisted of spray d rying an ammonia solution (1.2% 
w/v) with a pH of 13.5 .  During spray d rying, ammonia evaporates and is not 
present in the d ried powder any longer. 
Four  powders were spray d ried. The first powder was prepared by d issolving 
hemin in a sodium hyd roxide solution (0.7% w/v) at a pH of 13.5 to obtain a total 
concentration of 4.5% w/v. After pH adjustment the solution was filtered through 
a 1.2 µm filter. Hem in was not removed by filtration from the solution. After spray 
d rying, this powder thus contained sodium chloride and hemin. The hem in d rug 
load was determined to be 63% w/w. 
The second powder was produced by dissolving hemin in an ammonia solution 
(1.2% w/v) with a pH of 13.5. After spray d rying, this powder thus only contained 
pure hemin. This powder was used as a control in the dissolution experiments. 
Finally, spray d ried controls containing rhodamin B or inulin were prepared by 
dissolving the respective controls in a sodium hydroxide solution followed by pH 
adjustment before spray d rying. Rhodamin B served as a control for the in vivo 
deposition characteristics and thus the suitability of the aerosol box; inulin served 
as a control for the local effect of powder inhalation with sodium chloride. 
Spray drying was performed with a Buchi 190 Mini Spray Dryer (Buchi, Flawil, 
Switzerland) equipped with a two-fluid nozzle (0.5 m m). The solutions were 
sprayed at a fluid flow rate of 3.2 ml/min and an atomizing air flow rate of 800 
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1/h. The sett ings of the aspirator (14) and heater (14) resu lted in temperatures at 
the in let and out let of 180 °C and 120 °C, respectively. 
The obtained powders were stored i n  a vacuu m  des iccator at room 
temperatu re. 
Dissolution 
Dissolution experiments were carried out using an USP d issolution appa ratus 
I (Rowa Techn iek B.V., Leiderdorp, The Nether lands) at 37 °C and 100 rpm in 
1000 ml phosphate buffered solut ion with 10 mg hemin, corrected for d rug  
load. Samples from the  d issolut ion vessel were spectrophotometrica l ly  ana lyzed 
at 385 nm. 
Laser diffraction, scanning electron microscopy and cascade impactor 
analysis 
Particle  size distributions of the spray d ried samples were measured with a Helos 
Compact model KA laser diffraction apparatus (100 mm lens, Fraunhofer theory) 
equipped with a RO DOS d ispers ing system (Sympatec GmbH, Clausthal-Zel lerfeld, 
Germany) operated at a d ispersion pressure of 5 bar. Al l  measurements were 
performed in tri pl icate. The particle size d istribution in the exposure chamber 
was measured by p lac ing the complete aeroso l  box i n  the laser beam. To avoid 
scattering by the Perspex wa l l s, the l ight was d i rected through two opposing 
openings.  
Scann ing electron micrographs (SEM) were recorded with a J EOL JSM 6301-F 
Microscope (J EOL, Japan). The powder was dispersed on top of double-sided 
sticky carbon tape on meta l  d isks and coated with 150 nm of go ld/pa l lad ium i n  a 
Ba lzers 120B sputteri ng device (Ba lzers UNION, Liechtenstein). 
The aerodynamic partic le size distribution was measured with cascade impactor 
ana lysis using a multi-stage l iqu id  impi nger (Erweka, Heusenstamm, Germany) 
with a Twincer®- inha ler  [18] attached to the induction port. A solenoid va lve 
was used in combination with a t imer to control the f low (corresponding with 4 
kPa pressure d ifference) through the inha ler  and  the cascade impactor for the 
duration of 3 seconds.  The stages of the cascade impactor were fi l led with 20 
ml phosphate buffered sa l ine (PBS). A total amount of �100 mg was del ivered 
in 10 separate doses. The concentration of the d rug on the d ifferent stages was 
measured by UV absorbance at 385 nm; deposition was subsequently ca lcu lated 
as the percentage of the metered dose. The fine partic le fraction (< 5 µm at 
the flow rate corresponding with 4 kPa across the Twincer, FPF) was calcu lated 
by interpolation of the cumu lative mass p lot versus effective cut-off diameter. 
The FPF is expressed as a percentage of the metered dose. Al l cascade impactor 
experiments were carried out in  tripl icate. 
Aerosol box for passive pulmonary delivery of powders for inhalation 
As a proof of concept of HO-1 induction by inha lation of hemin a new device was 
developed to a l low passive, pu lmonary d ry powder del ivery to smal l  laboratory 
an imals .  The device, hereafter ca l led aerosol box (figure 1), is actua l ly an accessory 
for the Twincer®, an  effective dry powder inha ler  which del ivers h igh dosed 
formulations in  h igh ly  constant partic le  size d istributions (fine particle fraction 
of 40-50%) independent of the pressure d rop between 1 and 4 kPa [18] . The 
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efficient aerosol generation at low pressure d rops makes the Twincer® most 
su ita b le  for the aerosol box where the operator manua l ly  generates the air flow 
that d isperses the powder. The device consists of the Twincer®, a cyl inder with 
p iston to provid e a pressure d rop across the i nha ler  and transfer of the aerosol 
to last part of the device, the exposu re chamber in which a fan is bu i lt. M ice a re 
attached to the exposure cham ber. In total ,  up to twelve m ice can be attached to 
the exposu re chamber. 
About 15 mg of powder, equ iva lent to 9.45 mg active ingred ient (hem in, i nu l in or 
rhodamin  B) and 5 .55 mg sod ium ch loride, was d ispersed in the aerosol box. In 
this study, one d ose is defined as 5 minutes exposure to an aerosol that has been 
generated from 15 mg of d rug formu lation. 
Animals 
Female A/J mice (aged 8-10 weeks) were obtained from Har lan (Zeist, the 
Netherlands) a n d  were held at the Central Animal  Faci l ity of the Groningen 
U n iversity. The experiments were approved by the Committee on Animal  
Experimentation of the Un iversity Medica l  Center G ron ingen and were performed 
under  strict governmenta l law, adhering to the Pri nciples of Laboratory Animal  
Care. 
Experimental setup 
The mice used i n  this study were d ivided into 6 groups. G roup 1 consisted of 
one mouse that was not exposed to any aerosol and served as a contro l .  Groups 
2, 3, 4 (n=2 for each group) were exposed to 2, 4 and 6 doses of spray d ried 
hemin, respectively. Group 5 (n =2) was exposed to 6 doses of spray dried inu l i n  
and served as control for sod ium ch loride that was present in the spray dried 
powders. Inu l in ,  a natural ly occu rri ng o l igosaccharide was chosen because 
o l igosacchar ides contribute marg ina l ly to the osmotic pressure d ue to their  high 
molecu lar  wei g ht. Group 6 (n=2) was exposed to 6 doses of spray d ried rhodamin .  
G roup 6 was used to investigate the deposition of  d ispersed powder i n  the lungs 
of mice. Deposit ion of rhodamin  was visua l ized i n  4 µm sections of  frozen lung 
tissue by f luorescent microscopy. 
Western Blot 
Protein  sa mples were made from whole lung tissue us ing a son icator (Bandel i n  
sonopuls H D2070, Berl in, Germany). The  proteins were separated on molecu la r  
weight us ing  Sod i u m  Dodecyl Su lphate- Polyacry lamide Ge l  E lectrophoresis (SDS­
PAGE) and b lotted on a n itroce l l u lose membrane. The membrane was b locked 
overnight in 5% low fat m i l k  and the protei ns were detected with a nti-heme 
oxygenase-1 (Stressgen, Victoria, Canada) fol lowed by a peroxidase labeled goat­
a nt i-rabb it ant ibody (DakoCytomation, Heverlee, Belg i u m) .  As a protein  load ing 
control  the mem brane was stri pped us ing an 25mM G lycine-HCI buffer conta in ing 
1% SDS (pH:2) a nd sta ined for �-actin (Abeam loading control, Cam bridge, U K) 
fo l lowed by a p eroxidase l abeled goat-a nti-rabbit antibody (Dako). The bands of 
i nterest were v isua l ized us ing enhanced chemi lum inescence. 
Band-sizes of each g roup were quantified using Matlab 6 .5 .1 (The MathWorks 
Inc, Natick, USA) and the Dip image tool box (Qua ntitative Imaging Group, Facu lty 
of Appl ies Scien ces, Delft Un iversity of Technology, the N etherlands) [19, 20]. 
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In short, the g rey-scale images were made b inary with the Isodata threshold 
a lgorithm which ca lcu lates the best threshold va lue out of the g rey va lue  
h istogram of  the  image  (21] . Data are g iven as the  ratio between the  n u mber 
of pixel s  of the H0-1 band of i nterest d iv ided by the nu mber of pixels of the 
corresponding �-act in band.  
Histology 
H0-1 prote in  expression was demonstrated in  3 µm sect ions of paraffin e mbedded 
l u ng tissue with a ntibodies aga inst H0-1 (Stressgen 896, San Diego, CA, U n ited 
States). Presence of leukocytes was demonstrated in 4 µm sections of frozen l ung  
tissue with the  monoclonal  a ntibody a nti-CD45 (Pharmingen). 
Figure 1. (Top) The aerosol box, 
a utility for the Twincer® (A). By 
pulling the piston in the cylinder 
(8) an aerosol is created and can 
be transferred to the exposure 
chamber (C) to which 12 small 
laboratory animals can be fitted. 
A fan (D) creates a laminar airflow 
in the exposure chamber to 
minimize sedimentation effects. 
(Middle) Detail of the Twincer® 
attached to the aerosol box. 
(Bottom) Detail of mouse attached 





A series of experiments was ca rried out to measure the sol u bi l ity of hemin at 
d ifferent pH levels.  Hemin is practica l ly inso lub le  in water (at pH  -7) and organic 
solvents [22]. H owever, under a l ka l ine condit ions hemin i s  so lu ble. In a lka l ine 
solutions, hemin (FePP-CI) reacts with excess hyd roxide to form hemat in  (FePP­
OH). H ematin acts as an i ntermediate i n  a polymerization reaction which resu lts 
i n  a oxy-br idged d imer and probably other polymers [22] . 
FePP-CI + OH- -. FePP-OH + c1-
2 FePP-OH -. (FePP)p + Hp 
The solubi l ity of hem in (figure 2; sol id l i ne, pr imary y-axis) reached a max imum at 
pH 13.5 .  At pH >l3.S a large variation i n  solubi l ity was observed which ind icates 
the occu rrence of degradation reactions, such as hydro lysis, at h igh pH values. 
S ince the pH of the sod ium hyd roxide solution determines the a mount of hemin 
that can be d isso lved, the sod ium hydroxide concentration i s  the main parameter 
that determines the efficiency of the spray drying process. The h igher  the sodium 
hydroxide concentration, the higher the hem in concentrat ion in the solution. 
Figure 2. Solubility of hemin 
(solid line, primary y-axis) as a e function of pH and calculated 
content of hemin in spray dried .s 
powder (dotted line, secondary C: 
y-axis) as a function of pH. The . 2 'la 
calculated concentration of ... c 
Na OH versus pH is represented a, (.) 
by the dashed line (primary y- C: 0 
axis).(n=3) 
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On the other ha nd, it should be rea l ized that an increase i n  the sod ium hydroxide 
concentration requires i ncreased amounts of  hydroch loric ac id  for neutral ization.  
This effect wi l l  lead to a sh ift towards h igher sodium ch loride fractions in the 
powder, which of course reduces process effic iency i n  terms of d rug load. F inding 
the m ost efficient process condit ion i s  a matter of ba lanc ing between the solubi l ity 
of hemin, which is positively affected by the sod ium hyd roxide conce ntration, 
and the hemin drug load in the powder, which is negatively affected by the 
sod ium hydroxid e  concentrat ion.  These effects a re shown in figure 2 (dotted 





spray dried hemin 
at a magnification 
of 5000x. 
DRY POWDER INHALATION OF HEMIN 
With increasing pH the drug load of hemin in the spray dried product initially 
rose up to a maximum of 90% at a pH of 11.8. At this pH the total concentration 
of hemin and NaOH was only 2.5 mg/ml. Spray d rying of a solution with such a 
low concentration does not result in a high  yield. Therefore the pH  was increased 
to 13.5, which resulted in a solution with a total concentration of 45 mg/ml and a 
drug load of 63% after spray d rying as was confirmed by chemical analysis. The 
spray dried hem in powder consisted of highly irregular particles (figure 3) , which 
were in a size range that corresponded with laser diffraction (table 1). 
Table 1. Partic le size obta ined from RODOS dispersion (5 bar) at 10, 50 and 90% 
cumu lative undersize of the spray dried powders. All powders were spray d ried from 
a sod ium chloride solution, except pure spray dried hemin, which was spray d ried from 
ammonia. 
Formulation x10 (µm) xso (µm) x90 (µm) Span* 
Spray dr ied  hemin 1 .01 2 . 14 3 .67 1 . 25 
Spray d ried hemin from ammonia 0.95 2.06 3 .50 1 .24 
Spray d ried i nu l in 0.92 2 . 29 4.66 1 . 64 
Spray dried rhodamin B 0.87 2 .02 3 .42 1 . 26 
Spray d ried hem in from a neutralized sodium chloride solution displayed a faster 
dissolution profile compared to spray d ried hem in from NH3 as shown in figure 4. 
After 2 minutes 50% of spray dried hem in was dissolved, compared to 20 minutes 
for spray dried hem in from NH3, while the powders had approximately the same 
particle size (Table 1). Complete dissolution of the powder spray dried from the 
NH3 solution took 110 minutes. The powder with the fastest d issolution rate was 
used to perform further experiments (aerosol behavior and proof of concept). 
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Figure 4. Dissolution 
rate of spray dried hemin 
in the presence of NaCl 
(closed circle) and pure 
spray dried hemin from 
ammonia (open circle). 
(n=3) 
Figure 5. Cascade 
impactor analysis of 
spray dried hemin with 
NaCl after dispersion by 
the Twincer® at 4 kPa. 
Fine particle fraction 
(FPF) represents particles 
<6.8  µm. Error bars 
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In table 1 the particle size d istributions of the spray d ried powders a re shown. 
The part ic le size d istri butions are comparab le, on ly spray d ried i nu l i n  had a 
somewhat wide r  size d istri bution .  
Cascade impactor ana lysis (fig u re 5) showed a del ivered dose from the Twincer 
at 4 kPa of approxi mately 77% with a fine  particle fraction (< 5 µm) of 36% of the 
metered dose. 
Validation of aerosol box 
After  d ispersion i n  the aerosol box (figure 6B), most partic les (<90%) were between 
1 and 5 µm.  In the aerosol box the size d istri bution moved towards fi ner particles 
i n  t ime, ind icating sed imentation.  Larger agg lomerates (5-10 µm) sed iment 
fast and such agg lomerates a re no longer present after 1 minute. The change 
i n  part ic le size distri bution wi l l  not substantia l ly  affect the inha lab le  fraction 
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i n  the i nha led air however, s ince the vo lume fraction of such agglomerates i n  
t h e  aerosol i s  smal l .  Sed imentation was confirmed b y  a decl ine in  t h e  optica l 
concentration (i .e. amount of laser l ight that is b locked by the aerosol ) .  After 5 
m inutes the optica l concentration was 0.0%, whereas the starting concentrat ion 
was 1.54% on average. The amount of aeroso l  in  the exposure chamber after 5 
m inutes was therefore neg l ig ib le  due to sedimentation. Therefore, we exposed 
the mice for 5 m inutes per dose to the aerosol because a longer period wou ld  
have no addit ional  effect. 
Figure 6. (A) Geometrical 
particle size distributions of 
spray dried hemin as measured 
by RODOS dispersion at 5 bar 
and (BJ in the exposure chamber 
of the aerosol box immediately 
(----), 1 minute (• • • • • • • •), 2 
minutes (- - -), 3 minutes 
(- ••-), 4 minutes (----) and 5 
minutes (- • - •) after dispersion 
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Figure 7. Example of rhodamin 
fluorescence in lung tissue. 
The fluorescent signal (red) of 
rhodamine in lung tissue is shown 
to be present in the epithelial lining 
of the airways. fvlagnification: 20x 
1 0  
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To obta in a n  i n d ication of the amount of d rug that a mouse actual ly inha les, an  
in vitro measu rement was performed by withd rawing 20 m l/min  of  a ir  during 5 
m inutes from the exposure chamber. It was shown that this vo lume conta ined 
a bout 0.02% of each dose, an  a mount that conseq uently can be assumed as 
the admin istered dose. The assu mption of 20 m l/min  was on the low side, s ince 
respiratory m inute vo l u mes of mice of 45 - 50 m l/min have been described [23, 
24]. 
In vivo deposit ion of inha led powder in the l u ngs from the aerosol box was 
demonstrated by exposing mice to rhodamin  B. Rhoda min  B had a s imi lar  particle 
size d istribut ion as spray dried hemin (Tab le  1) . By using f luorescent microscopy, 
rhodamin  deposition on the epithel ia l  l i n ing of the ai rways was demonstrated 
(figure 7). Rhodamin  deposition was detected from the trachea u nt i l  the large 
a i rways. 
A - -- ,._,,, 
B 
C: 1 .6 
1 .4 ni 
1 .2 
::c: 1 .0 
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Control 2x 4x 6x 6x lnu 
Figure 8. (A) HO-1 protein expression. Protein bands for HO-1 (top) and {3-actin (loading 
control, bottom) detected by Western blot analysis are shown; each band represents 1 
mouse. From left to right: one control mouse that was not exposed to aerosol, 2 mice that 
were exposed to 2, 4 or 6 doses (2x, 4x and 6x) of spray dried hemin during 10, 20 or 30 
minutes, respectively, and finally 2 mice that were exposed to 6 doses spray dried inulin 
(6x inu) during 30 minutes. (8) Ratio of the HO-1 and �-actin band size as obtained with 
Western blot for the different groups. Error bars indicate highest and lowest values. 
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Figure 9. A representative picture of the HO-1 expression (dark red) in lung tissue of 
the control and after inhalation of 2, 4 and 6 doses of spray dried hemin is shown (25x 
magnification). Particularly, alveolar macrophages (indicated with an arrow) show an 
increased HO-1 expression after hemin inhalation. Magnification: 25x 
Figure 10. Leukocytes expressed in lung tissue. A representative picture of the leukocyte 
expression (CD45 positive cells) in lung tissue of the control and after inhalation of 2, 4 
and 6 doses of spray dried hem in is shown. Arrows in top pictures indicate airways; arrows 
in bottom pictures indicate areas with increased numbers of leukocytes surrounding the 
airways. Magnification: S0x 
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Proof of concept 
Different doses of spray d ried hemin were admin istered to achieve H0-1 
induction in lung  tissue. Figure 8 shows a clear relationship between the dose of 
spray dried hemin and the level of H0-1 protein expression in lung homogenate. 
Fu rthermore, inhalation of i nert powder (spray d ried inu l in) containing sodium 
chloride did not result in increased expression of H0-1. 
H0-1 protein expression was found to be particularly increased in alveolar 
macrophages (figure 9). The ai rway epithelium stains faintly and shows no 
d ifferences after hemin inhalation. The H0-1 expression as shown with H0-1-
staining in the s pray d ried inu lin exposed mice was comparable to control. 
The inflammatory side effects of spray dried hemin inhalation were stud ied by 
histolog ical staining of leukocytes in lung tissue. V isual observation showed 
increased numbers of leukocytes su rrounding the ai rways after i nhalation of 4 
and 6 doses of spray dried hemin, while i n  the control mouse and after i nhalation 
of 2 doses of spray d ried hemin this was not visible (figure 10). 
Discussion 
Hemin, as shown in this study, can be formulated as a powder for i nhalation 
by spray drying .  Furthermore, spray d ried hemin  resulted in  dose-dependent 
H0-1 induction after nose-only exposure of mice to the aerosol, showing that 
dry powder inhalation of hemin is possible and effective in inducing the H0-1 
metabolic pathway. 
Spray d rying of hemin was performed from two solutions that had initial high 
pH values. An advantage of spray d rying an ammonia solution that contains 
hemin is that ammonia evaporates du ring spray d rying, resulting in pure hemin 
powder. In contrast, spray d rying of the neutralized sodium hydroxide solution 
results in a powder that contains 37% w/w sodium chloride and 63% w/w hemin. 
However, the latter solution results i n  a powder that dissolves much more rapidly 
than the pure spray d ried powder. This is attr ibuted to the presence of sodium 
chloride in the spray dried powder which improves wetting and increases the 
surface over which dissolution occurs. The techn ique may be beneficial for other 
poorly soluble compounds too, especially for those compounds that have a pH­
dependent solub ility. 
Spray d rying has become one of the standard techniques for the preparation 
of inhalation powders [25,26]. One of the advantages of spray drying over 
conventional techniques such as mill ing is the improved control over the particle 
size. From both the sod ium hydroxide and ammonia solution the obtained 
powders were in the appropriate size range for inhalation, as measured with laser 
d iffraction and cascade impactor analysis. 
Clearly, the sodium chloride in the formulation did not increase H0-1 expression 
as was shown by the similarity in band size of H0-1 expression of the inulin 
control, after 6 doses, and the control that did not receive any aerosol. 
The su itab ility of the Twincer-based aerosol box for pulmonary administration 
in freely breathing mice was demonstrated in this study. The in vitro laser 
diffraction measu rements showed that an aerosol consisting of particles su itable 
for inhalation is present in the aerosol box for at least 5 minutes. Moreover, the 
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in vivo study with rhodamin B showed that the aerosol reached all pa rts of the 
lung. It should however be realized that the individual mouse receives only a 
small fraction, about 0.02%, of the total dose in the Twincer. The major limitation 
in this setup is the relative small volume that is inhaled by mice. 
One study exists where inhalation of hemin in human subjects has been 
investigated [13]. However, the dose in our study is much higher than the dose 
used in the human study. The nebulized dose in the human study was 2 ml of 
10-4 M hem in, which is equivalent to 1.6 µg/kg for a person of 80 kg. The  lowest 
dose in our study is estimated to be 171 µg/kg, which corresponds to at least 
100 times the dose used by Horvath et al. [13]. 
Since there was no information available on the dose-effect relationship of 
hem in we exposed mice to different doses. The dose escalation in our study was 
thus 171, 342 and 523 µg/kg. The relatively high doses that the mice inhaled led 
to concerns about the toxicity of hemin since it has been reported that hemin 
possesses oxidative properties especially at high doses which is due to excess 
iron [27]. Ambiguous effects have been ascribed to hemin [28]. In moderate 
amounts and bound to proteins it is an essential element in various biological 
processes [10,29]. Large amounts of hemin can be toxic by mediating oxidative 
stress and inflammation, which is mainly due to release of iron [27]. 
The higher doses indeed led to infiltration of leukocytes into the airways. This 
inflammatory cell recruitment could be the result of increased production of 
inflammatory mediators by epithelial cells in response to toxic effects of the 
increasing dose of spray d ried hem in. This possibility is in agreement with other 
in vitro and in vivo studies showing increased adhesion molecule expression 
and tissue infiltration of leukocytes after hemin administration to vascular cells 
[30,31]. On the other hand, we found that 171 µg/kg hemin did not result in 
increased numbers of inflammatory cells. However, inhalation of this dose of 
spray d ried hemin was sufficient for a clear increase in HO-1 expression in lung 
tissue, indicating that this was a safe and effective dose of spray d ried hem in.  
To conclude, we presented a novel preparation of a hemin formulation by 
spray d rying and showed proof of concept of the hemin formulation a nd a new 
pulmonary administration technique. The substance, hemin, induced the HO-1 
expression in a dose dependent manner. Futu re studies investigating the utility 
of inhaled hemin in treating disease states a re warranted. 
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The aim of this thesis was to investigate both the early and late effects of cigarette 
smoke and nitrogen dioxide (NO2) exposure and the potential dampening 
effects of heme oxygenase-1 (HO-1) in animal models for COPD. Additionally, 
we investigated the role of the specific immune response in the inflammatory 
response in COPD, i.e. the involvement of B cells and regulatory T cells. 
Nitrogen dioxide and COPD 
Short-term model 
To gain more insight into the contribution of NO2 exposure to COPD development 
we studied the effects of NO2, cigarette smoke, and their combination on 
pulmonary inflammation and emphysema development in mice. We hypothesized 
that combined exposure to NO2 and cigarette smoke would enhance both. We 
started with a short term model to gain more information on the early phases 
of inflammation by studying the effects of NO2 exposure, in relation to cigarette 
smoke in this respect (chapter 2). In this study we showed that 3 hours NO2 
exposure elicits increased levels of pro-inflammatory cytokines in the lung, while 
short-term cigarette smoke exposure elicits increased numbers of inflammatory 
cells in the lung. Intriguingly, in contrast to our hypothesis, the NO2 induced 
cytokine production was completely abolished when NO2 exposure was followed 
by short-term cigarette smoke exposure. Possible explanations for the 'down 
regulatory' effects of cigarette smoke on the NO2-induced inflammatory response 
include the presence of anti-inflammatory molecules in cigarette smoke, e.g .  
carbon monoxide (CO) [1], nitric oxide (NO) [2] and nicotine [3-5] . 
In order to unravel the dampening effects of cigarette smoke exposure on the 
NO2 induced inflammation, we performed an additional, similar experiment 
with carbon monoxide (CO) instead of cigarette smoke exposure. CO exposure 
indeed inhibited the NO2 induced increase in the levels of MCP-1, which was in 
accordance with the results found after smoke exposure. However, CO exposure 
had no effect on NO2 induced increases in the levels of IL-5 and IL--6. Therefore, 
the 'down regulatory' effects of cigarette smoke could partly be explained by the 
presence of CO in cigarette smoke. 
From this study we concluded that short-term NO2 and cigarette smoke exposure 
lead to different inflammatory responses in mice, which can probably both 
contribute to the development of COPD after long term exposure. Since COPD 
is a chronic disease, it is likely that the initial dampening effects of cigarette 
smoke will have faded away after long term exposure and the combination of 
cigarette smoke and NO2 may then cause increased pulmonary inflammation and 
enhanced development of COPD. 
Long-term model 
To find out whether the above is true we subsequently studied the long-term 
effects of NO2 and cigarette smoke exposure and hypothesized that combined 
exposure to NO2 and cigarette smoke enhances pulmonary inflammation and 
emphysema development in mice (chapter 3). Four weeks of NO2 exposure 
resulted in increased inflammation expressed as increased numbers of goblet 
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cel ls and eos inoph i ls, together with a smal l  increase i n  the levels of IL-6 and 
decreased level s  of IL-10. In contrast to short-term N02 exposure, long-term N02 
exposu re hard ly  affected the levels of inflammatory cytokines i n  this model .  Four  
weeks of  c igarette smoke exposure resu lted in i ncreased levels of  TNF-a, KC, IL-6, 
and MCP-1 together with increased numbers of eosinoph i l s, whi le there was no 
effect on numbers of neutrophi ls, macrophages, and lymphocytes. Remarkab ly, 
and contrad ictory to our hypothesis and the resu lts of the short-term study, 
long-term N02 exposure dampened the cigarette smoke induced increases i n  
the infl ammatory cytokines TNF-a and KC, with a trend for MCP-1. 
These dampen ing effects can be due to immune modulatory effects of N02 
which have been described earl ier [6-8]. N02 exposu re can impa i r  the fu nction of 
macrophages a nd epithel ia l  cel ls, leading to increased susceptib i l ity to i nfections 
and deve lopment of a lternatively activated macrophages. By decreasing the 
immune response to infections, N02 exposure may contribute to enhanced 
suscept ib i l ity to exacerbations in patients with COPD s ince the majority of 
exacerbations is associated with vira l  or bacteria l i nfections [9]. This is i n  
accordance with data showing associations between hospita l admissions for CO PD 
exacerbations a nd levels of a i r  pol lutants l i ke N02 [10]. Furthermore, i ncreased 
exacerbation rates have been suggested to cause accelerated lung function 
decl ine i n  patients with COPD [11]. Together, this may suggest a contributory role  
for a i r  pol lut ion in COPD development and/or p rogression. 
Summariz ing, we showed that short-term exposu re to N02, resu lts i n  a clear 
increase i n  leve ls of inflammatory cytokines i n  the lung, whi le after p rolonged 
N02 exposure these effects fade away. Additional ly, in contrast to our hypothesis, 
combined exposure to N02 and cigarette smoke exposure did not lead to an 
enhanced i nf lammatory reaction in the lungs in both models. In the short-term 
model this was due to anti- inflammatory effects of short-term c igarette smoke 
exposu re. In the long-term model this was caused by the b lunted inflammatory 
response after p rolonged N02 exposu re. These f indings were unexpected and 
we were not ab le  to clearly establ ish the contributory role  for N02 i n  cigarette 
smoke- induced pu lmonary inflammation in these mouse models . Future stud ies 
a re therefore needed to further d isentangle the contribution of N02 exposure to 
the inflammatory response in COPD, in particu lar with respect to susceptib i l ity 
to infections and  exacerbations. Combin ing N02 exposu re with an i nfectious 
stimu lus  m ight resu lt i n  a pronounced inflammatory response in the lungs, 
perhaps even establ ish ing an an ima l  model for COPD exacerbations. Longer 
exposu re durations, as i n  the human situation, should also be attempted to 
extend our fi nd ings. 
Specific immunity in COPD 
Recently, the ro le for the specific immune response in  COPD has gained 
increas ing attention. In this thesis we hypothesized that B cel ls contribute to 
the deve lopment of COPD by means of an antigen specific immune response. 
Addit ional ly, we hypothesized that Tregs a re i nvolved in the suppression of this 
B cel l  med iated immune response. In chapter 4 we demonstrated the presence 
of lymphoid aggregates in the a i rways and lung parenchyma of patients with 
134 
SUMMARY, DISCUSSION, AND FUTURE PERSPECTIVES 
COPD. In addition, similar aggregates were present in our smoking mouse model. 
These lymphoid aggregates consisted mainly of B cells interspaced by follicular 
dendritic cells and surrounded by T cells. With Vh gene analysis we revealed an 
oligoclonal process with ongoing mutations, which suggests an antigen d riven 
process. At present, it is unclear against which antigen(s) this B-cell reaction 
is  directed. At least three potential sources of antigens should be considered: 
microbial, cigarette smoke components or derivatives, and degradation products 
of lung extracellular matrix. 
In chapter 5 we demonstrated that Treg percentages were increased and (memory) 
B cells were decreased in peripheral blood of COPD patients compared to healthy 
individuals. Additionally, higher Treg percentages correlated with lower (memory) 
B cell percentages in peripheral blood, which supported our  hypothesis rega rding 
the involvement of Tregs in the B cell mediated immune response. Intriguingly, 
increased memory B cells, particularly class switched memory B cells were found 
in current smokers, regardless of the disease state. This observation supports 
the possibility of an antigen specific secondary immune response caused by 
direct smoke-elicited neo-antigens (e.g. smoke particles or matrix degradation 
products) in current smokers. 
B cells a re the key players of the adaptive immune system with respect to 
providing humoral immunity via the production of antibodies. The contribution 
of B cells in COPD could be the enhancement of innate responses by immune 
complex formation with lung matrix components. This process can cause lung 
tissue destruction and formation of degradation products of the lung matrix, 
which in turn may contribute to perpetuation of the inflammatory response. To 
what extent B cells contribute to COPD development and/or disease progression 
is still unclear. In this thesis we demonstrated the presence of B-cell follicles in 
lung tissue (chapter 4) and found decreased B cells present in peripheral blood 
of COPD patients (chapter 5). Together with other studies showing increased 
presence of B cells in the lungs of COPD patients [12,13], we propose an increased 
mobilization of B cells from the periphery to the lung, probably in response to 
increased presence of antigens in the lungs. 
In chapter 6, we showed that H0-1 upregulation was associated with reduced B­
cell infiltrates, but the reduced number of B-cell infiltrates was not accompanied 
by decreased emphysema development. This suggests that the presence of B-cell 
infiltrates may contribute but is not a prerequisite for emphysema development 
in this model. This is compatible with the results of d'Hulst et al, showing smoke 
induced emphysema development in scid mice, lacking functional B- and 
T-cells [14]. As yet, it remains unclear to what extent B cells contribute to the 
inflammatory response in COPD. However, since the majority of the smoking 
mouse models only resemble mild disease, it is conceivable that B cells might be 
more important in severe than in mild disease. This is supported by the data of 
Hogg et al who found increased numbers of airways containing B-cells and B cell 1, 
follicles especially in GOLD stage III and IV [13]. 
Tregs a re a special subset of CD4+ T lymphocytes, which a re important in 
controlling immunological tolerance and preventing auto-immune reactions by 
inhibiting T-cell responses [15]. Next to their effects on T cells, Tregs can a lso 
directly inhibit B-cell responses, by suppressing class switch recombination and lg 
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production in B cel l  fo l l ic les without necessari ly having to su ppress the adjacent T 
cel ls [16,17]. Tog ether with our  find ings on Tregs and B cel ls  described i n  chapter 
5, this suggests that Tregs cou ld also be involved in the suppression of the B-cel l  
mediated immune response in COPD. On ly three other  studies have assessed 
the presence of Tregs in COPD and they reported variab le  findings:  a decreased 
percentage of Tregs and Foxp3 m RNA expression in  lung tissue of emphysema 
patients com pared to control subjects [18], an increased percentage of Tregs 
in  BAL from COPD patients and hea lthy smokers compared to hea lthy never 
smokers [19], and an increased percentage of Tregs in BAL of hea lthy smokers 
compared to COPD patients and never smokers [20]. In a l l  three stud ies, Tregs 
were also assessed in periphera l  b lood but no d ifferences were found between 
COPD patients and hea lthy individua ls. Our study d iffered with respect to co­
expression of Foxp3 and showed an increased percentage of Tregs in periphera l  
b lood of COPD patients. One possib le explanation for our  observations cou ld 
be a decreased recru itment of Tregs from the circulation to the lung in COPD 
patients, lead ing to a decreased presence of local Tregs in  the l ung, which was 
a l ready shown by Lee et a l  [18]. Notwithstanding the relevance of these findings, 
the fu nctional ity of Tregs is probably more important than the mere presence of 
these cel ls i n  COPD. Lee et al were the fi rst to investigate Treg function in COPD, 
and found sim i l a r  Treg function in periphera l  b lood of COPD patients compared 
to hea lthy i ndividuals [18]. In chapter 5, HO-1 expression was used as a crude 
measure for Treg functional ity, but no differences in  H O-1 expression were found 
between COPD patients and hea lthy individuals us ing this method. 
Altogether, it can be concluded that Treg frequencies may be d ifferent between 
COPD patients and hea lthy contro ls, between d ifferent compartments, and 
a re a lso infl uenced by smoking status. No d ifferences were detected in  Treg 
fu nctiona l ity b etween COPD patients and hea lthy controls yet, but s ince Treg 
function can be d ifferent at the site of inflammation, depending on the local 
inflammatory e nvironment [21], it is crucial to study local Tregs i n  the lung 
in  COPD. Further studies a iming particu larly at  these local Tregs a nd their 
inflam matory e nvironment a re necessary to e lucidate the exact role  for Tregs in 
the inflam matory response in  COPD. 
Important questions that a rise from these findings a re 1- to which a ntigen(s) 
is this B cel l  response d i rected? 2- What is the potential role for these B cel ls 
i n  COPD deve l opment and/or disease progression? and 3- How does the local 
inflam matory response affect Treg presence and/or function in  COPD and how 
does this affect its role in development or prog ression of d isease? 
To find out to which antigen(s) this B-cel l  response is d i rected, d ifferent a pproaches 
can be used. The fi rst is a very broad screening for antibody titers in serum of 
COPD patients against the most l i kely antigens and compare these titers with 
healthy indiv iduals .  With this approach one is able to obta in  a first c lue whether 
antibod ies aga inst these potential antigens a re present in  COPD. Yet, this may 
seem a "search ing for a needle in a haystack" acquisition. N everthe less, a recent 
study a l ready detected the presence of anti-elastin antibodies in em physema 
patients, whi le  no a ntibodies against col lagen could be detected [18] .  These 
results ind icate an antigen-specific response aga inst e lastin, but defin itely need 
to be reproduced in more cohorts of COPD patients and healthy individuals. 
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Given our earlier findings regarding decorin expression in COPD [22,23], this 
would be an interesting additional target to start with. 
Another approach is to specifically aim at the antigen-specific B cells in the lung. 
In this case, one can choose to specifically isolate B cells from follicles by laser 
capture microscopy or isolate a certain B-cell population by flow cytometry 
analysis from lung homogenates of COPD patients. Next, the B-cell receptor can 
be cloned from these isolated B cells and expressed in a cell line. This can then 
be followed by a screening for antigen production in vitro. 
Finally, the capacity of circulating B cells from COPD patients and healthy 
individuals to switch to plasma cells and produce antibodies in response to 
polyclonal or antigen specific (lung matrix proteins or cigarette smoke extract) 
stimulation can be studied in vitro using ELISPOT and ELISA. 
The potential role for B cells in COPD development and/or progression can 
probably best be studied in animal models. Recently, the g roup of Kheradmand 
immunized mice with elastin peptides and found high anti-elastin titers together 
with increased numbers of activated macrophages and neutrophils, and an 
increase in MMP9 and MMP12 in BAL [24]. These findings indicate that the 
presence of anti-elastin antibodies can cause a COPD-like inflammatory reaction 
in the lungs, and suggest that presence of these antibodies may contribute to 
disease pathogenesis. Whether the presence of these antibodies ultimately 
leads to emphysema development in these mice is not clear yet; it could be that 
additional stimuli like cigarette smoke exposure are needed as well. Futu re animal 
studies combining the effects of smoking and the presence of these antibodies are 
probably crucial in elucidating the importance of these lung specific antibodies 
and the role for B cells and specific immunity in COPD pathogenesis. 
The effects of the local inflammatory environment on Treg p resence and function 
can be studied both in humans and in animal models. From resected human lung 
tissue Tregs can be isolated and the functionality of these cells can be studied in 
vitro. When sufficient lung material is available, Treg numbers and functionality 
can be compared between COPD patients and healthy controls. Additionally, the 
inhibitory capacity of these cells can be measured when they are cultu red in the 
presence of different inflammatory mediators or cigarette smoke extract. Similar 
experiments can be performed with dendritic cells, which are pre-stimulated with 
different inflammatory stimuli, to find out whether the inflammatory status of 
dendritic cells influences Treg function. 
In animal models, similar in vitro stimulation experiments can be performed 
as with human tissue, but in better defined g roups .  Tregs and dendritic cells 
obtained from acute and chronic smoke exposed mice can be compared with 
those of control mice e.g. with respect to proliferation and cytokine production. 
Furthermore, the role of Tregs in relation to B cells in the 'autoimmune' mouse 
model with elastin-antibody induced lung inflammation and also in similar 
models with other lung matrix proteins should be studied. Finally, when available, 
it would be very interesting  to study the development of smoke induced B-cell 
infiltrates and emphysema in mice (temporarily) lacking functional Tregs. 
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H0-1 expression in COPD 
Our general hypothesis stated that HO-1 is insufficiently upregulated in COPD 
patients leading to a higher susceptibility to the effects of cigarette smoke and 
oxidative stress. In chapter 6 we tested whether HO-1 modulation in our  smoking 
mouse model could dampen the development of ciga rette smoke-induced 
emphysema and lung inflammation. 
T he most important finding of this study was the protective effect of HO-1 
upregulation on  the development of cigarette smoke induced B-cell i nfiltrates, 
leading to reduced numbers of B-cell infiltrates in CoPP treated smoking mice. 
Additionally, we extended our p revious observations on B-cell infiltrates (chapter 
4) by the intriguing finding that the reduced number of B -cell infiltrates was 
accompanied by increased numbers of CD4+CD25+ Tregs in the CoPP smokers. 
Interestingly these findings are in accordance with earlier findings showing a direct 
link between Foxp3 and HO-1 expression and function of Tregs; both Foxp3 and 
HO-1 were shown to be expressed in Tregs and the suppressive effects of Tregs 
were shown to be mediated by HO-1 expression [25]. Furthermore, in a model 
of allergic airway inflammation, HO-1 upregulation increased Treg numbers and 
their suppressive capacity [26]. Moreover, in our smoking mouse model Tregs 
also seem to suppress B cells, which fits with existing literature [16,17], and with 
our findings in chapter 5 .  
Altogether, these findings support the concept that HO-1 expression i nfluences 
Tregs and demonstrate that this mechanism can suppress tobacco smoke induced 
B-cell infiltrate formation.  An important question that a rises from these findings 
is how HO-1 up regulation inhibits B-cell infiltrate formation and increases Treg 
numbers. As mentioned before, it has been shown that the suppressive function 
of Tregs is mediated by HO-1 expression [25]. In order to judge whether this was 
also the case in our study (chapter 6), it is important to know whether the HO-1 
expression in the Tregs was increased by the CoPP treatment. Unfortunately, we 
could not detect HO-1 expression in T cells in lung tissue, and therefore were 
unable to analyze this. On the other hand, contra ry to the earlier findings, a 
recent study showed that HO-1 expression is not necessa ry for the development 
of Tregs and Treg function in mice [27]. These contradictory findings indicate 
that although HO-1 expression seems to be involved in Treg function, Treg 
function might not necessa rily be dependent on the HO-1 expression in Tregs 
itself. It is very well conceivable that HO-1 expression of the su rrounding cells, 
for instance dend ritic cells and alveolar macrophages, regulates Treg function. In 
support of this theory we showed a clear increase in HO-1 expression in alveolar 
macrophages in the lung in chapter 6, which could have affected the Treg 
population in ou r  model contributing to the suppression of smoke induced B-cell 
infiltrates. These alveolar macrophages a re well known producers of inflammatory 
mediators in the innate immune response, but a re also described to regulate 
secondary immune responses, by inhibiting responses of dend ritic cells, possibly 
via nitric oxide, I L-10 and TNF-cx production [28-30]. The exact mechanisms of this 
immune regulatory function of alveolar macrophages have not been elucidated. 
Nevertheless, it is reasonable to speculate that a high HO-1 expression of these 
alveolar macrophages could lead to an increased inhibitory function of these cells, 
possibly via direct effects of CO. This could have contributed to the increased 
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Treg numbers (possibly also Treg function), and the reduced numbers of B-cell 
infiltrates in our model. 
In contrast to our hypothesis, HO-1 upregulation had no protective effects on the 
cigarette smoke induced increase in neutrophils, macrophages and inflammatory 
cytokines, and subsequent emphysema development. We had expected that 
upregulation would protect against the cigarette smoke induced oxidative stress 
in our model. Because the cells of the innate immune system i.e. epithelial cells, 
neutrophils and macrophages, are the first cells responding to oxidative stress 
in the lungs we had expected that upregulation of HO-1 particularly would have 
had impact on the numbers and activation state (production of inflammatory 
mediators) of these cells. Not finding effects on these cells and levels of 
inflammatory cytokines can perhaps be explained by the fact that the epithelium 
did not show an increased HO-1 expression after CoPP treatment. Th is maintains 
the possibility for the epithelial cells to respond to cigarette smoke by p roducing 
inflammatory mediators, which subsequently can be responsible for the 
increased numbers of neutrophils and macrophages. In fact, the majority of the 
inflammatory cytokines that were increased after smoke exposure in our study 
can be produced by epithelial cells in response to cigarette smoke [31-34], which 
supports this option. Additionally, we did not succeed to reliably measure HO­
activity levels in this model, and are therefore not sure whether CoPP treatment 
also increased HO-activity levels next to HO-1 p rotein levels, as intended. 
Since the CoPP treatment, which was used for the HO-1 induction in chapter 
6, was stressful for the mice and did not result in increased HO-1 expression in 
epithelial cells, we developed a new non-invasive method for local HO-1 induction 
in mice (chapter 7). The purpose of this study was to formulate hem in, the natural 
substrate for HO-1, as a powder for inhalation and to show p roof of concept of 
HO-1 expression in the lungs of mice by inhalation of hemin. We showed that 
hemin was successfully formulated as a powder for inhalation and the inhalation 
model allowed controlled HO-1 expression in the lungs of mice. This was p roven 
by a dose dependent increase in HO-1 protein expression after hemin inhalation 
in the lungs. Along with the dose dependent increase in HO-1 expression, there 
was also an increased recruitment of leukocytes. This corresponds with existing 
literature showing that large amounts of hemin can be toxic by mediating 
oxidative stress and inflammation [35], and in vitro and in vivo studies showing 
increased adhesion molecule expression and tissue infiltration of leukocytes after 
hemin administration [36,37]. In accordance with the CoPP treatment, the hemin 
inhalation showed an increased HO-1 expression in alveolar macrophages, but 
also not in epithelial cells. In a follow up study, the anti-inflammatory effects 
of low dose hemin treatment were investigated in our model of acute NO2-
induced pulmonary inflammation in mice. Contrary to our expectations, hemin 
treatment did not reduce NO2 induced pulmonary inflammation in that model 
and even agg ravated the inflammatory effects of NO2 for several parameters. 
These observations indicate that toxic and inflammatory side effects of the hem in 
treatment, even when using a relatively low dose, dominate the anti-inflammatory 
effects of the increased HO-1 expression. The fact that HO-1 expression was only 
increased in the macrophages and not in the epithelium may have contributed to 
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Figure 1: Proposed model for the inflammatory response in COPD 
Smoking together with environmental exposure to toxic gases (e.g. NO) triggers the 
innate immune system (i.e. epithelial cells and macrophages) to produce inflammatory 
mediators (e.g. TNF-a, IL-8, G/VlCSF and IL-1[3). This results in the recruitment and 
activation of inflammatory cells, which produce proteases and reactive oxidant species 
(ROS) causing destruction of the lung matrix. In parallel, epithelial cells produce excess 
mucus, and fibroblasts and epithelial cells produce TGF-/3, which both contribute to 
development of fibrosis and airway obstruction. Lung matrix degradation proteins 
and/or cigarette smoke derived particles can be processed by antigen presenting cells 
(APCs) and presented as neo-antigens to T cells. These T cells activate antigen specific B 
cells, leading to a specific immune response in the lung. Normally, this specific immune 
response is inhibited by adequately functioning Tregs. However, in COPD patients 
Tregs are dysregu/ated, which facilitates the tissue specific antibody production by B 
cells. These antibodies will cause more lung matrix destruction, an increased pool of 
lung matrix degradation proteins, and a perpetuation of the inflammatory response 
in COPD. HO-1 expression can have inhibitory effects on both the innate and the 
specific immune response in the lungs, by its expression in alveolar macrophages, Tregs 
and APCs. In COPD patients HO-1 expression has shown to be decreased in alveolar 
macrophages, which may contribute to an increased production of inflammatory 
mediators. A decreased HO-1 expression in Tregs or APCs could contribute to the 
specific 8-cell mediated immune response, possibly by affecting antigen presentation 
and functionality of Tregs. 
From these studies it can be concluded that our model of hem in inhalation in mice 
is a successful method to locally induce H0-1 expression in the lung, particularly 
in alveolar macrophages, but due to the toxic and inflammatory side effects not 
a good alternative for the CoPP treatment. For future long term experiments 
assessing the effects of H0-1 induction on COPD development, it is probably 
more appropriate to use H0-1 transgenic mice, or less toxic downstream products 
of the H0-1 system e.g. CO or bilirubin. 
Final conclusions 
When combining the findings of this thesis with existing literature we propose the 
following hypothesis regarding the inflammatory response in COPD. A schematic 
representation of the inflammatory response in COPD is depicted in Figu re 1. 
Next to the effects on the innate immune system, smoking together with 
environmental exposure to other noxious gases (e.g. N02), elicits a B-cell 
mediated antigen specific immune response in the lung possibly against lung 
tissue matrix degradation products or smoke particles. Tregs are involved in the 
suppression of this B-cell mediated immune response, probably at least partially 
via H0-1 expression. In healthy smokers, this B-cell mediated immune response 
is counterbalanced by a normally functioning specific immune response, 
including adequate Treg function. In COPD patients an altered specific immune 
response has been shown; increased Tregs and decreased B cells in peripheral 
blood (chapter 5) together with decreased Tregs and increased B cells in the 
lungs [12,13,18]. This altered specific immune response in COPD might contribute 
to the development and/or progression of the chronic inflammatory response in 
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Wat is COPD? 
Het beschreven onderzoek in d it proefsch rift gaat over de ontstek ingsreactie 
die aa nwezig is i n  de longen van mensen met de ziekte COPD. COPD is de 
Engelse afkorting voor  Chronic Obstructive Pu lmonary Disease en wordt in het 
Nederlands oak wel chron ische obstructieve longziekte genoemd. Het is een 
chron ische longziekte d ie  gekenmerkt wordt door een combinatie van c h ronische 
bronchitis (ontsteking van de luchtwegen) en emfyseem ("rek u it de long") 
(Figuur  1). De chronische ontsteking van de l uchtwegen zorgt voor verd ikk ing 
van de luchtwegwand en overmatige s l ijm productie wat resu lteert in vernauwing 
va n d e  l uchtwegen. B ij emfyseem is er sprake van afbraak van longb laasjes, 
waardoor er m inder capaciteit is voor zuu rstof opname en er gaten va l len in het 
longweefsel .  Door d it verl ies van longweefsel wordt oak het "ophang" systeem 
van de l uchtwegen aangetast, wat mede bijdraagt aan de vernauwi ng  van d e  
l uchtwegen. 
Figuur 1. Schematische weergave 
van een long met een voorbee/d 
van gezonde longblaasjes 
in vergelijking met kapotte 
longblaasjes (emfyseem) en een 
gezonde luchtweg in vergelijking 
met een ontstoken en vernauwde 
luchtweg (bronchitis). 
(Aanpassing van figuren afkomstig 








De belang rijkste symptomen va n COPD zijn chron isch hoesten, s lijm opgeven en 
benauwdheid bij inspann ing en bij gevorderde ziekte oak in rust. De d iag nose 
wordt g rotendeels gebaseerd op de longfu nctie. H ierbij wordt onder meer 
gekeken naar de long inhoud en de maxi male hoeveelheid lucht d ie in 1 seconde 
kan warden u itgeblazen. De ernst van de ziekte wordt vervolgens op bas is  van 
deze longfunctie parameters ingedeeld in 4 stadia, vol gens de zogenaamde 
GOLD criteria (G lobal  Initiative for Obstructive Lung Diseases). Patienten met 
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stadium 1 hebben weinig klachten en  zijn zich vaak nog niet eens bewust van 
de ziekte. Patienten met stadium 4 hebben een zeer beperkte longfunctie, die 
vaak gepaard gaat met ernstige benauwdheid bij inspanning en vaak ook in 
rust, chronisch hoesten en veel slijm opgeven. B ij deze groep patienten kan een 
bijkomende luchtweginfectie fataal zijn. Uiteindelijk heeft COPD vroegtijd ige 
sterfte tot gevolg en men heeft voorspeld dat COPD wereldwijd doodsoorzaak 
nr. 3 zal z ij n  in 2020. 
De belangrijkste behandeling is momenteel stoppen met roken. Door te 
stoppen met roken kan de versnelde achteruitgang in longfunctie geremd 
warden en kunnen de luchtwegklachten afnemen. Helaas bestaan er nog geen 
medicijnen die de ziekte kunnen genezen. De huidige medicijnen bestaan uit 
luchtwegverwijdende en ontstekingsremmende middelen, die de klachten 
kunnen verlichten en verergering van de klachten kunnen voorkomen. 
Hoe COPD precies ontstaat en wat de onderliggende mechanismen zijn voor 
de chronische ontstekingsreactie in de longen is nog grotendeels onbekend.  
Duidelijk is dat roken een belangrijke rol speelt in de ontwikkeling van deze 
ziekte. 90% van de COPD-patienten heeft gerookt of rookt nog steeds. Echter, 
niet alle rokers ontwikkelen COPD; "slechts" 15-20% van alle rokers ontwikkelt de 
ziekte. Dit geeft aan dat naast roken ook andere factoren van belang zijn bij de 
ontwikkeling van COPD. Hierbij kunnen we denken aan erfelijke eigenschappen, 
maar ook omgevingsfactoren zoals luchtverontreiniging of meeroken. 
Voor de ontwikkeling van nieuwe geneesmiddelen is verdergaand onderzoek 
naar het exacte ontstaansmechanisme van deze ziekte noodzakelijk. In dit 
proefsch rift hebben we op verschillende manieren onderzoek gedaan naar 
mechanismen d ie ten grondslag liggen aan het ontstaan van COPD en de 
chronische ontstekingsreactie i n  de longen. Hiervoor werd zowel in muizen als 
in mensen onderzoek gedaan. De verschillende studies zullen hieronder per 
onderwerp warden samengevat. 
Effecten van stikstofdioxide op de ontstekingsreactie in COPD 
Zoals hierboven beschreven, spelen naast roken ook andere factoren zoals 
luchtverontreiniging een belangrijke rol bij de ontwikkeling van COPD. 
Stikstofdioxide, ofwel N02, is een belangrijke luchtverontreinigende stof 
die geassocieerd is met toename van luchtwegklachten in mensen en met 
emfyseemontwikkeling in diermodellen .  Belangrijke bronnen van N02 uitstoot 
zijn de industrie, uitlaatgassen, sigarettenrook en binnenshuis stoken of koken 
met fossiele brandstoffen. 
Uit grootschalig bevolkingsonderzoek is gebleken dat het erg lastig is om 
de afzonderlijke gevolgen van blootstelling aan luchtverontreiniging en 
sigarettenrook op het ontstaan  van luchtwegklachten te onderscheiden. Dit 
komt doordat individuen vrijwel nooit aan een enkele verontreinigende stof 
warden blootgesteld. In welke mate luchtverontreiniging en/of N02 blootstelling 
bijdragen aan d e  ontwikkeling van COPD en mogelijk de effecten van (mee)roken 
kunnen verergeren is daardoor nog grotendeels onbekend.  
Om de bijdrage van luchtvervuiling op de ontstekingsreactie in COPD te 
bestuderen hebben we de acute en chronische effecten van roken in combinatie 
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met NO2 blootste l l ing onderzocht in een muizenmodel voor COPD (hoofdstukken 
2 en 3). In deze studies hebben we mu izen afzonderl ij k  b lootgesteld  aan rook en 
NO2 of aan de combinatie van rook en NO2. Op deze manier konden we zowel 
de afzonderl ij ke effecten van rook en NO2, als de gecombineerde effecten van 
rook en NO2 in kaart te brengen. Voor de blootste l l ing aan rook werden mu izen 
in onze rookmachine gezet. Om rook in te ademen zitten muizen in een soort 
korset met de neus i n  de schoorsteentjes van de rookmachine. Zo ademen ze de 
rook v ia de neus in, aangezien muizen a l leen v ia de neus ademhalen. Voor  de 
NO2 blootste l l ing werden de muizen in  een afgesloten box geplaatst, waarin de  
NO2 blootste l l ing plaatsvond. 
In het acute experiment (hoofdstuk 2) werden de mu izen gedurende 3 uu r  
b lootgesteld aan  NO2 en/of aan  de rook van 4 s igaretten gedurende 2.5 uur. De  
volgende dag  werden de mu izen opgeofferd en werden de longen u itgenomen 
om de versch i l lende ontstekingsparameters te ana lyseren. 
In het chronische experiment (hoofdstuk 3) werden de mu izen gedurende 4 weken 
dagel ijks blootgesteld aan NO2 en/of sigarettenrook en na 4 weken opgeofferd. 
Onze hypothese was dat de effecten van roken en NO2 blootstel l ing e l kaar 
zouden versterken en dat muizen d ie aan de combinatie waren blootgesteld 
de meeste ontsteking in de longen zouden krijgen. In het acute experiment 
b leek d it n iet het geva l te zijn .  Mu izen die al leen waren blootgesteld aan NO2 
hadden een sterke toename van versch i l lende ontstekingsmediatoren in de 
longen .  Deze mediatoren zijn  belangrijk bij de eerste afweer van de longen en 
zorgen ervoor dat ontstekingscel len warden aangetrokken naar de l ongen om 
daar bescherming te bieden. Mu izen die a l leen waren blootgeste ld aan rook 
hadden een kleine toename van een aantal ontstekingscel len in de l ongen, en 
een m inder sterke toename van de ontstekingsmed iatoren dan die we vonden 
na NO2 blootste l l ing .  De meest opva l lende bevinding was dat de muizen die 
blootgeste ld waren aan de combinatie van rook en NO2 helemaal geen toename 
van de ontstekingsmed iatoren in de longen hadden. Het leek er dus op dat de 
toename die we zagen in  de NO2 muizen ju ist geremd werd als deze muizen 
oak aan rook waren blootgesteld. Deze moge lijk remmende effecten van acute 
rook blootstel l ing zijn n iet nieuw en kunnen mogel ij k  veroorzaakt warden 
door de aanwezigheid van koolstofmonoxide (CO) in s igarettenrook. Van CO is 
bekend dat het i n  hoge concentraties g iftig is en  kan le iden tot CO vergift ig ing, 
maar recent zijn oak ontstekingsremmende effecten beschreven van lagere CO 
concentraties. Om uit te zoeken of CO de remmende factor in de rook was in ons 
acute experiment, hebben we vervo lgens muizen blootgesteld aan de combinatie 
van NO2 en CO in p laats van rook. Dit experiment l iet ontstekingsremmende 
effecten van CO zien op versch i l lende ontstekingsmediatoren. S lechts 1 van de 
ontstekingsmed iatoren die na NO2 blootste l l ing verhoogd was, werd geremd na 
CO blootste l l ing .  H ieruit konden we concluderen dat de aanwezigheid van CO in  
sigarettenrook slechts voor een deel de remmende effecten van rook op de NO2 
ge·rnduceerde ontsteking kan verklaren. 
B ij langdurige b lootste l l ing aan sigarettenrook verwachtten we dat de acute 
remmende effecten van rook ten iet zouden warden gedaan door de  toxische 
effecten. Onze hypothese voor de chronische stud ie bleef daarom ongewijzigd en 
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de verwachti ng was dat we met chronische b lootste l l ing j u ist wel de verergerde 
ontsteking zou d en vinden na gecombineerde b lootste l l i ng aan NO2 en rook. 
Oak bij de chron ische stud ie  (4 weken) b leken de resu ltaten tegengesteld aan 
onze verwachting .  Na chronische NO2 blootste l l ing waren de acute effecten van 
NO2 op de ontstekingsmediatoren helemaal verdwenen.  Terwij l  chronische rook 
b lootste l l i ng  wel le idde tot een verhog ing van bepaalde ontsteki ngsmediatoren .  
Opva l lend was dat in de groep die b lootgesteld werd aan de combi natie van 
rook en N O2 d eze effecten van rook verdwenen waren. In d it geva l leek er dus 
een rem mend effect te zijn van chronische NO2 blootste l l i ng .  In de l iteratuur zijn 
verge l ijkbare effecten va n NO2 blootste l l i ng  besch reven. Als mogel ij k  verklar ing 
wordt gegeven dat NO2 de afweerreactie van de longen aantast en dat daardoor 
dus geen ontstekingsmediatoren geproduceerd warden i n  reactie op  de NO2 
b lootste l l i ng .  D e  afwezigheid van een goede afweerreactie door de longen zou 
kun nen l eiden tot een verhoogde gevoel igheid voor infecties. Gezien oak de 
aa nwezig heid van NO2 in s igarettenrook zouden deze effecten van NO2 mogel ijk  
een verklar ing kunnen zijn voor de verhoogde gevoel igheid voor infecties in 
patienten met COPD. 
Samenvattend kunnen we concl uderen dat de gecombineerde b lootstel l i ng  aan 
N O2 en rook om versch i l lende redenen zowel in het acute a l s  chronische model n iet 
resu lteerde in een versterkte ontstekingsreactie in de longen.  Deze bevindingen 
wa ren onverwacht en tegengesteld aan onze hypothese. Toekomstige studies 
zijn daarom noodzake l ij k  om de b ijdrage va n NO2 b lootste l l i ng  aan de rook 
ge·i'nduceerde o ntstekingsreactie i n  COPD verder  te ontrafe len .  
De specifieke immuunrespons in COPD 
Het mensel ijke immuunsysteem kan warden onderverdeeld in een specifiek 
(verworven) en een aspecifiek (aangeboren) deel. De eerste afweer tegen een 
bepaa l d  pathogeen (ziekteverwekker) wordt voora l g ekenmerkt door een 
aspecifieke immuunreactie. Deze is d i rect werkzaam, ka n reageren tegen een 
breed spectru m va n pathogenen, maar is daardoor wel minder  specifiek. Tijdens 
deze respons warden veel  ontstekingsmediatoren geproduceerd, waardoor 
ontstek ingscel len  word en aangetrokken en/of geactiveerd voor de eerste afweer. 
De specifieke i m m u u n reactie komt wat late r op gang,  maar is wel specifiekvooreen 
bepaa ld  pathogeen, en zal  u iteindel ijk  zorgen voor een m eer  gerichte en sterke 
afweer. Bovend ien zorgt de specifieke immuunreactie vaak voor een langdurige 
bescherm ing door de productie van ant i l ichamen en de vorming van g eheugen 
ce l len .  In som mige geva l len  kan het specifieke immuu nsysteem oak reageren 
tegen l ichaamseigen antigenen, wat kan le iden tot een auto- immuunziekte. 
Lange tijd werd de chronische ontstekingsreactie in de long en van COPD-patienten 
voornamel ij k  toegesch reven aan een verhoogde aanwezigheid en/of activiteit 
van cel len en m ediatoren van het aspecifieke immuunsysteem. Recente stud ies 
hebben echter aangetoond dat oak ce l len  van het specifieke immuunsysteem 
mogel ijk  een belang rijke rol spelen in deze chronische ontstekingsreactie. 
Om meer i nzicht te krijgen in de daadwerke l ij ke bijdrage van deze specifieke 
immuunreactie i n  de ontstekingsreactie i n  COPD hebben we de aa nwezigheid 
van 2 typen cel len van het specifieke immuunsysteem in  COPD bestudeerd, te 
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weten B-cel len en T-cel len. B-cel len zijn  de ce l len die de anti l ichamen p roduceren 
d ie belangrijk  zijn bij de specifieke afweer tegen pathogenen. Uit eerdere stud ies 
is gebleken dat er een toename is van B-cel len en B-cel- infi ltraten (cl usters van 
B-cel len) in de longen van COPD-patienten. Echter, momenteel is de rol en dus 
de re levantie van deze B-cel len in COPD nag onduidel ijk. 
T-cel len kunnen warden onderverdeeld in versch i l lende soorten waaronder 
he lper T-cel len en regulerende T-cel len. He lper T-cel len zijn actief betrokken en 
noodzake l ij k  voor een sterke anti l ichaam respons door B-ce l len. Regu lerende T ­
cel lenvormen een aparte subsetvan T-cel len, d ie immuunreacties kunnen rem men. 
Afwezigheid en/of d isfunctie van deze regu lerende T-cel len kan bijdragen aan het 
ontstaan van auto- immuunziekten of chronische ontstekingsreacties. Gedacht 
wordt daarom dat deze regu lerende T-cel len mogel ij k  oak betrokken kunnen zijn 
bij de chron ische ontstekingsreactie in COPD. 
Onze hypothese was dat er een specifieke immuunreactie is van B-cel len i n  de 
longen van COPD-patienten, d ie belang rijk  is b ij de ontwi kke l ing en vererger ing 
van de ziekte. Daa rnaast denken we dat regu lerende T-cel len belang rijk zijn bij  
het remmen van deze B-cel gemed ieerde immuunreactie. Mogelijk d raagt een 
verminderde aanwezigheid en/of functie van deze regulerende T-cel len b ij aan 
de chronische ontstekingsreactie in COPD. 
Om deze hypothesen te testen hebben we de aanwezigheid van B-cel- infi ltraten en 
de specifieke eigenschappen van deze B eel infi ltraten bestudeerd in  longweefsel 
van COPD-patienten en in muizen u it ans rokende mu izenmodel (hoofdstuk 
4). Daarnaast hebben we gekeken naar de aanwezigheid van regu lerende T­
cel len, B-ce l len en geheugen B-cel len in bloed van COPD-patienten en gezonde 
vrijwi l l igers (hoofdstuk 5). 
In hoofdstuk 4 hebben we de aanwezigheid van B-cel - infi ltraten aangetoond in 
longen van COPD-patienten en in longen van muizen die langere tijd aan rook 
waren blootgeste ld .  Vervo lgens hebben we laten z ien dat deze B-ce l - infi ltraten 
voornamel ij k  bestaan u it B-cel len, maar omringd zijn door helper T-ce l len. Door 
met genetische ana lyse te kijken naar de anti l ichamen d ie geproduceerd warden 
door versch i l lende B-cel len uit hetzelfde infi ltraat hebben we aangetoond dat 
deze cel len nagenoeg a l lemaal hetzelfde anti l ichaam maken en waa rschijn l ij k  
specifiek tegen 1 antigeen reageren. Waartegen deze B-ce l len in de long reageren 
is op het moment nag onduidelijk en wordt verder onderzocht. Het zou kunnen 
zijn, dat de B-ce l len reageren tegen producten (antigenen) d ie aanwezig zijn in 
s igarettenrook en neers laan i n  het longweefsel . Een andere mogel ijkheid is ,  dat 
er door de siga rettenrook ge"i"nduceerde ontstekingsreactie i n  de longen afbraak 
van het longweefsel plaatsvindt. Van deze afbraakproducten is bekend dat ze 
ontstekingsreacties op kunnen wekken. Mogelijk kunnen deze afbraakproducten 
door het immuunsysteem als l ichaamsvreemd warden herkend en kunnen B­
cel len vervolgens anti l ichamen gaan maken tegen deze afbraakproducten. 
Deze anti l ichamen kunnen dan een ongewenste immuunreactie veroorzaken 
die gericht is tegen het e igen longweefsel, met daardoor nag meer afbraak van 
het longweefsel a l s  gevo lg, le idend tot een auto-immuunreactie. De antigenen 
waartegen de B-cel len reageren kunnen theoretisch oak van bacterien of virussen 
afkomstig zijn .  
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In hoofdstuk 5 hebben we aanwezigheid van hogere percentages regulerende T­
cellen en lagere percentages B-cellen aangetoond in bloed van COPD-patienten 
in vergelijking met gezonde vrijwilligers. Daarnaast vonden we dat hogere 
percentages regulerende T-cellen gecorreleerd waren met lagere percentages B­
cellen. Deze bevindingen waren een beetje onverwacht, gezien de reeds bekende 
toename van B-cellen in longweefsel van COPD-patienten en de hypothese over 
de afwezigheid en/of disfunctie van regulerende T-cellen in COPD. Echter voor 
beide eel typen geldt dat we a Ileen naar de aanwezigheid in bloed hebben gekeken 
en dat daar waarsch ijnlijk andere factoren van invloed zijn op de aanwezigheid 
van deze cellen dan in de long. Het is daarom lastig om deze bevindingen te 
vergelijken met bevindingen die gedaan zijn in de long. Niettemin suggereren 
deze resultaten dat er een veranderde specifieke immuunreactie is in patienten 
met COPD. 
Naast regulerende T-cellen en B-cellen hebben we oak gekeken naar de 
aanwezigheid van geheugen B-cellen. Geheugen B-cellen warden gevormd na 
een specifieke reactie van B-cellen tegen een antigeen en zorgen voor een snelle 
immuunreactie bij herhaalde blootstelling aan hetzelfde antigeen. Opvallend 
was dat we een toegenomen percentage vonden van deze geheugen B-cellen 
in bloed van rokende COPD-patienten en gezonde vrijwilligers. Verhoging van 
geheugen B-cellen in bloed van actieve rokers suggereert dat roken zorgt voor 
een continue a ntigeen prikkel, die een specifieke immuunreactie opwekt wat 
deze toename veroorzaakt in het bloed. 
Wat betreft de rol van het specifieke immuun systeem in COPD kunnen we 
tot nu toe conc luderen dat er aanwijzigen zijn voor een veranderde specifieke 
immuun respons in COPD-patienten; aanwezigheid van B-cel-infiltraten in de 
long en veranderde verhouding tussen B-cellen en regulerende T-cellen in bloed. 
Daarnaast lijkt roken een antigeen specifieke immuun respons op te wekken, 
maar tot op heden is nag onduidelijk waartegen deze respons precies gericht 
is. 
H0-1 expressie in COPD 
Een intrigerend eiwit wat mogelijk een rol kan spelen in de ontwikkeling van 
COPD is het 'beschermende' enzym haem oxygenase-1 (HO-1). HO-1 is het 
enzym dat de afbraak van hemoglobine tot bilirubine, vrij ijzer en koolstof 
monoxide (CO) reguleert in het lichaam. HO-1 is een stressrespons eiwit wat 
voornamelijk ge·1nduceerd wordt door oxidatieve stress. Een belangrijke bran van 
oxidatieve stress is roken.  Van zowel bilirubine, vrij ijzer als CO zij n  beschermende 
eigenschappen beschreven en via deze reactieproducten kan inductie van HO-1 
mogelijk bescherming bieden tegen de schadelijke effecten van rook. 
Eerder onderzoek heeft een verminderde aanwezigheid aangetoond van 
HO-1 in ontstekingscellen in de longen van COPD-patienten. Daarnaast is er 
een genetische variant gevonden in het HO-1-gen wat geassocieerd is met 
emfyseemontwikkeling. 
Onze hypothese was dat in COPD-patienten het HO-1-eiwit onvoldoende is 
opgereguleerd waardoor deze patienten gevoeliger zijn voor de schadelijke 
effecten van s iga rettenrook en oxidatieve stress. 
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Om meer inzicht te krijgen in de mogelijke rol va n H0-1 in COPD hebben we 
in hoofdstuk 6 onderzocht of verhoging of verlaging van de H0-1-expressie 
de ontwikkeling van emfyseem en de ontstekingsreactie in de longen kon 
be"invloeden in een rokend muizenmodel. 
Hiertoe hebben we muizen gedurende 20 weken blootgesteld aan sigarettenrook 
en door het toedienen van een H0-1 verhogende of remmende stof geprobeerd 
de H0-1-expressie te verhogen of verlagen. 
We zijn  erin geslaagd met de toediening van d e  H0-1 verhogende stof de 
eiwitexpressie van H0-1 in de long te verhogen .  De verlaging van de H0-1-
expressie was echter niet overduidelijk. Daarnaast b l  eek oak de rookexpositie een 
hoge H0-1-expressie te veroorzaken, wat overeen komt met de bovengenoemde 
stressrespons van H0-1 na een oxidatieve prikkel (= roken). 
In tegenstelling tot onze verwachting had de verhoogde H0-1-expressie geen 
beschermende effecten op de toename in emfyseem en ontstekingsmediatoren 
in de longen van de muizen die aan rook waren b lootgesteld. Opvallend was wel 
dat de toename van H0-1-expressie zorgde voo r  een verminderde aanwezigheid 
van B-cel-infiltraten in de longen van rokende m u izen. Een mogelijke verklaring 
voor deze verminderde aanwezigheid van B-cel- infiltraten is de toegenomen 
aanwezigheid van de regulerende T-cellen in deze muizen .  Dit komt overeen 
met de bestaande literatuur  waarin beschreven is dat regulerende T-cellen B­
cel-responsen kunnen remmen. En  waarin een relatie i s  beschreven tussen H0-
1-expressie en regulerende T-cellen, die laat zie n  dat de functie van reg ulerende 
T-cellen afhankelijk is van de H0-1-expressie. 
Onze resultaten ondersteunen het concept dat H0-1-expressie belangrijk is b ij 
de functie en/of aanwezigheid van regulerende T-cellen, zoals beschreven in de 
literatuur. Daarnaast suggereren ze dat regulerende T-cellen betrokken zijn b ij 
het remmen van de rookgemedieerde B-cel-respons. 
Een nadeel van de gebruikte methode van de H0-1-verhoging was dat de muizen 
wekelijks ge·1njecteerd moesten warden met de H0-1 verhogende stof wat leidde 
tot huidirritatie op de plaats van injectie. Om voor vervolgstudies de methode 
van H0-1-verhoging te verfijnen hebben we een  minder ing rijpende methode 
ontwikkeld om de H0-1-expressie te verhogen in de longen van muizen, welke 
besch reven is in hoofdstuk 7. In tegenstelling tot de methode met de injectie van 
chemische stoffen, wordt b ij deze nieuwe methode het natuurlijke substraat van 
H0-1, hemine, in poedervorm door muizen ge·1nhaleerd. Voor de ontwikkeling 
van deze methode hebben we hemine geformuleerd als een droogpoeder 
met de juiste eigenschappen om een goede depositie in de  longen te kunnen 
bewerkstelligen. Om deze formulering te testen hebben we een kleine g roep 
muizen verschillende doses van het heminepoeder laten inhaleren. Dit experiment 
liet een mooie dosisresponsrelatie zien tussen de hoeveelheid ge"inhaleerd 
poeder en de H0-1-expressie in de longen. Dus hoe  meer he mine er ge·1nhaleerd 
was, hoe hoger de H0-1-expressie was in de longen .  Daarnaast bleek er ook een 
relatie te zijn  tussen de hoeveelheid ge·1nhaleerd hemine en  de aanwezigh eid 
van ontstekingscellen in de longen van de muizen. Een hoge dosis hemine 
resulteerde in een zeer hoge H0-1-expressie, maa r  ook in de aanwezigheid van 
ontstekingscellen, een negatieve bijwerking van e e n  te hoge hemine-depositie. 
Bij een lage dosis hemine was dit effect op ontsteking scellen niet waarneembaar 
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en was er nog steeds een du idelijke toename van de H0-1-expressie. De lage 
dosis hemine is daarom het meest geschikt voor toepassi ng  i n  vervolgstudies. 
Algemene conclusie van dit proefschrift 
Met de  verschillende stud ies d ie beschreven zijn in d it p roefschrift hebben we 
getracht meer inzicht te krijgen in  het ontstaansmechan isme van COPD en de 
mechanismen die ten g rondslag l iggen aan de chronische ontstekingsreactie in  
de longen. 
Als we onze bevindingen combineren met de bestaande literatuur komen we tot 
de  volgende hypothese over de chronische ontstekingsreactie i n  COPD: 
• Roken en/of expositie aan luchtverontreiniging en meeroken veroorzaakt 
eerst een ontstekingsreactie i n  de  longen, die vooral gekenmerkt is door 
ontstekingscellen en ontsteki ngsmediatoren van het aspecifieke immuunsysteem 
(hoofdstuk 2). 
• Naarmate de ontstekingsreactie langer duurt en er schade ontstaat van het 
longweefsel, gaan ook cell en van het specifieke immuunsysteem, in het b ijzonder 
B -cellen, een rol spelen in de ontstekingsreactie (hoofdstuk 4,6). 
• Deze B-cel reactie is mogelijk gericht tegen afbraakproducten van longweefsel 
of producten van sigarettenrook die neergeslagen zijn in longweefsel. 
• Regulerende T-cellen zijn belang rijk bij het controleren van deze B-cel-respons, 
mogelijk via de expressie van H0-1 (hoofdstuk 6). 
• In 'gezonde' rokers wordt deze specifieke B-cel-respons tegengewerkt door een 
goed werkend specifiek immuunsysteem met goed functionerende regulerende 
T-cellen. 
• In COPD-patienten is sprake van een veranderd specifiek immuunsysteem; 
toename van regulerende T-cellen en afname van B-cellen in bloed (hoofdstuk 
5) en het omgekeerde in longweefsel (literatuur). Dit veranderde specifieke 
immuunsysteem d raagt mogelijk bij aan de ontwikkeling en/of de verergering 
van de chronische ontstekingsreactie in COPD. 
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Wat m ij betreft is promoveren een echte teamsport, waarbij een goed team om 
je heen een eerste vereiste is. 
Tijdens m ijn promotietraject maakte ik deel u it van een goed, betrouwbaar, 
maar voora l  oak geze l l ig team van col lega's, fami l ie  en vrienden. Via deze weg 
wil ik iedereen bedanken die deel u itmaakte van mijn team en zij n steentje 
heeft b ijgedragen aan de totstandkoming van mijn  proefschrift. Een aantal 
teamgenoten wi l i k  h ierbij nag in het b ijzonder noemen. 
Mijn team van begeleiders; 
Barry, onder jouw le id ing began ik m ijn AIO carriere en dankzijjouw enthousiasme 
g ingen we voortva rend van start. Ik had nag geen letter gelezen of j ij nam me al 
mee op sleeptouw naar het CDL, d i rect muizen opofferen !  Je leerde me gel ij k  de 
fijne kneepjes van het longen ophangen en introduceerde me bij Pieter op het 
CDL. Tijdens de eerste anderhalf jaar was je m ijn  d i recte begeleider en tijdens die 
periode heb i k  veel van je opgestoken. Vooral j e  enthousiasme Ue ging het l iefst 
na e lk experiment op je knietjes door de gang! )  werkte erg inspirerend. Daarnaast 
was je natuur l ij k  oak gewoon een erg geze l l ige col lega, bedankt voor a l ies! 
Hu ib, j ij was de opperbaas, ofwel 1 • pro motor, tijdens m ijn AIO project. Vanaf 
het begin hield j ij de g rate l ij nen van het project i n  de gaten. Tijdens onze 
besprekingen was je a ltijd positief kritisch, wat m ij scherp h ie ld en waardoor i k  
veel van je heb geleerd. Vers in m ijn geheugen staan nag onze besprekingen 
over de patientenstudie, waarbij je m ijn  kenn is over a.a .  longfuncties en 
med icatie gebru ik  bij COPD patienten enorm hebt bijgespijkerd, m ijn  dank 
h iervoor is g roat! Daarnaast heb ik je inbreng b ij de d iermodel werkbespreking 
op maandagmorgen altijd zeer gewaardeerd. Je was daa rbij zeer ge"interesseerd 
in de praktische u itvoering van de experimenten, wat ans ertoe dwong goed 
na te denken over de uitvoering ervan. Je hamerde voora l op het zo 'random' 
mogel ij k  u itvoeren van de experimenten en het l iefst l iet je ans de muizen zelfs 
'b l ind '  opofferen !  
Machte ld, j ij raakte pas echt betrokken bij mijn project na het vertrek van Barry. J ij 
werd vanaf toen m ijn eerste aanspreekpunt bij de pathologie en vanaf het begin 
had je een pos itieve en voora l oak een creatieve inbreng. Je was enthousiast 
met elk behaa ld  resu ltaat en met je creativiteit inspireerde je mij om oak met 
deze onverwachte resu ltaten iets nuttigs te doen en om te zetten in een goed 
manuscript. Onze samenwerki ng was goed, d i rect, zo nu en dan kritisch, maar 
vooral geze l l ig .  Ik hoop deze dan oak nag lang voort te zetten en ben b l ij dat je 
mijn copromotor bent, bedankt! 
Wim, j ij was a ls 2• promotor, met name in het begin, voora l  betrokken bij m ijn  
AIO project tijdens de maandel ijkse d iermodel besprekingen a ls de g rate l ijnen 
van het project besproken werden. Naarmate m ijn project vorderde raakte je 
meer d i rect betrokken, wat uite indel ijk resu lteerde in onze hu id ige samenwerking 
binnen het B eel project. Ik vond het erg prettig dat je deur a ltijd open stand (en 
nag steeds staat!) voor het kijken van interessante coupes of een d ringende vraag. 
Daarnaast heb i k je inbreng b ij het formuleren van pol itiek correcte antwoorden 
op kritische vragen van reviewers a ltijd zeer gewaardeerd, bedankt! 
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Dirkje, j ij was a ls 3• promotor oak voora l t ijdens de maandel ijkse d iermodel 
besprekingen d i rect betrokken bij m ijn  project. Tijdens d eze besprekingen was 
je in breng g roat; je dacht a ltijd goed mee en stelde kritische vragen, waar ik vee l  
van ge leerd heb.  Oak bij het  beoorde len va n m ijn manuscripten was je a ltijd  
positief kritisch en leverde je  goed com mentaar, waar  i k  veel aan heb gehad, 
bedankt !  
Het analisten team; 
Marie en Marjan ,  waar  zou i k  geweest zijn  zonder j u l l ie?! Vanaf het begin stonden 
ju l l i e  voor me k laar, maakten ju l l ie  me wegwijs op het lab en  h ie l pen ju l l i e  me 
b ij het opofferen van de m uizen, het vele  snij, k leur  -en facswerk en  natuurl ijk 
de LMI scores! Samen waren ju l l ie een ijzersterke combi natie, waar i k  met heel  
vee l  p lezier mee samenwerkte. Marjan was altijd relaxed en ka lm en  voerde 
de experi menten zeer gedegen uit .  Marie was een goede tegenpool en meer 
van het type 'the unstoppable', erg fanatiek, maar  beleefde daardoor soms wel 
wat 'onrustige' (en wa rme!) momenten als ze dacht dat er  iets misgegaan was. 
Marjan, helaas heb je ons team inmidde ls  verlaten, maar i k  ben erg b l ij datje nog 
steeds bij ans op  het lab rond loopt zodat we geregeld even bij ku nnen k letsen. 
Ik zou g raag in  de toekomst weer eens met je samenwerken !  Marie, ik ben erg 
b l ij dat we nu n ag steeds samenwerken op het B eel project en ik hoop dat we 
d ie  samenwerkin g  nag lang kun nen  voortzetten !  
Dames, super dat ju l l ie m ijn  paran imfen wi l len zijn !  
De biotechnicus; 
Beste Pieter, jij was (en bent) mijn steun en toeverlaat op het CDL. J ij was a ltijd 
zeer betrokken bij m ijn  d ierexperimenten en ik  kon a ltijd op je rekenen.  Sa men 
met Ba rry leerde je m ij de fijne kneepjes van het longen ophangen en i n middels 
zijn we een goed 'ophang'  team geworden.  Daarnaast heb je enorm vee l energ ie 
gestoken in  onze N02 opste l l i ng en kwa m je a lt ijd  met creatieve ideeen om onze 
opstel l i ng  te verbeteren.  Het heeft ans heel veel energie gekost, maar uiteindel ij k  
hebben w e  hem goed lopend gekregen !  Ge lukkig houdt o nze samenwerking 
hier n iet op  en kan ik  nag steeds op  je rekenen tijdens m ijn  n ieuwe project, 
bedankt! 
Het lab; 
Tijdens m ijn  AIO project heb ik  alt ijd met veel p lezier op het O&O lab gewerkt. 
Ha ns, Lyd ia, Ma rn ix, Monique, Bea, Rian ne, Inge, Marian, Lorian, M irjam, Tineke 
en Theo, bedan kt voor ju l l ie h u l p  en de gezel l ige werksfeer! Anke en Rikst Nynke, 
bedankt voor j u l l ie begele id ing bij d e  Vh-gen ana lyses op het DNA lab. Gemma 
en H i lde, b io log ie  studenten, bedan kt voor ju l l ie  bijdrage aan m ijn  onderzoek. 
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